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Abstract
Over the past decade, it has become apparent that the human polybromo-1 protein
(BAF180) has a critical role in cancer. BAF180 is known to be a driver mutation in clear
cell renal cell carcinoma, where it has been found to be mutated in approximately 40% of
cases. Mutations have also been found in several other cancers, including intrahepatic
cholangiocarcinomas and epithelioid sarcomas. BAF180 is the chromatin targeting
subunit of the PBAF (Polybromo-associated BRG1-associated factor) chromatin
remodeling complex, a role facilitated by its nine domains: six bromodomains, which
recognize and bind to acetylated lysines on histones; two BAH (bromo-adjacent
homology) domains, found to be critical for PCNA ubiquitination following DNA
damage; and one HMG (high mobility group) box, the DNA binding component.
Furthermore, proper expression of BAF180 has also been linked to cardiac development
and cell cycle regulation.
Despite these associations, the molecular level interactions of full-length BAF180
have yet to be studied; only the phenomenological effects of BAF180
deficiency/mutation have been studied. It is crucial that we understand the binding
dynamics and specificities of wild type and mutated BAF180, since it is the recognition
component of PBAF.
Expression of the recombinant full-length BAF180 protein has been difficult
because of the complex nature of this protein, its unusual codon usage, and size. After E.
coli expression failed, other expression systems were investigated and the yeast Pichia
pastoris was chosen. Pichia was chosen for several reasons: its codon usage is similar to
10

that of BAF180 and it is a eukaryotic system possessing eukaryotic protein folding
machinery and capable of performing post-translational modifications. Under control of
the GAP promoter, full-length BAF180 has been successfully expressed in Pichia
pastoris. This is the first time that full-length BAF180 has been cloned and expressed in a
heterologous host. It was purified using anion exchange chromatography.
The ability to express and purify full-length BAF180 is a huge first step towards
increasing the understanding of the molecular mechanisms of this protein and its
association with cancer development.
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Chapter 1 : Background
1.1 Introduction
Though discovered in the early 2000s, the complex interconnecting roles of
human polybromo-1 or BAF180 are just starting to be understood. Though a lot of
unknowns remains, it has been established that BAF180 plays roles in the development of
the heart and the thymus (Sections 1.4.2.2 and 1.4.2.3), genomic stability and DNA repair
(Section 1.4.3), and cell cycle regulation (Section 1.4.4) (Figure 1.1). Mutations in
BAF180 are commonly observed in cancers (Section 1.5); most notably, it is mutated in
41% of clear cell renal cell carcinoma cases.1 When BAF180 is mutated or its expression
is affected, there are deleterious effects on normal cell function, such as increased cell
proliferation and impaired DNA repair (Figure 1.2).

BAF180

Tumor Suppressor
Genomic Stability

Cell Cycle Regulation
G1 phase arrest
G2 phase arrest
Cyclin B1 repressor

Centromere cohesion

DNA Repair
Development
Heart

Double Strand Break Repair
Non-Homologous
End Joining

Transcriptional
silencing

Post Replication Repair
PCNA
ubiquitination

Figure 1.1: Diagram illustrating the roles of BAF180 in normal cells.
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Thymus

BAF180

Tumor Suppressor
Mutations
Low expression
Knockout
Genomic Instability

Cell Cycle
Deregulation

Increased cell
proliferation

Increased
migration

Increased tumor
size and grade

Aneuploidy

Centromere
Dissociation

Development
Disrupted DNA Repair
Heart

Ventricular
Septal Defects

Thymus

Embryonic
Lethality

Hypoplasia

Figure 1.2: Diagram illustrating the consequences of mutations or alteration of expression of BAF180. The
consequences of cell cycle deregulation, genomic instability, and disrupted DNA repair has the potential to
cause cancer.

1.2 Mutation Susceptibility
When analyzing the DNA sequence of PBRM1 (the gene that encodes BAF180)
some interesting trends are seen. There are a lot of repeats, particularly A- and T-tracts.
Base repeats have been known to increase the chances of point mutations during
replication.2-6 Poly-A tracks have been found to influence gene transcription both by
stopping translation and creating frameshift mutations.7 The PBRM1 gene has 4905 base
pairs (isoform two, GenBank ID: AAG48933.1); within the gene, there are numerous
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two, three, and four repeats of all the bases (Table 1.1). BAF180 has nine alternate
splicing isoforms.
Table 1.1: The number of two or more base pair repeats found in the PBRM1 gene (GenBank ID:
AAG48933.1). Numbers above the table refer to the number of consecutive of bases. The numbers in the
box refer to how many times that base-tract is found in the mRNA sequence.

Base Two
A
394
U
245
C
232
G
207

Number of Sequential Bases
Three Four Five Six Seven
135
54
21
7
1
69
16
9
1
0
48
11
4
1
0
39
7
0
1
0

1.3 Domain Organization
The human polybromo-1 protein (BAF180) is encoded by the PBRM1 gene
(Figure 1.3) and is considered to be the chromatin-recognition subunit of PBAF
(polybromo-associated BRG1-associated factor). PBAF is involved in gene transcription.
The PBRM1 gene is located at 3p21.1. BAF180 is comprised of nine domains: six
bromodomains, two bromo-adjacent homology domains, and one HMG-box. It is
considered to be homolog to yeast Rsc1, 2, and 4 (or a gene fusion product of them).8-9

Brd1

Brd2

Brd3

Brd4

Brd6

Brd5

BAH1

BAH2

HMG

Figure 1.3: Domain organization of BAF180. BAF180 has 6 bromodomains (brd), the most of any known
bromodomain-containing protein; 2 BAH (bromo-adjacent homology domains); and 1 HMG (high mobility
group) box. The full-length protein has never been expressed in a heterologous host. The domain sizes and
distances are approximately to scale [AAG48933.1]. BAF180 is encoded by the PBRM1 gene.
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1.3.1 Bromodomains
Within chromatin, DNA is wound around a core of eight histone proteins (two
each of H2A, H2B, H3, and H4). In this state, DNA is highly compacted and therefore
less accessible to replication- and transcription-mediating proteins. For replication and
transcription to occur, the DNA needs to become accessible. This is believed to occur
when post-translational modifications (PTMs) on the histone tails cause the interactions
between the negatively-charged DNA backbone and the positively-charged amino acid
resides on the histones weaken. PTMs refer to the modification of the side chain of an
amino acid by the addition of a molecular group, such as phosphate or ubiquitin. Of
interest in this work is the acetylation of lysine residues. The N-terminal tails of histones
are rich in lysine residues and the acetylation of the ε-amino group on the side chain is
generally associated with transcriptional activation.10-13 It is hypothesized that the
neutralization of the positive charge of the amino group on the lysine side chain weakens
the DNA-histone interactions. Acetylation is carried out by histone acetyltransferases, a
group of proteins which transfer an acetyl group from acetyl-CoA to the ε-amino group
of lysine.
Bromodomains were first identified in the 1990s as a domain found in the
Drosophila brahma gene and are the only known recognition module that bind acetylated
lysines. Within the human proteome, there are 46 proteins which contain at least one
bromodomain.10,12-14 Of these, 15 function as transcriptional regulators and 8 function as
chromatin remodelers (Figure 1.4).10,14 Bromodomain-containing proteins are divided
into eight groups based on their structural similarity; the bromodomains of BAF180 are
15

classified into group 8.10,14 Figure 1.5 shows all known bromodomains grouped into
families based on structural similarity; the functions of each are denoted by a colored dot.
Functions within a family can vary, though consensus is seen in some families (as in
families 2 and 8; see Figure 1.5).

Transcription
Initiator
TAF1
TAF1L
Unknown
Function
BAZ2B
BRD9
BRPF3
KIAA1249
LOC93349

Transcription
Activator

Transcriptional
Regulator
ATAD2
BRD1
BRD2
BRD3
BRD4

BRD7
BRD8
BRDT
BAZ1B
SP140

BRPF1

TRIM28
PRKCBP1
SP100
TIFα
SP110

Methyltransferase
ASH1L
Transcription
Factor
FALZ

Histone
Methyltransferase
MLL

Transcription
Elongation
TRIM33A

Splicing
Regulator
SMARCA2

Insulin
Signaling
PHIP

BRWD3

Histone
Acetyltransferase
EP300
CREBBP
PCAF

Chromatin Remodeling
Factor
BAF180
BAZ1A
BAZ1B
WDR9

JAK-STAT
Signaling

BRDT
SMARCA2
SMARCA4
CECR2

Scaffold
Protein
BRD1

Transcriptional
Repressor
BAZ2A
TRIM66
ZMYD11

Figure 1.4: Functions of bromodomain-containing proteins. The majority are transcriptional regulators or
chromatin remodeling factors.
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Figure 1.5: Phylogenic tree of the bromodomain-containing proteins based on structural similarity.
Bromodomain-containing proteins are divided into 8 families. The molecular functions of each
bromodomain within a particular family varies, though some similarities can be observed (family 1 –
transcriptional regulator, family 8 – chromatin remodeling). This figure is based on figure 1B from
Filippakopoulos, 2012.14 Functional information from Filippakopoulos, 201214 and Muller, 2011.12
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The ability of bromodomains to recognize and bind to acetylated lysines is critical
for several cellular functions, including transcription, replication, and DNA repair.10,13,15
The importance of this is demonstrated in the number of diseases caused by mutation or
incorrect expression of different bromodomains. Among them are numerous cancers,
mental disorders, immune disorders, and metabolic diseases.16 BRD4 (of the BET family
of bromodomains) forms a fusion protein with the NUT protein, which causes NUT
midline carcinoma (NMC), a rare aggressive cancer with no available treatments.10,16
Other examples of bromodomains involved in cancers include ASH1L (hepatocellular
carcinoma), BRD7 (breast cancer), ATAD2 (breast cancer, colon cancer, lung cancer,
uterine cancer, stomach cancer, and lymphoma), and BPTF (neuroblastomas and lung
cancers).16 A mental disorder, Rubinstein-Taybi syndrome, is often associated with
mutations of CREBBP.16 BRD1, SMARCA2, and BAF180 are linked to schizophrenia
and bipolar disorders.16 SP140 is linked to Crohn’s disease and BRD2 is linked to
rheumatoid arthritis. BAZ1B has associations with type II diabetes and obesity.16 This is
not a comprehensive list, but the relationship between bromodomain dysfunction and
diseases is clear.
Epigenetic based treatments for various diseases, such as cancer, are becoming
more popular and the inhibition of bromodomains has emerged as a treatment option.
Most of the small molecules developed so far target proteins in the BET family
(bromodomain and extra-terminal domain family) and all of the bromodomain inhibitors
currently in clinical trials target the BET family (BET bromodomains were classified as
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“most druggable”).17 Table 1.2 shows the status of the bromodomain inhibitors currently
in clinical trials, as well as the targeted conditions.
The other seven families of bromodomains have generally been ignored, as early
studies predicted that bromodomains outside of the BET family would be harder to
target.17 Vidler et al. scored the bromodomains of BAF180 “intermediate” to “difficult”
druggability, with brd1, 3, and 4 considered “difficult” targets and brd2 and 5, considered
“intermediate” targets; brd6 did not have a score.17
This analysis has recently been called into question when two groups created an
inhibitor that selectively targets brd5 of BAF180.18-19 Vidler et al. based their analysis on
the assumption that the water molecules in the binding pocket remained. Both
Myrianthopoulos and Sutherell created compounds which were able to bind to
bromodomain 5 selectively with good affinity, while displacing water molecules.18-19
Sutherell et al. published their compound in April 2016 and showed that it had a KD =
124 nM for BRD5.18 Myrianthopoulos et al. published in September 2016 and their
compound had a KD = 3.3 µM for BRD5.19 Both compounds were able to displace
BAF180 from chromatin.18-19 Structural analysis conducted by Vidler et al. demonstrated
that the binding pocket of the fifth bromodomain of BAF180 is unusual when compared
to other bromodomain structures; it appears to have a shorter ZA loop and some key
residues located in the binding pocket are shifted, resulting in a smaller binding site.17
This may be a reason why newly developed molecules selectively target brd5.
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NCT02296476
OTX105/MK-8628
Ocoethix GmbH
NCT02303752
OTX105/MK-8628 Merck Sharp & Dohme Corp. NCT02698189

Ocoethix GmbH

OTX105/MK-8628

OTX105/MK-8628

Company

Drug

1
1
1b
1
1/2
1/2
1

1

2
1

1
1
1/2
1/2

3
1/2

2

1

1

1

1B

1
1/2
1b/2
1

1B

Phase

Recruiting
Terminated
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting

Recruiting

Recruiting
Recruiting
Recruiting
Recruiting
Not yet
recruiting
Recruiting

Recruiting
Recruiting

Recruiting
Not yet
recruiting

Recruiting

Recruiting

Recruiting

Completed
Terminated
Withdrawn
Recruiting

Active

Status

No
No
No
No
No
No
No

No

Yes
Yes

Yes
Yes

No

Yes
No

Yes

Yes

Yes

Yes

Yes

Yes
Yes
Yes
Yes

Yes

Structure
Disclosed?

Solid tumors, advanced solid tumors
Neoplasms
Metastic castration-resistant prostate cancer
Metastic castration-resistant prostate cancer
Advanced cancer
Advanced cancer
AML, acute myelogenous leukemia, myelodysplastic syndrome

Myelodysplastic syndromes, AML

Cancer
Drug interactions

Peripheral nerve tumors
Diabetes mellitus, type 2, coronary artery disease, cardiovascular
diseases
Multiple indications cancer
Advanced cancer, bresat cancer, non-small cell lung cancer, AML,
multiple myeloma
Cancer
NUT midline carcinoma
Cancer

Multiple myeloma
Acute myelocytic leukemia, myelodysplastic syndrome,
myelodysplastic/myeloproliferative neoplasm, myelofibrosis

Lymphoma

Condition
Solid tumors: NUT midline carcinoma, triple negative breast cancer,
non-small cell lung cancer with ALK fusion protein or KRAS mutation,
castrate-resistant prostate cancer, pancreatic ductal adenocarcinoma
Acute myeloid leukemia, diffuse large B-cell lymphoma, acute
lymphoblastic leukemia, multipple myeloma
Glioblastoma multiforme
AML
AML
NUT midline carcinoma, triple negative breast cancer, non-small cell
lung cancer, castration-resistant prostate cancer

Table 1.2: Bromodomain inhibitors currently in clinical trials. All of the drugs listed target the BET family
of bromodomains. Of note is Resverlogix Corp.’s RVX000222, which has progressed to phase three
clinical trials for diabetes and cardiovascular diseases. Data gathered from clinicaltrials.gov on 16 January
2017.20

1.3.1.1 Structure and Binding Mode
The bromodomain structure consists of a left-handed helix bundle composed of
four α-helices (αZ, αA, αB, αC) connected by three loops (ZA-, BC-, AB-loops) (Figure
1.6A). Specificity is conferred by the ZA and BC loops10,13-14,16,21-22 which form a
hydrophobic binding pocket. The acetylated lysine residue forms a hydrogen bond with a
highly conserved asparagine residue located near the end of the αB helix (Figure
1.6B).10,13-14,21-23 Water residues located within the hydrophobic binding pocket also form
hydrogen bonds with the acetylated lysine (Kac).19,21
Factors influencing acetyl-lysine specificity and affinity are (1) amino acid
residues neighboring the binding pocket and (2) histone post-translational modification
patterns. Amino acid residues surrounding the hydrophobic pocket have been
demonstrated to influence acetyl-lysine recognition by interacting with residues that
surround the acetylated lysine on the histone.10,19,21-22 Different post-translation
modification (PTMs) patterns on the histones have been shown to influence binding
affinity at a specific acetyl-lysine residue; surrounding PTMs may increase or decrease a
bromodomain’s affinity for a specific acetylated lysine.10,14,22 Interestingly, some
bromodomains have demonstrated an ability to bind to two acetylated lysines at a time
within the same binding pocket.14,24 For example, the first bromodomain of the BET
protein BRD4 has been shown to bind both acetylated lysines of H4K5/8ac at once; a
crystal structure shows that both acetylated lysines are in the binding pocket (PDB ID:
3UVW).14
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Figure 1.6: Crystal structure of a bromodomain. (A) The crystal structure of bromodomain 3 of BAF180
[PDB ID: 3K2J; structure not yet published: Filippakopoulos, P., Picaud, S., Keates, T., Chaikuad, A., Pike,
A.C.W., Krojer, T., Sethi, R., von Delft, F., Arrowsmith, C.H., Edwards, A., Weigelt, J., Bountra, C.,
Knapp, S., Structural Genomics Consortium]. Labeled are the structural segments found in every
bromodomain. The αZ-helix is located at the N-terminal end of the protein. (B) The crystal structure of
bromodomain 2 (of BAF180) bound to an acetylated peptide [PDB ID: 2KTB].{Charlop-Powers, 2010
#616} The binding pocket is located between the ZA- and BC-loops of the structure. The αZ-helix is
located at the N-terminal end of the protein. Light blue: αZ-helix. Purple: ZA-loop. Green: αA-helix. Pale
pink: AB-loop. Orange: αB-helix. Hot pink: BC-loop. Dark blue: αB-helix.{Berman, 2000 #1292;Xu, 2009
#1085} Images manipulated using Protein Workshop.{Moreland, 2005 #1293}
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Domains adjacent to the bromodomain (BRD) often include PHD zinc fingers,
other bromodomains, and bromo-adjacent homology domains (BAH).10,14 These
neighboring domains have been shown to act together to increase the binding affinity for
a bromodomain-containing protein to an acetylated lysine site. For example, BRD2
(bromodomain-containing protein 2), which has two tandem bromodomains, has a much
higher affinity for H4K5/12ac (Kd=360 µM) than for the singly-acetylated H4K12ac
(Kd=2.9 mM).10 TRIM33, which has a PHD (plant homology domain) zinc finger
followed by a bromodomain, has been shown to bind H3K9me3 and H3K14ac
simultaneously.10,13

1.3.1.2 The Bromodomains of BAF180
BAF180 has six bromodomains, the most of any known bromodomain-containing
protein. Of particular interest is the question of why BAF180 has six bromodomains. At
most, other bromodomain-containing proteins contain two. It is accepted that
bromodomains bind to acetylated lysines, but the specific interactions of the BAF180
bromodomains are unknown. It is possible that the bromodomains work in concert (as the
tandem bromodomains of BRD4 do) and it is possible that they work independently
(further discussion in Sections 1.3.1.1).10,14,23-24
Filippakopoulos et al. performed a very thorough SPOT array of histone H3
peptides with various combinations of post-translational modifications (acetylation, trimethylation, phosphorylation, etc.). The data indicates that modifications surrounding the
acetylated lysine do have an impact on binding affinity. For example, brd4 (of BAF180)
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had “strong” affinity for H3K4ac, but “very strong” affinity for H3K4/9ac. This suggests
that brd4 of BAF180 may be able to bind two acetyl-lysines simultaneously, in a manner
similar to the BET protein BRD4(1).14,24 Brd4 of BAF180 had “strong” affinity for
H3K9ac, but “weak” affinity for a peptide containing additional acetylation sites on K4
and K14, and two phosphorylation sites on S10 and T11 (H3K4/9/14acS10/T11p, where
‘p’ means phosphorylation). It had no affinity for a peptide containing a tri-methylation
mark on K4, acetylation at K9 and K14, and phosphorylation on S10 and T11
(H3K4me3K9/14acS10/T11p, where ‘me3’ refers to tri-methylation). The data also
demonstrates that brd4 of BAF180 is a fairly ubiquitous binding partner, as it showed
‘very strong’ affinity for about 74% of peptides tested.14 Data presented in that
publication also supports the hypothesis that the bromodomains work together, as some
multiply modified peptides were recognized by more than one bromodomain.
The bromodomains of BAF180 have been expressed individually and their
affinities for specific acetyl-lysine sites on histones has been studied.12,14,27-30 However,
there has been some divergence in results, in terms of recognition patterns and affinities
(Table 1.3). This may be due to several factors: different lengths of the bromodomains,
differing peptide lengths, and differing peptide locations may be influencing the results.
In addition, the affinities are hard to compare because different methods were used to
quantitate the affinities (nuclear magnetic resonance, isothermal titration calorimetry,
fluorescence anisotropy, dot blot, peptide/SPOT array).12,14,23,27-30
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Table 1.3: Comparison of the individual acetylated lysine sites on histones 1-4 recognized by the
bromodomains of BAF180. The specificity data between publications varies, with little consensus between
them. This may be a reflection of the different techniques used, thus emphasizing the need to a
comprehension study of all the individual bromodomains’ binding sites.14,27-28
Histone H1-4 Histone H2A Histone H2B
Reference
Reference
Reference
Bromodomain
14
14
27
14
27
K33, K80,
K84, K89

PB1(1)
PB1(2)

K62, K74,
K80, K84

PB1(3)
PB1(4)
PB1(5)
PB1(6)

K84

Histone H3
Reference
14
27
K56, K64,
K122
K36
K14
K14

K15
K36

K85

K15 K15

K23 K15
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Histone H4
Reference
14
27

K4 K44, K91
K9

K18, K36,
K56, K64 K115
K9
K37, K122 K14, K115 K23
K85
K36, K112 K14
K43 K24, K116 K56, K115

K12

A study was recently published wherein the researchers investigated the effect of
point mutations of individual bromodomains. Porter and Dykhuizen reported that
endogenous BAF180 isolated from HeLa lysate specifically recognizes H3K14/18/23/
27ac, as evidenced during a peptide pull-down assay.23 Porter and Dykhuizen suggest that
the second bromodomain of BAF180 is the most critical for BAF180’s tumor suppressor
properties. They created six constructs wherein a single point mutation was introduced
into the binding pocket of a different bromodomain and introduced the constructs into
Caki2 cells (clear cell renal cell carcinoma (ccRCC) cells lacking BAF180). They used
immunoprecipitation with BAF180 and BRG1 antibodies to confirm that the mutants
were integrated into the PBAF complex, though with weaker binding than is seen for
wild type.23 Then they examined the effects of these mutations on cell growth and gene
expression.
When wild type BAF180 was introduced into Caki2 cells, the growth rate
decreased significantly. In contrast, introduction of the mutant brd1, 2, 4, and 5 BAF180
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constructs had no effect on cellular growth, meaning the cells continued to grow at a rate
similar to control cells that lacked BAF180. Analysis of gene expression patterns for all
the cells demonstrated that the mutant brd1, 2, 4, 5, and 6 BAF180 proteins were unable
to bring about the up-regulation of apoptotic genes that is usually observed when wild
type BAF180 is introduced. The mutation in brd3 had no effect on gene expression as
compared to wild type BAF180.23
The crystal structures of the first five bromodomains (BRDs) of BAF180 are
similar to the structures of other bromodomains. Bromodomain 6 diverges from this
pattern slightly as it has a fifth α-helix (Figure 1.7).14 This is the only published crystal
structure of brd6 (PDB ID: 3IU6). However, Filippakopoulos et al. included about 35
extra amino acids on the C-terminal end past where brd6 is predicted to stop.31 In the
same article, brd6 was shown to bind strongly (via SPOT peptide array) to H2AK36ac
and H2BK85ac.14 Another study by Charlop-Powers et al. used a dot blot array and saw
that brd6 interacted with H2BK24ac and H2BK116ac.27 This difference might be
attributable to a few things: first, the cloned brd6 domains were of different lengths in the
two publications (Filippakopoulos et al. used amino acids 741-885 and Charlop-Powers
et al. encompassed amino acids 743-821).
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BRD6
BRD4

BRD5

BRD3
BRD2
BRD1

Figure 1.7: Comparison of the crystal structures of each of the six bromodomains from BAF180. Notably,
brd6 contains an extra C-terminal helix (grey). The αZ-helix is located at the N-terminal end of the protein.
Light blue: αZ-helix. Purple: ZA-loop. Green: αA-helix. Pale pink: AB-loop. Orange: αB-helix. Hot pink:
BC-loop. Dark blue: αB-helix. [PDB IDs: brd1 – 3IU5; brd2 – 3HMF; brd3 – 3K2J; brd4 – 3TLP; brd5 –
4Q0N; brd6 – 3IU6].{Filippakopoulos, 2012 #627;Berman, 2000 #1292} Images manipulated using
Protein Workshop.{Moreland, 2005 #1293}
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By comparison of the same reference sequence and analysis by multiple domain
prediction software, brd6 is located around amino acids 743-850 (CDD:743-850;
ProSite:785-830; Interpro:743-851; SMART:743-849; MOTIF Search:649-706;
Pfam:751-835).31-36 Filippakopoulos added about 35 extra amino acids to the C-terminal
end and Charlop-Powers did not actually clone the whole domain. As Filippakopoulos et
al. had 35 extra amino acids past the boundary of predicted brd6, it is possible that their
structure is flawed. Studying the sequence data of the crystal structure reveals that the
fifth α-helix of brd6 begins at Thr863 (PDB ID: 3IU6); this is outside of the predicted
domain boundaries (Figure 1.8).

Figure 1.8: Sequence overlay of the brd6 structure. Brd6 is predicted to occur at amino acids 743-850
(CDD prediction). Filippakopouplos et al. cloned AA741-885, resulting in 35 extra amino acids. The fifth
α-helix (the anomaly separating it from other bromodomain structures) begins at Thr863, outside of the
predicted domain boundary. Sequence display image from PDB ID: 3IU6.14,37
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Additionally, the peptides used for testing interactions were of different lengths
and different positions; this has been shown to influence the recognition of a specific
acetyl-lysine site by the bromodomain.14,21-22 Third, they used different techniques for
evaluating binding partners. Filippakopoulos et al. used SPOT arrays14 and CharlopPowers et al. used dot blot arrays.27 It would be interesting to test whether the different
constructs have different acetylated lysine recognition patterns, when using the same
qualitative and quantitative methods.

1.3.2 Bromo-Adjacent Homology Domains
Bromo-adjacent homology (BAH) domains are believed to mediate proteinprotein interactions.8,32,38 The BAH domain was first identified in BAF180 and was
named as such because it was adjacent to the bromodomains.8 Since that initial discovery,
BAH domains have been found in a wide variety of proteins, only some of which contain
an adjacent bromodomain.8 Generally, BAH domains are classified into two groups: Sir3like BAH domains, which bind to nucleosomes, and RSC-like. The RSC-like BAH
domains have not been extensively studied and their binding partners still need to be
determined.9
BAF180 contains two BAH domains, proximal to the six bromodomains. Based
on sequence and structure comparisons, these BAH domains fall into the RSC-like class.
Indeed, the BAF180 protein is believed to be the human homolog or fusion of the yeast
Rsc1, Rsc2, and Rsc4 proteins.8-9
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The BAH domains in BAF180 are still relatively unexplored and the exact
function is still unknown; however, some inferences can be drawn from other BAH
domain-containing proteins. The mammalian ORC1 (origin recognition complex subunit
1) protein contains a BAH domain which has been shown to recognize and bind to a
methylated lysine on histone H4.38-39 Analyses of the structures indicate that the first
BAH domain of BAF180 may also recognize methylated lysines, as the methyl-lysine
binding pocket is fairly conserved between ORC1 and BAH1 of BAF180.38 Pull-down
assays of BAH1 of BAF180 demonstrated preferential binding to histone H3, but not to
any of the other histones.9 Additionally, the BAH domain of yeast Rsc2 was able to
independently associate with histone H3 in vivo, albeit at lower levels than full-length
Rsc2.9 Experiments further demonstrated that BAH1 domain of BAF180 is capable of
interacting with H3 as well.9
BAH domains can also bind to chromatin: the two BAH domains of the enzyme
DNA cytosine-5 are localized at replication foci during S-phase.8 Likewise, BAF180 is
found to localize at kinetochores40 (the region of chromosomes that connect to the mitotic
spindle).41 The BAH domains of BAF180 may play a role in maintaining genomic
stability, since BAF180 is found at kinetochores and is known to be important for DNA
repair and genomic stability. The roles of the BAH domains in BAF180 remain unknown.
A crystal structure of the first bromo-adjacent homology domain of chicken
polybromo was determined by X-ray diffraction in 2005 (Figure 1.9) The BAH domain is
composed primarily of β-strands. The ten β-strands are connected by a few helices and
form a barrel structure.42
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Using the crystal structures as a guide, two conserved residues near the predicted
H3 binding pocket were mutated in Rsc2 (W436A/W436L and K437E). All three of the
mutations impacted histone H3 binding in a negative manner both in vivo and in vitro.9

Figure 1.9: Crystal structure of the first bromo-adjacent homology (BAH) domain of chicken polybromo,
as determined by X-ray diffraction. The structure is composed of 10 β-strands that form a barrel structure,
connected by helices [PDB ID: 1W4S].{Oliver, 2005 #1055;Berman, 2000 #1292} Image manipulated
using Protein Workshop.{Moreland, 2005 #1293}

The BAH domains are critical for proper ubiquitination of PCNA during postreplication repair.43 Data suggests that the BAH domains are not capable of associating
with the PBAF complex themselves, as a construct containing just the BAH domains was
unable to bind with BAF200 or BRG1, both components of PBAF. Therefore, its role in
PCNA ubiquitination is likely independent of the ATPase activity of PBAF.43 The same
study also found that the BAH domains were localized throughout the cytoplasm and
nucleus,43 although this may be a consequence of experimental conditions and the exact
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amino acid sequences used in the tested construct. More experiments need to be done for
clarification, as the de-localization of the BAH domains of BAF180 seemingly
contradicts the data demonstrating that the BAH1 of BAF180 binds to histone H3.9

1.3.3 High Mobility Group Box
High mobility group (HMG) domains were first identified in 1973 by Goodwin et
al., who noted the unusual electrophoretic mobility of these proteins in Triton-urea
gels.44-46 There are three structurally distinct classes of HMG domains: HMGnucleosomal binding family (HMGN), HMG-AT-hook family (HMGA) and HMG-box
family (HMGB). HMG-box domains mediate the interactions between certain proteins
and DNA in either a sequence- or non-sequence-specific manner.44,47-48 Generally,
proteins with sequence-specific motifs bind to promoter DNA and those with nonsequence-specific bind to genomic DNA.48 HMG box-containing proteins bind to the
minor groove of B-type DNA at the entry/exit points of nucleosomes, resulting in
distortion of the DNA strand; they also recognize already distorted DNA, such as fourway junctions, bulges, and kinks (Figure 1.11).44-45,47,49 The DNA bending and unwinding
that occurs when an HMG-box binding is a result of intercalation of hydrophobic
residues into the minor groove of DNA; these hydrophobic residues are flanked by basic
residues which bind to the phosphodiester bond of DNA, thus stabilizing the
DNA:protein complex. Sequence-specific HMG-box domains usually only intercalate
with DNA at one site.47 This bending may aid in “opening” the DNA-histone complex to
allow for transcription factors to bind.44-45,50-51
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HMG-box domains also promote non-homologous end joining (NHEJ) by
bending the ends of the DNA so that they have more energetically favorable
interactions52 and influence transcription by distorting the nucleosomal complex.45
Additionally, when the HMG-box binds to bent DNA, the conformation changes such
that the acidic tail of the domain is available to interact with histones, thus weakening the
binding of the histone to the nucleosome.47 This may be one mechanism by which
BAF180 is involved in chromatin remodeling. PTMs may influence the specificity and
binding capabilities of the HMG-box. In BAF180, two serines have been found to be
phosphorylated (S1405 and S1453, isoform 1).53 PTMs on other HMG-box-containing
proteins have been known to alter the biological interactions of protein:protein and
protein:DNA type.45
BAF180 has an HMG-box domain (50 amino acids in isoform 2: AAG48933.1)
located on the C-terminus (Figure 1.3). The function of BAF180’s HMG-box is unknown
though several inferences can be made. The particular domain of BAF180 (of the HMGB
type) likely binds in a sequence-specific manner, since it most closely resembles HMGBcontaining transcription factors (has only one HMGB domain).44,47-48 Though the general
structure of HMG-box domains is three α-helices in an L-shaped configuration (Figure
1.10),44,47 the HMG-box of BAF180 differs in that it has a shorted third α-helix and an
extended basic N-terminus.44,46 This difference likely plays a role in its sequencespecificity, as the N-terminal strand and the third helix (also called the ‘minor wing’) are
responsible for the sequence specificity of an HMG-box.47 The assembly of BAF180 into
the PBAF complex has been demonstrated to be dependent on the HMG-box and/or the
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C-terminus of BAF180.43 It is possible that the PTMs present in the HMG-box impact the
ability of BAF180 to assemble into the PBAF complex.54 The HMG-box domain may
affect the role of BAF180 in embryonic development, as other HMG-box containing
proteins have been found to.

Figure 1.10: The crystal structure of HMG domain A of the HMGB1 protein. Note the L-shaped
configuration of the α-helices. The blue helix is at the N-terminus and the red at the C-terminus [PDB ID:
1CKT].{Ohndorf, 1999 #1108;Berman, 2000 #1292} Image manipulated using Protein
Workshop.{Moreland, 2005 #1293}

A

B

Figure 1.11: The HMG-box domain of the HMGB1 protein of Rattus norvegicus bound to cisplatinmodified DNA. (A) Ribbon view; (B) Surface view [PDB ID: 1CKT].{Ohndorf, 1999 #1108;Berman, 2000
#1292;Xu, 2009 #1085} Images manipulated using Protein Workshop.{Moreland, 2005 #1293}
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BAF180 is known to be critical for proper heart development in human embryos
(see Section 1.4.2.2 below) and normal development has been demonstrated to require
the proper expression of various other HMG-box-containing proteins.44 HMG-boxcontaining proteins have also been shown to be important for maintaining genomic
stability in yeast; absence of several different proteins of this type were associated with
increased genomic instability and hypersensitivity to DNA damage.44 These same effects
are seen in BAF180 KO cells (discussed in Section 1.4.4). This leads to the supposition
that some of BAF180’s roles in maintaining genomic stability and proper DNA damage
repair may stem from its HMG-box. BAF180’s roles in embryonic development and
NHEJ may be a consequence of the HMG-box domain.

1.3.4 BAF180 Binding Hypotheses
The binding mechanism by which BAF180 binds to nucleosomes is currently
unknown and is made even more complicated because BAF180 has three-types of
domains (6 bromodomains, 2 BAH domains, 1 HMG-box). With regard to the
bromodomains, recognition of an acetyl-lysine site may be a singular event or may be
cooperative. Bromodomains have been shown to be able to recognize and bind more than
one acetyl-lysine at a time.14,24 The di-acetylated histone sequence has a stronger bond to
the bromodomain than a single acetylated site. It is also possible that more than one
bromodomain binds to the nucleosome at a time; they may recognize sites on the same
histone, on multiple histones, or on adjacent nucleosomes. For example, the
bromodomains might bind to more than one H3 protein (Figure 1.12A). This could be a
result of sterics, which would prevent more than one bromodomain from binding to the
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same histone. If only one bromodomain is bound at a time, the bromodomains may
function as some sort of signaling mechanism; for example, bromodomain 1 binds to its
specific acetylated lysine site and results in transcription of protein X. This hypothesis is
supported by the large variety of PBAF subunits involved in maintaining cell state.56-62
There are a few possibilities for the overall binding mechanism of BAF180.
Hypothesis 1: The HMG box binds to the DNA surrounding the histone core and
BAF180 changes conformation such that the bromodomains are bound to their preferred
acetylated lysine sites (Figure 1.12B). Hypothesis 2: The bromodomain recognizes the
acetylated lysine site first and then the HMG box binds to the DNA surrounding the
histone core, creating a stabilizing effect (Figure 1.12C). Again, it is possible that more
than one bromodomain binds at a time. Hypothesis 3: the HMG box binds to something
besides the nucleosome-associated DNA. This is less likely than the others, as the HMG
box domain is found primarily in chromatin remodeling and transcription-related
proteins.44,47-48
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Figure 1.12: Diagram of possible binding mechanisms between BAF180 and nucleosomes. (A) The
bromodomains might bind to more than one histone and/or more than one nucleosome at any given time.
The pattern of bound bromodomains might have an influence on which gene is transcribed. (B) The HMG
box of BAF180 may bind to the DNA surrounding the nucleosome first, followed by the binding of the
bromodomain(s). Again, perhaps more than one bromodomain is bound at a time. (C) The bromodomains
first bind to acetylated lysines and then the HMG box binds to the DNA, creating a stabilizing effect
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1.4 Known Biological Functions of BAF180
As part of the PBAF complex, BAF180 is believed to be the chromatinrecognition subunit, allowing targeted gene transcription. In addition, BAF180 has
numerous individual roles in development and DNA repair and it is often mutated in
cancers (Figure 1.13).

Cancers

Development

Brain
Thymus
Liver

Esophagus

Thymus

Breast
Lung

Heart

Kidney
Bladder

Figure 1.13: Visual listing of the roles of BAF180 in development and its presence in cancers.

1.4.1 PBAF and Transcription
The BAF (BRG-associated factor) and PBAF (polybromo-associated BRG1
factor) complexes control gene expression in the human body by remodeling chromatin
to alter the accessibility of DNA to transcription factors. They is accomplished by sliding,
displacing, or replacing nucleosomes.56,58-59,62-65 The BAF and PBAF complexes are the
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homologs of yeast SWI/SNF complexes and as such are generally referred to as
SWI/SNF. Both complexes (BAF and PBAF) have a core catalytic subunit that possesses
ATPase activity, the energy from which is used to remodel nucleosomes. In addition,
they also contain various other subunits, some that are common to both complexes (such
as BRG1) and some that are unique (such as BAF180) (Figure 1.14 and Table 1.4).56,5859,62-65

BAF
BAF45B/C/D
BRM
SS18/CREST
BCL11A/B
BCL7A/B/C
BRD9
ARID1A/B

BAF57
SNF5
BAF170
BAF155
BAF60A/B/C
BAF53A/B
β-actin
BRG1

PBAF
BAF45A
BAF180
BRD7
ARID2

Figure 1.14: The unique and shared subunits of the BAF and PBAF complexes.15

It was recently reported that components of the SWI/SNF complexes are mutated
in 20% of all cancers.58 The BAF and PBAF complexes have distinct roles in gene
transcription; for example, PBAF is required for the ubiquitination of H2AK119 at sites
of DNA damage.66 The exact roles of the individual subunits of the complexes is
beginning to be understood. For example, BAF180 is believed to be the chromatinrecognition component. However, the precise protein(s) involved in binding to the DNA
wrapped around nucleosomes have not yet been identified.
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Table 1.4: The subunits found in the BAF and PBAF complexes and their individual domains.15,39,67

Subunit
Present in
BAF45B/C/D BAF
BRM
SS18/CREST
BCL11A/B
BCL7A/B/C
BRD9
ARID1A/B
BAF57
SNF5

BAF
BAF
BAF
BAF
BAF
BAF
Both
Both

BAF170

Both

BAF155
BAF60A/B/C
BAF53A/B
β-actin

Both
Both
Both
Both

BRG1
BAF45A
BAF180
BRD7
ARID2

Both
PBAF
PBAF
PBAF
PBAF

Domains
Tandem PHD domains, zinc finger
DNA-dependent ATPase, bromodomain, HAS, BRK,
SnAC
N-terminal conserved region
Zinc finger
N-terminal conserved region
Bromodomain
ARID/BRIGHT, DNA binding domain
HMG box
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Tandem PHD domains, zinc finger
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BAF180 interacts with at least BRG1 and BAF200 when assembled in the PBAF
complex. The bromodomains and BAH domains were not able to associate with BRG1
or BAF200 on their own, but the HMG domain was able to.43 This suggests that the
HMG domain is the site through which BAF180 interacts with other components of the
PBAF complex. This has interesting implications for the mutant BAF180 proteins in
cancers. Most of the mutations result in the loss of all or part of the HMG domain,
implying that these mutants are unable to associate and form the PBAF complex, which
would impair transcription since the PBAF and BAF complexes are shown to interact
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with nucleosomes differently. This hypothesis is in accordance with results from Gao et
al. demonstrating that a mutant BAF180 protein (without the HMG-box) was unable to
associate with other subunits of the PBAF complex.68 This raises an important question:
If the mutant proteins of BAF180 are expressed and not immediately degraded by
proteases or the ubiquitination degradation pathway, and they cannot associate with
PBAF, what are the mutant BAF180 proteins doing in the cell? Does the mutant bind
with something else, causing a deleterious effect or is the problem merely that it does not
associate with PBAF? And since BAF180 is the chromatin-targeting subunit of PBAF, if
BAF180 doesn’t associate with the other subunits of PBAF, maybe PBAF cannot bind to
the DNA site of transcription, or at least it cannot pick the right site. The PBAF complex
can still form in the absence of BAF180.69-70 When BAF200 was knocked down,
BAF180 levels also decreased, suggesting that BAF200 recruits BAF180 to the PBAF
complex or influences its stability. When BAF180 was knocked down, levels of BAF200
did not change.71 We still do not understand how this data relates to the binding of
BAF180 to nucleosomes.

1.4.2 Development
1.4.2.1 Retinoic Acid Pathway
Retinoic acid (RA) mediated transcription is controlled by two nuclear proteins: a
retinoic acid receptor (RAR) and a retinoid X receptor (RXR). By themselves, RAR and
RXR are not active, but when they come together to form a heterodimeric complex, they
are able to bind to specific DNA sequences called RA response elements (RAREs). These
elements consist of two repeats of a conserved hexameric motif (PuG(G/T)TCA, where
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“Pu” represents a purine base) separated by 1, 2, or 5 base pairs. For repeats separated by
2 or 5 bases (referred to as DR2 or DR5), the RXR subunit interacts with the 5' motif,
while RAR subunit interacts with the 3' repeat. In DR1 elements, the interactions are
reversed (Figure 1.15).72

A
2 or 5 base
pairs spacing

RXR

RAR

5'

3'

B
1 base pair
spacing

RAR

RXR
3'

5'

Figure 1.15: The RAR/RXR complex binds to a hexameric repeat in the DNA. If the spacing between
repeats is 2 or 5 base pairs, the RXR protein binds on the 5' end of the sequence and the RAR protein binds
on the 3' end. If the spacing is only 1 base pair, the orientation is flipped: the RAR protein binds at the 5'
end and the RXR protein binds on the 3' end.

In the absence of retinoic acid, the RAR/RXR complex forms and retains binding
to the RARE sequences, but performs a repressive role. The RAR/RXR complex recruits
the co-repressors NCoR (nuclear co-repressor) and SMRT (silencing mediator for
retinoid and thyroid hormone receptor) complexes, which contain histone deacetylase
proteins, thus repressing transcription by compacting chromatin.72-73 The full pathway is
detailed in Figure 1.16.
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Figure 1.16: The retinoic acid-mediated transcription pathway. The presence of retinoic acid induces
structural changes, allowing transcription factors (such as BAF180 in PBAF) to bind.
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In the presence of retinoic acid, the RAR/RXR complex switches from a
transcriptional repressor to a transcriptional activator. Retinoic acid is transported to the
nucleus by CRABPII (cellular retinoic acid binding protein), where it can then bind to the
RAR/RXR complex.74 When retinoic acid binds to the ligand-binding site, RAR and
RXR undergo a conformational change which increases the affinity of the complex for
the DNA RARE sequences.72 The conformational changes create a new hydrophobic cleft
which causes the co-repressors to dissociate. The coactivators p160, p300/CBP, and
CARM-1 now bind and proteins possessing histone acetyltransferase (HAT) activity are
recruited. Once the histones have been acetylated, SWI/SNF complexes are recruited,
sliding the nucleosomes and allowing for transcriptional machinery to bind to the gene
promoter. The coactivators then dissociate and the SMCC complex (Srb and Mediator
protein containing complex) is recruited. The SMCC complex then recruits the
transcriptional machinery, such as RNA PolII.73,75
Studies have demonstrated that the retinoic acid pathway is crucial for heart
development, as absence of retinoic acid in quail and mouse embryos resulted in impaired
heart development.76-77 The role of BAF180 in the retinoic acid pathway was elicited by
Wang et al., who investigated the effects on heart development in BAF180 knockout
mice. Mice which lacked BAF180 showed a decrease in the expression of CRABPII and
RARβ2, two important genes involved in the retinoic acid pathway: BAF180 was
demonstrated to be present at the promoter sites of these genes through ChIP (chromatin
immunoprecipitation) assays.78 More details can be found in the heart development
section (Section 1.4.2.2).
44

1.4.2.2 Heart
Wang et al. first elicited the role of the BAF180 protein in heart development in
2004 when it was found that BAF180 knockout mice (KO) died mid-gestation. Further
investigation revealed heart defects to be the likely cause. The absence of BAF180
resulted in severe hypoplasia (underdevelopment, thinning) of the cardiac ventricular free
walls (outer walls of the heart) and ventricular septal defects (hole in the wall separating
right and left ventricles).78
Several experiments were conducted to determine if the observed heart defects
were a direct or an indirect result of BAF180 KO. The possibility of inappropriate cell
death during development of the cardiac tissues was ruled out after experiments indicated
that apoptotic cells were not present in the developing heart of either normal or BAF180
KO mice.78 Incorrect cell differentiation was eliminated as a possibility after cardiac
biomarker analysis revealed normal expression in BAF180 KO hearts.78
Microarray analysis revealed that the absence of BAF180 had an impact on the
expression levels of numerous genes, many of which were structurally- or metabolicallyrelated. In particular, two growth arrest-specific genes were up-regulated, supporting the
theory that the heart defects may be a result of growth arrest and that loss of BAF180 is
directly responsible for the observed cardiac defects.78
Building on the observation that placenta in BAF180 KO mice was abnormal,
Wang et al. set out to determine if this could be the cause of the heart defects. Two types
of experiments were performed to determine if the defective placenta had an impact on
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the developing embryo’s heart. Studies wherein the placenta was derived from wild type
(WT) cells and the embryo was derived from mutant BAF180 KO cells demonstrated that
the heart defects still occurred even when placental development was normal. The inverse
experiment, wherein the placenta was derived from mutant BAF180 KO cells and the
embryo was derived from WT cells, showed that no heart defects were present, even
though the placenta was abnormal. This suggested that the placenta defects did not play a
role in cardiac defects.78
Comparing the phenotypic similarities of BAF180, RXRα, and PPARγ null mice
led to the investigation of BAF180’s role in the retinoic acid pathway (RXRα and PPARγ
are involved in the retinoic acid signaling pathway). The PBAF complex is known to
mediate the transcriptional activity of RXRα and PPARγ in vitro,79 so the researchers set
out to determine if BAF180 specifically is required for the transcription of some RArelated genes in vivo. Quantitative RT-PCR indicated that elimination of BAF180
resulted in a 5-8 fold down-regulation of the retinoic acid transporting protein CRABPII,
and a slight down-regulation in the expression of RARβ2, a retinoic acid binding protein.
In normal cells, exposure to retinoic acid will increase the expression of RARβ2 (~100
fold) and CRABPII (5-8 fold). However, after treatment with retinoic acid, BAF180 KO
cells exhibited no response for CRABPII expression and decreased effect on RARβ2
expression. ChIP analysis further linked BAF180 to the transcription of RARβ2 and
CRABPII. BAF180 was found to be present at the RARβ2 and CRABPII promoters,
where its occupancy level at the RARβ2 promoter increased in the presence of retinoic
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acid. This data suggests that the observed heart defects in BAF180 KO mice may be
partially linked to the role of BAF180 in the retinoic acid pathway.78
A later study by the same lab revealed that these heart defects might be due to
improper coronary vessel formation.80 Mice lacking BAF180 showed underdevelopment
of coronary vessels in the epicardial and myocardial layers of the developing heart.80 It is
possible that the hypoplasia observed in their previous study may be related to this, as
underdevelopment of the coronary vessels results in reduced blood circulation, impeding
the growth of cardiac cells. Another study, by Singh et al., showed that the expression of
BAF180, along with two other SWI/SNF subunits, was higher in the heart as compared to
the rest of the embryo during early development, again supporting the critical role of
BAF180 in cardiac development.81
Taken together, these studies strongly suggest that the cardiac defects observed in
BAF180 KO mice are a direct result of the loss of BAF180, at least partially due to the
role of BAF180 in coronary vessel development and the retinoic acid pathway.

1.4.2.3 Thymus
Proper immune system function is critical to everyday health. Improper immune
function not only leaves the person more vulnerable to pathogens, but also makes them
more susceptible to auto-immune diseases, wherein the body’s own T cells attack specific
tissues (examples include rheumatoid arthritis and Crohn’s disease). The thymus is an
organ in the lymphatic system which produces the T cells.82 T cells target and destroy
infected cells.83-84
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Wurster et al. selectively deleted BAF180 in late development T cells to discern
the effect on thymus and T cell development. A cre recombinase cassette was used to
specifically delete the BAF180 gene in T cells, leaving normal BAF180 levels throughout
the rest of the embryo, including the placenta and heart. This is important as previous
studies demonstrated that lack of BAF180 caused placental and heart defects, causing
embryos to die mid-gestation.78 Due to the nature of the cre recombinase cassette,
BAF180 is not deleted until later in development, allowing normal BAF180 levels in T
cells during early embryonic development.85
While overall T cell and thymic development were unaffected, a few changes
were observed in peripheral CD4 T cells. A general down-regulation of the CD44 antigen
(a surface glycoprotein involved in cell-cell interactions, adhesion, and migration)86 was
seen, though it was not determined if this was a direct or indirect result of the loss of
BAF180. Additionally, a small increase in the expression of a few cell cycle inhibitors
was observed, corresponding with a slight decrease in the proliferative response to
stimuli. A decrease in the expression of proteins involved in nucleosome assembly,
transcription, and DNA binding was observed, along with an increase in expression of
proteins involved in ribosome biogenesis and translation. Interestingly, the gene most
affected by BAF180 deletion was IL-10, which was significantly up-regulated.85 IL-10 is
an anti-inflammatory cytokine produced in many types of immune cells. It can regulate
the innate and adaptive immune responses by inhibiting T cell activation and
differentiation in lymph nodes and suppress pro-inflammatory responses in tissues.87 So
overall, IL-10 hinders the immune response to pathogens. When IL-10 expression
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increases as a result of BAF180 deletion, the immune response decreases. It was
determined that BAF180 binds directly around the IL-10 locus, suggesting that BAF180
directly affects the expression levels of IL-10. As can be imagined, in the absence of
BAF180, the PBAF complex is replaced by BAF complex, which likely has an impact on
binding patterns around the IL-10 locus. When PBAF was replaced with BAF, increased
acetylation of histones was observed, suggestive of increased transcription; further tests
were not performed to investigate this intriguing data.85

1.4.3 DNA repair
Malfunctions in DNA repair and genomic instability are hallmarks of cancer.
BAF180 has a multitude of roles in double-strand break repair66 (via non-homologous
end joining and homologous recombination) and post-replication repair.43 In addition,
BAF180 was found to be important for maintaining genomic stability and preventing
aneuploidy.88

1.4.3.1 Genomic Instability
In mice, genomic instability was shown to be caused by a lack of cohesion
between the centromeres of chromosomes. This lack of cohesion can also lead to
aneuploidy, where a cell contains an abnormal number of chromosomes. When BAF180
was depleted in mouse embryonic stem cells, the distance between centromeres
increased, suggesting less cohesion between them. This appears to be exclusive to
centromeres, as the distances between telomeres and chromosomal arms showed no
significant change. To determine the route by which BAF180 affects the centromeric
cohesion in chromosomes, levels of other cohesion genes were tested in BAF18049

deficient cells. It was found that the levels of the cohesion genes were normal, indicating
that BAF180 did not affect the transcription of these genes.88
Cancer-associated mutants of BAF180 were unable to restore cohesion to
BAF180-depleted cells or reduce the cell’s sensitivity to DMSO-induced DNA damage.
Three different point mutations were introduced in Rsc2, a homolog of BAF180: Rsc2H458P (which corresponds to H1205P in BAF180 isoform 9, located in second BAH
domain); Rsc2-T67P (corresponding to T232P in BAF180, brd2); Rsc2-M280I
(corresponding to M523I in BAF180, brd4). Yeast cells lacking Rsc2 are temperature
sensitive and are sensitive to DMSO-induced DNA damage. Mutant Rsc2-H458P showed
patterns of sensitivity similar to Rsc2 KO cells, but mutants Rsc2-T67P and Rsc2-M280I
showed reduced sensitivity, indicating that these mutants were able to partially restore
normal function. None of the mutants were able to restore cohesion between
centromeres.88
Insufficient cohesion between centromeres can have several repercussions,
including mis-segregation of chromosomes, formation of micronuclei, and lagging
chromosomes. Mis-segregation of chromosomes during mitosis results in acentric
chromosomes, chromosomes which lack a centromere.89 Because they lack a centromere,
they cannot attach to the spindle during mitosis and as such are lost during replication.90
An acentric chromosome that has become enclosed by a nuclear membrane is called a
micronuclei;90 micronuclei are commonly seen in cells with defective cohesion. Lagging
chromosomes are another common characteristic of centromeric cohesion. Lagging
chromosomes are chromosomes that are left near the spindle equator after anaphase (due
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to improper segregation), while other chromosomes move toward the spindle poles.
These can also become micronuclei.91-92 Both acentric chromosomes and lagging
chromosomes can cause aneuploidy in a cell,93 wherein the individual cell has a different
number of chromosomes than a wild type cell. Aneuploidy, micronuclei, and lagging
chromosomes were each identified in BAF180 deficient cells.88
Loss of cohesion negatively impacts recombination-based DNA repair. Therefore,
loss of cohesion and chromosomal instability may be two ways in which BAF180 helps
prevent tumorigenesis. When BAF180 is depleted from a cell, cohesion between
centromeres greatly decreases, and as a result, chromosomal instability increases.88 This
lack of cohesion and increase in chromosomal instability suggests that BAF180 may have
a role in homologous recombination (HR), as other proteins, such as BRCA1, have dual
roles in cohesion and HR.63

1.4.3.2 DNA Double-Strand Break Repair
BAF180 also plays a role in double-strand break (DSB) repair by silencing
transcription near the break sites. When transcription is not silenced, DSB repair is
delayed; since most irradiation-induced DSBs are repaired rapidly,66 this delay can lead
to chromosomal translocations, as well as deletions.52 PBAF was found to silence
transcription around DNA breaks. When BAF180 was depleted in reporter cells,
transcription of the reporter gene (they used yellow fluorescent protein) was not silenced,
suggesting that BAF180 is needed to silence transcription around DNA breaks. If
transcription isn’t repressed, rapid DSB repair is impaired.66 Additionally, when
BAF180-depleted cells were exposed to irradiation, the non-homologous end joining
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(NHEJ) DNA repair pathway, a key mechanism by which DSBs are repaired,66 was
compromised.94
By treating siBAF180 cells with DRB (5,6-Dichlorobenzimidazole 1-β-Dribofuranoside), a transcription inhibitor, Kakarougkas et al. determined that the role of
BAF180 in DSB repair is dependent on active transcription. In siBAF180 cells, DNA
damage levels were high at 20 minutes post-IR, as indicated by a high number of
γH2AX; when BAF180 was re-introduced, levels of γH2AX were similar to control
cells.94 γH2AX is used as a biomarker to measure the quantity of DNA double-stranded
breaks.95 Wherever double-stranded breaks form, H2AX is immediately phosphorylated,
becoming γH2AX; therefore, the presence of γH2AX can be used to determine the extent
of double-stranded breaks in a 1:1 ratio.95 The phosphorylation of γH2AX is the first step
in recruiting DNA repair proteins.95 When siBAF180 cells (which were unable to stop
transcription) were treated with DRB (which stops transcription), the DNA damage levels
decreased to around that of the control cells, indicating that stopping transcription
restored DNA damage repair function. This means that when transcription is stopped,
BAF180 is not needed for double strand break repair.94
A protein’s function can be influenced by the presence of PTMs. S963 (number
corresponding to isoform 8 of BAF180) was found to be phosphorylated by ATM (ataxia
telangiectasia mutated).96 ATM is a kinase that is critical for DSB repair.96 This
phosphorylation site is located between the sixth brd and the first BAH domain. Two
mutant constructs (a phosphomutant S963A and a phosphomimic S963E) were created by
Kakarougkas et al. to determine if phosphorylation was critical to BAF180’s role in DSB
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repair. When the phosphomutant was added to siBAF180 cells, no significant change was
seen, indicating that the phosphomutant did not help DNA repair, meaning that
phosphorylation is important to BAF180’s role in DNA DSB repair. When the
phosphomimic was added, levels of damaged DNA were similar to control cells,
indicating that proper DNA repair function was restored. This suggests that
phosphorylation of BAF180 at S963 is a crucial step in DSB repair.94
Some of the tumor suppressor properties of BAF180 may be related to its
functions in DNA repair. Cancer-associated mutations were unable to restore normal
DSB repair function in BAF180 KO cells,94 suggesting that cancer cells with mutations in
BAF180 have a dysfunction in mediating DSB repair. Mutations which eliminated the
phosphorylation site S963 were also unable to restore normal DSB repair functioning.94

1.4.3.3 Ubiquitination of PCNA
The BAH domains of BAF180 are required to ubiquitinate PCNA (proliferating
cell nuclear antigen).43 PCNA regulates replication past sites of DNA damage and its
ubiquitination is a necessary step in re-priming past damaged DNA forks during postreplication repair (PRR).97
When BAF180 was depleted, cells were unable to produce the proper levels of
ubiquitinated PCNA, which leads to an inability to replicate past DNA lesions.98 After
UV-irradiation, BAF180-depleted cells had far lower levels of chromatin-bound PCNA
(both ubiquitinated and non-ubiquitinated) and decreased levels of Rad18, the E3 ligase
that ubiquitinates PCNA, when compared to control cells (where BAF180 was present at
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normal levels). It has been reported that BAF180 does play a role in regulating the cell
cycle,99 therefore experiments were conducted to determine if the reduced levels of
chromatin-bound PCNA were an indirect consequence of BAF180 impacting the cell
cycle. Ubiquitination of PCNA and its binding to chromatin occurs during the S-phase;
post-IR, the proportion of cells in S-phase actually increased, indicating that the lower
levels of chromatin-bound PCNA and Rad18 are not an indirect consequence of cell
cycle changes occurring upon depletion of BAF180.98 This suggests that BAF180 is
directly responsible for the observed changes in chromatin-bound PCNA and Rad18, and
therefore indirectly responsible for the decreased ubiquitination levels. The BAF180
orthologue Rsc2 was found to be located near replication forks,98 strongly suggesting that
BAF180 may be as well.
Additionally, PCNA remained ubiquitinated longer in flag-BAF180 FL cells than
in control cells during S-phase;43 there was very little ubiquitinated PCNA detected in G1
and G2 phase cells. Interestingly, the levels of BAF180 were highest in S-phase cells,43
suggesting that the S-phase specific function of BAF180 (i.e. ubiquitination of PCNA)
requires higher levels of BAF180 than other phases, which has interesting implications
since PBAF (and hence BAF180) is involved in transcription and has not been found to
be limited to one phase of the cell cycle. It would be interesting to perform FACS
(fluorescence-activated cell sorting) analysis on several components of the PBAF and
BAF complexes to see how the protein levels change throughout the different phases of
the cell cycle.
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To determine which domain(s) of BAF180 are involved in PCNA ubiquitination,
Niimi et al. created flag-tagged constructs of the different domains (bromodomains, the
BAH domains, and the HMG domain). They found that levels of ubiquitinated PCNA
between full-length flag-tagged BAF180 and flag-BAHs were similar; cells with the flagbrds and flag-HMG constructs were unable to ubiquitinate PCNA, which suggests that
the BAH domains are required for PCNA ubiquitination and that the other domains of
BAF180 are not necessary. Additionally, BAF180 did not need to be in complex with
PBAF in order for the BAH domains to facilitate ubiquitination.43

1.4.3.4 DNA Repair Conclusion
The tumor suppressor properties of BAF180 might stem from its roles in various
DNA repair mechanisms, as discussed above. Cancer cells with a mutation in or
decreased expression of BAF180 could be compromised with regards to DNA repair in
four ways:
(1) Genomic instability: An increased distance between centromeres leads to an
increase in genomic instability, which may in turn prevent recombinatorial-based
DNA repair mechanisms.88
(2) Inability to ubiquitinate PCNA: Ubiquitination of PCNA is a key step in the
post-replication repair pathway. The BAH domains of BAF180 are required for
proper ubiquitination levels. Lack of the BAH domains likely leaves much of the
DNA unrepaired.43,98
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(3) Silencing of transcription at DNA double-strand breaks: At sites of active
transcription near DNA DSBs, BAF180 is needed for the proper repair of these
breaks. BAF180 silences transcription at sites of DSBs, allowing for the rapid repair
of damaged DNA.94
(4) HMG box and NHEJ: As mentioned in an above section (Section 1.3.3), an
HMG-box binds to DNA and facilitates NHEJ by bending the ends of the DNA.
Assuming this domain is the DNA-binding component of BAF180, deletion of this
box likely hinders NHEJ (and transcription) because BAF180 can no longer bind to
DNA. Many cancer mutants lack the HMG box.44,52

1.4.4 p21 and the Cell Cycle
BAF180 has been shown to influence the cell cycle progression in many types of
cells. Evidence has demonstrated that the loss of BAF180 caused cells to replicate and
grow faster than control cells (see Section 1.5.2 on ccRCC). Reintroduction of BAF180
into these cells reduced cell proliferation and induced G1100 and G299 arrest, showing a
direct link between BAF180 and cell cycle progression. The role of BAF180 in G1 cell
cycle arrest is due, at least in part, to its regulation of p21 expression. In the absence of
BAF180, the mRNA levels of p21 decreased, resulting in fewer cells in G1 arrest.100 p21,
also known as cyclin-dependent kinase inhibitor 1, is used by cells to enter G1 and G2
phase arrest.39 Flow cytometry and subsequent cell cycle analysis revealed that, upon reintroduction of BAF180, more cells were entering G1 arrest than control cells which
lacked BAF180.100 BAF180 has also been found to be critical for cellular senescence.101

56

Treatment with nutlin-3, which is used to induce p53-dependent transcription,101103

usually leads to a substantial increase in p21 levels; however, when BAF180 was

knocked down, the levels of p53-induced p21 were significantly lower.101 Chromatin
immunoprecipitation experiments demonstrated that BAF180 regulates the expression of
p21 directly by binding to its promoter in vivo.100
Cellular damaging agents, such as TGF-β and γ-irradiation, have been shown to
up-regulate p21 expression, causing subsequent entry of the cell into G1 or G2 arrest,
respectively (Figure 1.17). Their effect on up-regulation of p21 was diminished in
BAF180-deficient cells. Interestingly, while the up-regulation of p21 was similarly
diminished in both TGF-β and γ-irradiation treated cells, there was no effect on G2 arrest
(Figure 1.17),100 indicating that BAF180’s role in G2 arrest may be through another
pathway.99 The role in p21 expression is believed to be part of the mechanism by which
BAF180 influences the cell cycle. When BAF180 is mutated, it cannot bind to the p21
promoter and therefore G1 cell cycle arrest is prevented. Interestingly, a recent study by
Chowdhury et al. showed that changes in BAF180 expression did not affect p21 levels in
ccRCC cell lines A704 or 786-O.68 Xia et al.’s study was performed in breast cancer
cells100 and Burrows et al., whose data supports that of Xia et al., performed their analysis
in human fibroblasts and mammary cells.101 It is plausible that the effect of BAF180 on
p21 is tissue specific.
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Figure 1.17: Diagram of the role of BAF180 in p21 expression and cell cycle arrest. (A) When a cell is
deficient in BAF180, through mutation or knockdown, there is deregulation of the cell cycle, resulting in a
high rate of cell proliferation. Additionally, less p21 is produced, as BAF180 is required for its
transcription. (B) and (C) Flow chart showing how different treatments, TGF-β and γ-irradiation, affect the
cell cycle. In normal cells, upon treatment, there is an increase in p21 expression, resulting in G1 and G2
phase arrest, respectively. In BAF180-deficient cells that are treated with TGF-β, there is less p21 and no
G1 phase arrest. But if a cell is exposed to γ-irradiation, G2 arrest can still occur, though there is less
p21.100

Expression of p21 is regulated primarily by p53;104 however, p21 is also known to
be regulated by the retinoic acid (RA) pathway in a manner independent of p53.101,105
BAF180 binds to the promoters of CRABPII and RARβ2, both key components of the
RA pathway; when there is less BAF180, there is less CRABPII and RARβ2.78 So
BAF180 could affect p21 in an indirect manner by affecting the retinoic acid pathway.
Additionally, BAF180 is known to bind to the p21 promoter, thereby affecting p21
transcription directly.100 So BAF180 may influence p21 transcription in an indirect and
direct manner (Figure 1.18).
In bladder cancer cells, PBRM1 was found to be required for G2 phase cell cycle
arrest by inhibiting the expression of cyclin-B1.99 This does not contradict the results that
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Xia et al. published, as they did not examine cyclin-B1; they focused solely on p21 and
p53.
Retinoic acid pathway

p53

G2 arrest

p21 expression

G1 arrest

Decrease p21
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acid, inducing transcription

Binds to promoter
CRABPII brings
retinoic acid to nucleus
Mutations

Decreasing BAF180
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CRABBPII and RARβ2
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Figure 1.18: Plausible overall pathway for the regulation of p21 expression by BAF180 and p53.74,78,100-101
For clarity, different colored arrows have been used to denote the different consequences. Blue arrows
demonstrate the consequences of BAF180 mutations, while green arrows show the consequences of
decreasing the amount of BAF180 in the cell.

Additionally, BAF180 was found to be required for replication senescence,101 a
state different from cell cycle arrest (temporary); in senescence, cell growth is
permanently stopped.106 Once again, the role of BAF180 in senescence is related to its
role in regulating the expression of some p53-controlled genes.101

1.4.5 p53 Induced Degradation of BAF180
BAF180 levels have been shown to be reduced upon activation of p53 by nutlin3.102 This activation of p53 led to a decrease in BAF180 protein levels. The reduction of
BAF180 levels was demonstrated to be at the protein level, as RT-PCR revealed little
change in the mRNA levels. Experiments showed that proteasomes were responsible for
the degradation of BAF180, as the treatment of cells with proteasome inhibitors reduced
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the level of degradation (i.e. more BAF180 remained). Further experimentation
determined that an E1 ubiquitin ligase is responsible. Therefore, BAF180 degradation is
controlled by a p53-dependent ubiquitin related pathway.102 Connecting this to section
1.4.4 on p21, the reduction of BAF180 by a p53-dependent pathway leads to a decrease
in p21 expression and a loss of G1 phase cell cycle arrest (Figure 1.18).

1.4.6 Psychiatric Disorders
Medications for schizophrenia and bipolar disorder have targeted the same gene
for more than 60 years. These treatments are only effective for a small proportion of
patients.107 In recent years, the lack of effective treatment options has led to numerous
genome-wide association studies. Several of these studies identified PBRM1 as a
significant risk locus for schizophrenia, bipolar disorder, major depressive disorder, and
psychosis.107-117 A study by McMahon et al. discovered that PBRM1 is overexpressed in
the prefrontal cortex of people with bipolar disorder.113 Unfortunately, the clinical impact
of these discoveries remains undetermined.

1.4.7 HIV and Tat protein
During an HIV infection, the Tat protein promotes HIV virus replication and
controls transcription occurring at the LTR promoter (long terminal repeat: a type of
retroviral promoter).21,53,118-119 At the LTR, PBAF is recruited by the Tat protein,
rearranging nucleosomes to promote transcription.120 BAF180 interacts with the Tat
protein through acetylation sites at K50/K51, resulting in suppression of Tat protein
expression.121-122 BAF180 association with Tat was increased in the presence of p300, as
shown in co-immunoprecipitation of BAF180 and Tat.
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1.5. Cancers
Since Varela et al. published that PBRM1 is mutated in ~40% of clear cell renal
cell carcinoma cases,1 the number of studies relating PBRM1 mutations to cancers has
exponentially increased. PBRM1 is now linked to more than 30 types of cancers (Table
1.5).123-125 Mutations of every type (frameshift, substitution (synonymous and missense),
and truncation) have been identified, though truncation mutations (presence of a
premature stop codon) are the most frequent (Figure 1.19).123-125 Mutations have been
seen to affect all nine domains, though mutations are also found between domains. Figure
1.20 displays the domain organization of wild-type BAF180 (A) and several mutants seen
in cancers (B). It has been speculated that cancer-associated mutations of BAF180 may
impair the ability of the PBAF complex to bind to nucleosomes, as BAF180 is believed to
be the histone targeting component. Each of the six bromodomains of BAF180 are
capable of binding to acetylated lysines present on histones, though it is unknown
whether this occurs singularly or in tandem. Deletion of any of the bromodomains would
affect the ability of BAF180 to bind histones, either by weakening the binding
interactions or eliminating them completely (depending on the severity of the truncation).
The inability of BAF180 to bind precludes the other subunits of the PBAF complex from
being recruited; therefore, PBAF-mediated transcription cannot occur.
Discussed in upcoming sections are some of the cancers for which specific studies
on PBRM1 (BAF180) have been conducted. Most of the studies published have noted
that PBRM1 was mutated, but they did not explore further. Therefore, an overall
discussion of BAF180 in cancers is not possible.
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Table 1.5: The frequency of PBRM1 alterations in different types of cancers. PBRM1, the gene for
BAF180, has been found to be mutated in more than 30 types of cancers. Data was collected from
cBioPortal.123-124

Cancer
Frequency of alterations in PBRM1
Clear cell renal cell carcinoma
(ccRCC)
39%
Neuroendocrine Prostate Carcinoma
24%
Cholangiocarcinoma
18-23%
Cutaneous Squamous Cell Carcinoma
10%
Breast Cancer
2-14%
Bladder Cancer
2-10%
Uterine Carcinomas
4-9%
Stomach Adenocarcinoma
3-8%
Diffuse Large B-Cell Lymphoma
3-8%
Esophageal Carcinoma
2-8%
Pancreatic Carcinomas
1-7%
Prostate Adenocarcinoma
1-7%
Lung Carcinoma
2-6%
Melanomas
1-6%
Mesothelioma
5%
Papillary RCC
4%
Colorectal Adenocarcinoma
3-4%
Head and Neck Carcinoma
2-4%
Thymic Carcinomas
2-4%
Hepatocellular Carcinoma
1-4%
Thyroid Carcinomas
3%
non ccRCC
3%
Gallbladder Carcinoma
3%
Cervical Squamous Cell Carcinoma
3%
Sarcoma
1-3%
Adenoid Cystic Carcinoma
2%
Ovarian Carcinoma
2%
Neuroblastoma
2%
Chromophobe Renal Cell Carcinoma
2%
Gliomas
1-2%
Adrenocortical Carcinoma
1%
Chronic Lymphocytic Leukemia
1%
Pediatric Ewing Sarcoma
1%
Multiple Myeloma
1%
62

BAF180 MUTATION TYPES
Unclassifiable
12%
Substitution - Stop codon
20%
Complex Frameshift
1%

Deletion Frameshift
24%

Substitution - Different amino
acid
25%

Deletion In Frame
2%
Insertion Frameshift
7%

Substitution - Same amino acid
9%

Figure 1.19: Chart of the frequency of different types of mutations of PBRM1 (BAF180) in cancers. Data
was collected from COSMIC database.125

A.

BAF180:

B.

ccRCC_1:

Brd1

Brd2

Brd3

Brd4

Brd5

Brd6

BAH1

BAH2

HMG

ccRCC_2:
ccRCC_3:
Breast Cancer:
Lung Cancer:
Ovarian Cancer:
Pancreatic Cancer:

Figure 1.20: (A) The domain organization of wild-type BAF180 and (B) various truncated mutant proteins
observed in cancers.
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1.5.1 Cell Proliferation
The effect of BAF180 on cell proliferation appear to be cell line specific. In some
cases, knockdown of BAF180 resulted in increased proliferation1,68-69,99-100,126 while in
others, knockdown resulted in decreased proliferation68,127 or no effect1,68-69 (Table 1.6).
Similarly, re-expression of BAF180 into BAF180-deficient cell lines showed either
decreased proliferation68-69,99-100,126-127 or no had effect on proliferation68 (Table 1.7). For
example, Varela et al., Gao et al., and Xiao et al. demonstrated that knockdown of
BAF180 results in increased proliferation in cell line 786-O,1,68,126 but Murakami et al.
reported that BAF180 knockdown decreased proliferation in this cell line,127 suggesting
that more studies need to be conducted in order for any true conclusions to be drawn.
Interestingly, Gao et al. found that in some cell lines, for re-expression or
knockdown of BAF180 to have an effect on cell proliferation, the cells needed to have
BRG1, the ATPase subunit of the PBAF complex.68 Murakami et al. found that cells
needed HIF1α in order for BAF180 to have a tumor-suppressor effect127 though Gao et al.
did not find any correlation to levels of HIF factors.68
Gao et al. demonstrated that a tumor-associated BAF180 mutation (missing the
HMG-box and C-terminus) was not able to suppress proliferation in A704 cells (kidney
adenocarcinoma cells), but was able to suppress growth in Caki2 cells (clear cell renal
cell carcinoma cells). They also showed that a mutant lacking the first two bromodomains
was able to reduce proliferation, though a mutant lacking all six bromodomains was not
able to.68 Along that line, a recently published study by Porter and Dykhuizen
demonstrated that single point mutations in BAF180 were able to abrogate its tumor64

suppressive effects. Mutations in the first, second, fourth, and fifth bromodomain were
unable to reduce proliferation in Caki2 cells, though wild type BAF180 could (Section
1.3.1.2).23
Table 1.6: Differing results on the effect of BAF180 knockdown on cell proliferation. The origin of the cell
lines are as follows: bladder carcinoma: UM-UC-3; renal cell carcinoma: ACHN, 786-O, SN12C, TK10,
UMRC2, KC-10, 769-P, RCC10, A498, A704; Clear cell renal cell carcinoma: Caki1

Effects of BAF180 Knockout on Cell Lines
Knockdown BAF180, increased proliferation
Author

Cell line +/- for
KD method
BAF180
transfection, injection into
+
mice

Huang99

Cell Line
Mice in vivo injection of UMUC-3

Varela1

ACHN

+

siRNA

Varela1

786-O

+

siRNA

Varela1

SN12C

+

siRNA

Varela1

TK10

+

Gao68

Mice in vivo implant of 786-O

+

siRNA
lentiviral, implant into
mice

Xiao126

ACHN

+

miRNA targeting PBRM1

Xiao126

786-O

+

miRNA targeting PBRM1

Knockdown BAF180, decrease proliferation
Gao68

UMRC2

+

shRNA

Murakami127 786-O

+

shRNA

Murakami127 KC-12

+

shRNA

Murakami127 769-P

+

shRNA

Murakami127 RCC10

+

shRNA

Murakami127 A498

+

shRNA
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Knockdown BAF180, no effect on proliferation
Author
Gao68
Gao68
Chowdhury69
Chowdhury69
Varela1

Cell line +/- for
BAF180
+
+
+
+
-

Cell Line
786-O (ex vivo)
SN12C
Caki1
A498
A704

KD method
shRNA

lentiviral
siRNA

Table 1.7: Differing results of the effect of BAF180 re-expression on cellular proliferation. The origin of
the cell lines are as follows: bladder carcinoma: UM-UC-3, 5637; renal cell carcinoma: ACHN, 786-O,
A704, SKRC20, SLR24; Clear cell renal cell carcinoma: Caki2, RCC4; breast cancer: HCC1143;
endometrial adenocarcinoma: EJ.

Effects of Reintroduction of BAF180 into Cell Lines
Re-express BAF180, decrease proliferation
Author
Xia100
Gao68
Gao68
Chowdhury69
Chowdhury69
Huang99
Huang99
Huang99
Xiao126
Xiao126

Cell Line
HCC1143
A704
Caki2
A704
Caki2
UM-UC-3
EJ
5637
ACHN
786-O

Cell line +/- for
BAF180
+
+
+
+
+

Method
Transfection
Lentiviral
Lentiviral
Lentiviral
Lentiviral
Up-regulation
Up-regulation
Up-regulation
miRNA targeting PBRM1
miRNA targeting PBRM1

Re-express BAF180, no effect on proliferation
Gao68
Gao68
Gao68

SKRC20
SLR24
RCC4

-
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Lentiviral
Lentiviral
Lentiviral

It should be noted that Varela,1 Gao,68 Xiao,126 Chowdhury,69 and Murakami127
performed their studies in renal cells, while Xia100 and Burrows101 used mammary cells,
Burrows101 used fibroblasts, and Huang used bladder cells.99 The discrepancies in
BAF180’s tumor suppressor capabilities between different cell lines should be a focus of
future studies; experiments in all these cell lines using a singular technique performed by
the same lab would go a long way towards addressing this disagreement. The reasons
behind the different proliferation responses of cell lines to BAF180 is still unknown,
though Gao et al. presents several plausible explanations.68

1.5.2 Clear Cell Renal Cell Carcinoma
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell
carcinoma (~92% of cases).128-129 Of these, ~40% of cases carry a mutation in the
PBRM1 gene,1 though mutations of PBRM1 are rarely found in other types of renal
carcinomas.130 This makes it the second most commonly mutated gene in ccRCC, after
VHL (mutated in 75-80% of cases).131-132
In cancer, there are “driver” and “passenger” mutations. A “driver” mutation is
considered to promote tumorigenesis, whereas a “passenger” mutation does not
contribute to cancer development.133-138 Additionally, a “driver” gene is one in which
mutations occur at a rate higher than expected by chance alone.131 Loss of PBRM1 is
considered to be a driver event in ccRCC.128,131,139
Interestingly, in ~90% of ccRCC cases, the 3p arm of one copy of chromosome 3
is deleted, which encompasses four tumor suppressor genes: VHL, PBRM1, SETD2, and
67

BAP1.128,131-132,139-143 This deletion results in loss of heterozygosity. Knudson’s
hypothesis proposes that for tumor suppressor genes, “two hits” are required to bring
about cancer. In this case, the “first hit” would be loss of heterozygosity (LOH). The
“second hit” is the mutation of the remaining copy of the gene; this mutation may result
in the production of a protein which has lost its function or is only partially functional, or
result in loss of protein expression altogether.23,68-69,131,144 PBRM1, as a tumor suppressor
gene, follows this “two hit” approach.139

1.5.2.1 Mutations in BAF180
Mutations in the PBRM1 gene are found in approximately 40% of ccRCC
tumors.1 Of these, approximately 82% of them are truncating mutations,145 either by
frameshifts or nonsense mutations. Interestingly, mutations in BAF180 are mutually
exclusive with mutations of BAP1 (BRCA1-associated protein 1), a nuclear
deubiquitinase protein.139-140,144,146-148 Most mutations are thought to be destabilizing,
resulting in no protein expression. Some mutations might be expressed but are predicted
to have detrimental functional effects.131,140,144-145,149
In one study by Pena-Llopis, 53% of samples tested were negative for PBRM1. Of
these, 90% had a mutation in the gene. In the 47% of samples that were positive for
PBRM1, 90% had wild-type BAF180/PBRM1.144 It should be noted that the researchers
used an antibody recognizing an epitope on the C-terminus, which is often absent in
BAF180 mutant proteins.144 Actually, most publications use the same antibody from
Bethyl Labs (Bethyl A301-591A), which recognizes an epitope at the C-terminus. It is
possible that the antibody fails to recognize the mutant proteins, as the C-terminus is
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often missing from the mutant BAF180 proteins. A study by da Costa et al. used an
antibody that recognized an epitope on the N-terminus of BAF180 (Sigma-Aldrich
HPA015629) and showed that in 112 immunostained ccRCC samples, 34 (30.4%)
showed negative expression and 78 (69.6%) showed positive expression of BAF180.150
More experiments need to be conducted using both N- and C-terminus recognizing
antibodies on the same samples. Nonsense-mediated mRNA decay likely prevents most
truncated proteins from being expressed, though it is possible that some escape this
cellular checkpoint.
Silencing of the PBRM1 promoter via hypermethylation has also been proposed
as a possible mechanism for PBRM1 inactivation.145 Promoter hypermethylation of
tumor-suppressor genes is commonly observed in cancer.151 However, Ibragimova and
colleagues found that hypermethylation of BAF180 is actually a rare event in ccRCC, as
is the hypermethylation of BAP1, SETD2, and some other chromatin modifying genes.
The authors point out this is not unusual, as some tumor-suppressor proteins commonly
have promoter hypermethylation, while other do not. They propose that the deletion of
the 3p21 region (which affects four tumor-suppressor genes) is more favorable to
oncogenesis than the inactivation of one gene by hypermethylation.151 Some
consequences of the frequent mutations of BAF180 in ccRCC are discussed in other
sections (Sections 1.4.1 and 1.5.2).

1.5.2.2 Gene Expression Signature in BAF180¯ ccRCC Cells
The gene expression profile of BAF180-deficient cells is substantially different
from that of BAF180-proficient cells. Many of the genes differentially expressed upon
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BAF180 re-expression are involved in cell adhesion, cell proliferation, chromosomal
instability, and hypoxia response.69,139,149
Most of the genes affected by loss of BAF180 were down-regulated (1910/2235
genes in Kapur et al.139 and 485/613 genes in Wang et al.)149 Both groups looked at gene
expression in clear cell renal cell carcinoma (ccRCC) cases, where VHL, PBRM1, BAP1,
SETD2, PTEN, and KDM5C are known “driver” genes (see Section 1.5.2). The
significant differences in the number of genes affected may be because Wang et al.
selected samples that had only PBRM1 mutations (no VHL, BAP1, SETD2, PTEN, and
KDM5C mutations),149 while Kapur et al. did not report any such selection criteria.139
Additionally, Wang et al. investigated methylation of CpG sites in the genome and found
that, of the 1405 differently methylated sites, 1229 were hyper-methylated, which would
result in gene silencing. They do point out, though, that not all of the genes may be
directly regulated by PBRM1. The Wang study also investigated effects in miRNA
expression; again, most of the affected miRNAs were down-regulated.149
Re-expression of BAF180 into Caki2 cells led to the up-regulation of genes
involved in cell adhesion and actin cytoskeleton.69 This is in agreement with Wang et al.
and Kapur et al., who reported that BAF180-deficient cells had down-regulation of the
same genes, as compared to control samples.139,149 This is also in accordance with
phenomenological data demonstrating that knockdown of BAF180 results in increased
cell migration.1 Re-expression of BAF180 also resulted in the up-regulation of apoptotic
processes, carbohydrate metabolic processes and response to hypoxia genes. Downregulation of genes involved in the cell cycle was observed in the same cells.69
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BAF180-deficient cells have been noted as having a hypoxia signature1,69
meaning the genes that are expressed when a cell is hypoxic are expressed when a cell is
normoxic (i.e. normal oxygen levels) if BAF180 is absent. Gao et al. found that reexpressing BAF180 resulted in decreased expression of HIF-target genes (hypoxia
inducible factor),68 though it had no effect on HIF1α and HIF2α themselves. Chowdhury
et al. found that re-expressing BAF180 increased the expression of HIF-target genes.69
Also, Murakami et al. found that knockdown of BAF180 in hepatitis B cells and ccRCC
cells resulted in down-regulation of HIF-target genes,127 correlating with data from
Chowdhury et al.69

1.5.2.3 Clinical Significance of BAF180 Mutations
Multiple groups have attempted to correlate the presence of BAF180 mutations to
clinical relevance. However, the studies provide conflicting data with regards to
correlation between BAF180 mutations and tumor size, differentiation, and patient
prognosis.128,131-132,139,145,147-148,150,152-153 It is generally accepted that patients with
mutations in BAP1 have a worse prognosis than patients with a mutation in BAF180.131132,139,147,153

Additionally, it has been proposed that BAF180 be used as a biomarker, but

more investigations need to be conducted before that can happen.68,139,142,145,148,154-155

1.5.3 Epithelioid Sarcoma
Epithelioid sarcoma is a rare sarcoma that occurs in the soft tissue of the
extremities (referred to as “conventional type”), most often in young adults.156-158 It has a
high metastatic rate. A second type of epithelioid sarcoma, referred to as “proximaltype”, occurs in the pelvic area.156-158 Loss of PBRM1 expression was found 82.6% of
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epithelioid sarcoma cases. It should be noted, though, that the sample size was relatively
small (23 cases), so this percentage may be artificially high. There was no difference in
PBRM1 expression between the two locations of epithelioid sarcoma (conventional and
proximal) nor between the three types of tumors (spindle, epithelioid, rhaboid); loss was
observed in all of them. The researchers did not notice a correlation between PBRM1
expression and cellular morphology, nor did there appear to be a correlation between
PBRM1 and prognosis. However, there was a correlation between PBRM1 mutations and
mutations in INI1 (a core subunit of SWI/SNF), which frequently occurred together.156

1.5.4 Bladder Carcinoma
In bladder cancer, PBRM1 acts as a tumor suppressor by repressing gene
expression of cyclin B1, a cell cycle checkpoint protein.99 Huang et al. found that mRNA
and protein levels of PBRM1 were significantly lower in bladder cancer cells than in
normal cells. Additionally, lower levels of PBRM1 were associated with poor patient
survival rates in bladder cancer.99,150 Cancer cell proliferation, migration, and tumor sizes
all increased when expression levels of PBRM1 were reduced. As proposed in other
studies, PBRM1 may prove to be an effective biomarker of tumor grade. Overall, PBRM1
is mutated in 2-10% of bladder cancers.123-125

1.5.5. Breast Carcinoma
Several studies have analyzed potential mutations and expression levels in breast
cancer. Pereira et al. found that, in ER- (estrogen receptor negative) tissues, 25% of the
samples had PBRM1 mutations and most of these resulted in loss of heterozygosity
(LOH).159 More in-depth examination of PBRM1 mutations was performed by Xia et al.
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Duplications in various exons (as revealed by PCR analysis) were common and 25 of the
52 tumor samples had LOH for BAF180. Further analysis revealed that BAF180 plays a
role in the regulation of p21 expression and induces G1 arrest upon reintroduction into
BAF180-deficient breast cancer cell lines.100 Real time PCR and western blotting have
demonstrated that breast cancer tumor samples and cell lines have reduced expression of
the BAF180 protein, as compared to paired normal tissues.51,160 Additionally, low
BAF180 expression had a strong correlation with higher tumor stage and worse survival
prognosis.160

1.5.6 Malignant Mesothelioma
PBRM1 has been found to be deleted in several cases of malignant mesothelioma
(MM). Loss of chromosome 3p21 is common in epithelial MM, resulting in the deletion
of nine genes. This region includes PBRM1 (BAF180) as it is located at 3p21.1.
Interestingly, this deletion also encompasses BAP1, which is sometimes deleted in
ccRCC. Mutations in these chromatin modifiers are mutually exclusive in ccRCC, though
that does not appear to be the case in MM.161 PBRM1 was found to be deleted in both
types of MM (pleural and peritoneal), though the losses were more common in pleural
MM.162-163 Two point mutations in PBRM1 were found161 and determined to be
hemizygous mutations, because there was deletion of the other copy of the gene.164
Monoallelic gene loss was observed in 12/33 cases (36%) and biallelic deletion in 3/33
cases (9%).164 They also confirmed that depletion of BAF180 caused increased
proliferation in a malignant mesothelioma cell line.164 cBioPortal reports deletion of
PBRM1 gene in a frequency of 5% in patients with pleural MM.123-124
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1.5.7 Cancers of the Biliary Tract
Cancers of the biliary tract include intrahepatic (ducts within the liver) and
extrahepatic (ducts outside the liver) cholangiocarcinomas and gallbladder carcinoma.
Like in different types of renal carcinomas, the mutational frequency of PBRM1 differs
between biliary tract locations. PBRM1 seems to be most frequently mutated in
intrahepatic cholangiocarcinoma (ICC), ranging from 11-14% of samples.165-167 PBRM1,
ARID1A, BAP1, and SMARCB1 seem to be tied for third most mutated gene in ICC.167
PBRM1 has been suggested to be a driver mutation for ICC and patients had a worse
prognosis when PBRM1 was mutated.165-166 In extrahepatic cholangiocarcinomas, the
frequency was 3.5-5%.165,167 BAF180 is under-expressed in 53% of gallbladder
carcinomas.168

1.5.8 Lung Carcinoma
In evaluating EGFR/KRAS/ALK-negative lung adenocarcinoma tissue samples,
Ahn et al. found one nonsense mutation, E830* in PBRM1.169 EGFR, KRAS, and ALK
are driver mutations in lung cancer. In 2005, Sekine et al. analyzed non-small-cell and
small-cell lung cancer cell lines and did not unearth any mutations or abnormal
expression patterns. However, it should be noted that they used cancer cell lines and used
only RT-PCR and western blot to draw their conclusions.170 Izumchenko and colleagues
investigated mutations found in adenocarcinoma in situ (AIS) and minimally invasive
adenocarcinoma (MIA) and found PBRM1 to be mutated in one AIS patient’s samples.171
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Chapter 2 : Motive and Challenges
2.1 Motive
Ever since Varela et al. reported that PBRM1 is mutated in 41% of clear cell renal
cell carcinoma (ccRCC) cases,1 the human polybromo-1 protein (gene: PBRM1; protein:
BAF180) has garnered the attention of medical researchers. PBRM1 is the second most
mutated gene in ccRCC (the first being VHL), as well as a known driver mutation of that
cancer.2-3 It has been found to be mutated (at lower frequencies) in more than 35 other
cancers, such as cholangiocarcinomas,4 metastasizing pleomorphic adenomas,5
esophageal squamous cell carcinoma,6 and breast cancer.7-8 As of November 2016,
COSMIC (Catalogue of somatic mutations in cancer) has more than 1,100 unique
PBRM1 mutations in its database, many of which are nonsense mutations.9 Nonsense
mutations often result in the elimination one or more domains; in extreme cases, the
mutated PBRM1 may only code for 2 or 3 domains.1
The tumor suppressor properties of BAF180 likely stems from its many roles in
DNA repair. BAF180 is critical for proper centromeric cohesion10 (important during
recombinatorial repair) and silencing transcription at double-strand breaks.11 The BAH
domains of BAF180 have been found to be critical for proper ubiquitination of PCNA
during post-replication repair (PRR).12 The HMG box, though not well-studied in this
protein, likely promotes non-homologous end-joining (NHEJ) by its interactions with
DNA.13-15 Therefore, mutant BAF180 cancer cells could be compromised with regards to
DNA repair in four ways: the chromosomes are further apart and have less cohesion,
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which leads to genomic instability and prevents recombinatorial DNA repair; BAF180deficient cells cannot stop transcription at double-stranded breaks, thereby hindering
DSB repair; mutant BAF180 without BAH domains cannot ubiquitinate PCNA, which
obstructs most of the PRR pathway; and deletion of the HMG box likely hinders NHEJ
and transcription because BAF180 can no longer bind to DNA.
Phenomenological studies of BAF180 in mammalian cells have been conducted
and provide valuable information on “cause and effect” of BAF180 in a cell. On the other
end of the spectrum, several groups have expressed the bromodomains individually and
studied their interactions with acetylated peptides.16-21 But these studies do not provide
insight into the exact mechanisms/interactions of BAF180.
A critical gap in knowledge still exists between the two: how do the domains of
BAF180 work together to bind to the nucleosome and what changes result from the
binding of different domains? It has been shown that domains within the same protein
have the ability to work together to recognize multiple post-translational modification
(PTM) sites, thus increasing the binding affinity of the protein to the nucleosome.17,22-25
Therefore, it is logical to hypothesize that the domains of BAF180 might do the same
thing. The ability to study distinct interactions is crucial to increasing our understanding
of the role of BAF180 in cancer development and its progression. Only by studying the
mechanisms of full-length BAF180 can we begin to develop better treatment options for
cancer patients.
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2.2 Challenges
BAF180, the chromatin-remodeling subunit of the PBAF complex, is a
complicated protein with 1634 amino acids (isoform 2) and 9 domains: 6 bromodomains,
2 BAH (bromo-adjacent homology) domains, and 1 HMG (high mobility group) box
(Figure 2.1).
Signals for Ub of PCNA in PRR

Brd1

Brd2

Brd3

Brd4

Brd6

Brd5

Bind different acetylated lysine residues on histones

BAH1

BAH2

•

•

HMG

Promotes NHEJ by bending the
ends of the DNA so that they
have more energetically
favorable interactions
Influences transcription by
distorting the nucleosomal
complex

Figure 2.1: Diagram of the 9 domains of BAF180 with likely functions. Sizes of the domains and distances
between are approximately accurate for isoform 2 (Genbank: AAG48933.1). The overall size is 1634
amino acids.

Recombinant expression of full-length BAF180 has proven to be extremely
difficult and frustrating. There could be many reasons why this is so. First, it must be
recognized that BAF180 is a very large protein with 9 domains. Large, multidomain
proteins are inherently difficult to express in any heterologous system and have a higher
likelihood of folding improperly. Proteins are usually expressed by cloning and
expressing the individual domains separately. Secondly, it has numerous rare codons,
even compared to the overall usage of Homo sapiens. Third, its DNA can form multiple
complex secondary structures, making it difficult for PCR modification to occur. Fourth,
99

its DNA sequence has many base runs (A-tracts, etc.), thus increasing the probability that
polymerase might skip bases during PCR.

2.3 Conclusion
This is the first time full-length BAF180 has been successfully expressed and
purified in a heterologous host. The creation of recombinant BAF180 will enable
researchers to conduct detailed mechanistic studies of the precise binding interactions of
the entire protein. The ability to study distinct interactions is crucial to increasing the
understanding of the role of BAF180 in cancer development and its progression. In
studying the exact mechanisms by which BAF180 performs its many roles, scientists can
begin to develop better treatment options for cancer patients.
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Chapter 3 : Recombinant Expression of BAF180 in E. coli
Expression of heterologous proteins is a time-consuming and difficult task, as the
specific characteristics of the individual protein must be considered alongside the
characteristics of the expression system. Escherichia coli (E. coli) is the most commonly
used heterologous protein host, because it is cheap and easy.26-30 Additionally, the fast
cell growth of E. coli makes it an efficient factory for the production of large amounts of
recombinant protein; large quantities can often be produced in one day and the
recombinant protein can comprise up to 50% of the total cellular protein content.26
However, this fast production can be a disadvantage as well, especially when expressing
eukaryotic proteins. It can often result in misfolded, insoluble, and/or inactive proteins,
which are often sequestered in inclusion bodies.26,28 Proteins found in inclusion bodies
can be resolubilized and/or refolded after cell lysis, but this is a difficult process and is
not always successful. Furthermore, as is increasingly understood, the production of an
active protein does not depend solely on proper folding; often, a specific posttranslational modification (PTM) is required in order for a protein to be active. E. coli is
unable to perform post-translational modifications.
The successful expression of heterologous proteins in E. coli is often dependent
on the protein size and the presence of rare codons. Large proteins are more difficult to
express than smaller proteins, and often larger proteins form inclusion bodies.26 Another
problem is rare codons and codon bias. Codon bias is the preference for a particular
codon of an amino acid. These codon biases affect protein translation. For example,
translation of glutamine is highly biased in humans: 26.5% of codons for glutamine are
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CAA, whereas 73.5% are CAG. The codon usage is often different between hosts, as
demonstrated when comparing the codon usage for arginine between humans and E. coli
B strains. In humans, the AGA codon is used 21.5% of the time, but in E. coli it is only
used 5% of the time. The CGC codon is used 18% of the time in humans, but used 40%
of the time in E. coli. These so-called “rare codons” (such as those for arginine) can lead
to translational stalling, premature termination, frameshifts, and mis-incorporation of
amino acids.26-28
One of the most commonly used promoters for E. coli expression is the T7
promoter.26 T7 actually refers to the use of T7 RNA polymerase, which has transcription
rates five times higher than the native RNA polymerase (of E. coli).26,28 Cell strains
denoted with “DE3” have the T7 gene present in its genome. The T7 gene itself is
controlled by the lacUV5 promoter. When IPTG (isopropyl β-D-1-thiogalatopyranoside)
is added, the lacUV5 promoter is induced, resulting in expression of the T7 polymerase,
which in turn causes expression of the heterologous protein.26,28
The pET30a vector and Rosetta(DE3) cells were used for expression of BAF180
in E. coli. The pET30a vector from Novagen was chosen for expression of BAF180
because the pET30 vectors were readily available. The pET30 system of vectors possess
kanamycin resistance and a T7 promoter; thus, expression of the recombinant gene is
inducible by the addition of IPTG. For expression, the Rosetta(DE3) E. coli cell strain
was chosen. It is a derivative of BL21(DE3), which is deficient in lon and ompT
proteases and has the T7 gene on a chromosome. Rosetta possesses a plasmid with
chloramphenicol resistance, which codes for 7 rare tRNAs: AUA, AGG, AGA, CGG,
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CUA, CCC, and GGA.26,28 There are a few other cell strains that have the ability to make
some rare tRNAs, but Rosetta is capable of producing more rare tRNAs than other
strains. The BAF180 gene sequence contains a lot of rare codons, so it was reasoned that
expression in the Rosetta(DE3) strain would give the highest probability of success.

3.1 Materials
The BAF180 gene sequence (pBabepuroBAF180; isoform 2; Genbank:
AF177387.1) was a gift from Ramon Parson’s lab (Addgene #41078).7 EcoRI-HF (cat.
R3101), TriDye 1 kb ladder (cat. N3272), Instant Sticky-end Master Mix (cat. M0370)
and Calf Intestinal Phosphatase (cat. M0290) were purchased from New England
BioLabs (Ipswich, MA). Zyppy™ Plasmid Miniprep Kit was purchased from Zymo
Research Corp. (Irvine, CA). Wizard® SV Gel and PCR Clean-Up Kit (cat. A9281) was
purchased from Promega Corp. (Madison, WI). Micropulser electroporator and 0.2 cm
electroporation cuvettes (cat. 1652086) were from Bio-Rad, Inc. (Hercules, CA). Tris
hydrochloride and kanamycin sulfate were purchased from Amresco (VWR: Radnor,
PA). Rosetta(DE3) cells (cat. 70954), pET30 vectors (cat. 69909-3) and NaCl were
purchased from EMD Millipore (Billerica, MA). DH5α cells (cat. 18259012), lysozyme
(cat. BP535), BME (betamercaptoethanol, cat. BP176), LB broth Miller (cat. BP1426),
and ampicillin (cat. BP1760) were purchased from ThermoFisher Scientific (Waltham,
MA). Chloramphenicol (cat. 227920250), IPTG (Isopropyl β-D-1-thiogalactopyranoside,
cat. 302790250), and PMSF (phenylmethylsulfonyl fluoride, cat. 215740050) were
purchased from Acros Organics (NJ). Urea, DTT (dithiothreitol, cat. 43815), and TCEP
(Tris(2-carboxyethyl)phosphine hydrochloride, cat. 646547) were from Sigma-Aldrich
106

(St. Louis, MO). DTE (dithioerythritol, cat. 2185D) was from Research Organics
(Cleveland, OH). The Digital Sonifier 450 and accessories were from Branson
Ultrasonics (Dansbury, CT).

3.2 BAF180 Expression in E. coli
3.2.1 Cloning
BAF180 was cloned into the E. coli strain Rosetta(DE3) using the pET30a vector.
The BAF180 gene sequence (pBabepuroBAF180; isoform 2; GenBank: AF177387.1)
was a gift from Ramon Parson’s lab (Addgene #41078).7 As received, the BAF180 gene
had been inserted into the pBabepuro vector using EcoRI on both the 5' and 3' ends. The
5' EcoRI site was immediately upstream of the start codon and only 50 base pairs
separated the 3' EcoRI site and the stop codon. For time efficiency, the 3' restriction
enzyme site was not changed. Both pBabepuroBAF180 and pET30a were digested with
EcoRI and purified using the Promega Wizard® SV Gel and PCR Clean-Up Kit. pET30a
was dephosphorylated using Calf Intestinal Phosphatase to prevent re-ligation and gel
purified again. The BAF180 gene (4961 bp) was ligated into pET30a (5422 bp) using a
5:1 (insert:vector) ratio with Instant Sticky-end Master Mix. The resultant plasmid
(BAF180-pET30a) was 10,381 base pairs (Figure 3.1). 2 µL of the ligation reaction was
immediately transformed into chemically competent DH5α cells using the protocol
outlined in the pET30 manual.7 Cells were then grown on LBK plates (50 µg/mL
kanamycin) overnight at 37 °C. 12 colonies were produced. Each colony was grown in 15
mL LBK overnight at 37 °C and 250 rpm. 5 mL of this was used to prepare freezer stock
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and 10 mL was miniprepped. The minipreps were used to confirm the plasmid size
(Figure 3.2A).

Figure 3.1: Plasmid map of BAF180-pET30a. The BAF180 gene sequence is highlighted in teal in the
vector.

When a gene is inserted into a vector using the same restriction enzyme site on
both the 5' and 3' ends, it is possible for the gene to be inserted in the 3' to 5' direction,
instead of the correct 5' to 3'. BAF180 was inserted into pET30a using EcoRI on both the
5' and 3' ends of the gene (Figure 3.1), so the 12 transformation products were screened
for insert direction using PCR and restriction enzyme digests. For PCR, a forward primer
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for the T7 promoter (on the vector) and a reverse primer for bromodomain 2 were used to
confirm that BAF180 was inserted in the correct direction. The correct product size (1064
bp) was seen on the gel (Figure 3.2B). Additional PCR reactions were performed to
confirm that full-length BAF180 was inserted into the pET30a vector. To perform
diagnostic digests, a restriction enzyme was chosen that cut twice within the BAF180pET30a plasmid. The product sizes would change depending on the insert direction
(Figure 3.3). Unfortunately, results were inconsistent, possibly due to mixedtransformation colonies (where some of the cells had the insert and some did not).
A.

Transformation products:
BAF180-pET30a (10,383 bp)

B.

T7 → D2

10 kb
10 kb
8
6
4 5
3

3
2
1.5
1

2

0.5

1.5
1

Figure 3.2: Screening of the BAF180-pET30a transformants. (A) Four of the transformants were
miniprepped and run on a 1% TBE agarose gel. The expected plasmid size was 10,383 bp. The bands
slightly above the 10 kb band on the ladder were believed to be BAF180-pET30a. It was thought that the
other bands seen were supercoiled plasmids. (B) PCR screen to confirm the correct insert size. The T7 →
D2 product was 1064 bp.
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Correct Direction:

Incorrect Direction:
8892 bp

6888 bp

3493 bp

1489 bp

Figure 3.3: Theory behind using restriction enzyme diagnostic digests. If BAF180 had been inserted in the
5' to 3' direction (“correct” direction), digestion of BAF180-pET30a with EcoRV would have resulted in a
product approximately 6900 base pairs (bp) and 3500 bp. Insertion of BAF180 in the 3' to 5' direction
(“incorrect”) would have resulted in products approximately 8900 bp and 1500 bp.

After it was confirmed that BAF180 had been inserted in the 5' to 3' direction, one
of the miniprepped BAF180-pET30a plasmids was transformed into electrocompetent E.
coli Rosetta(DE3) cells using the Bio-Rad Micropulser electroporator on the “ec2”
setting. A 0.2 cm electroporation cuvette was used. The electroporation procedure
outlined in the Micropulser manual was followed.31 The cells were then grown overnight
on LBCK plates (35 μg/mL chloramphenicol and 50 μg/mL kanamycin).

3.2.2 Expression
To test for BAF180 expression, the following variables were manipulated: growth
temperature (30 °C and 37 °C); lysis conditions (native and denaturing); incubation
temperature during lysis (4 °C to 25 °C); incubation time during lysis (30 minutes to
overnight); IPTG concentration (0.25 mM, 0.50 mM, 1.0 mM, 1.5 mM); induction time
(1-24 hours); elimination of possible protein oxidation during lysis by addition of
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reducing agents (5% BME, 100 mM DTT, 100 mM DTE, 20 mM TCEP); and inhibition
of proteases using PMSF (Table 3.1). No protein band around 190 kDa was ever seen on
SDS-PAGE gels.
Table 3.1: Variables manipulated while attempting to express BAF180 in E. coli cells.

Variables Tested:

Actions Taken:

Growth Temperature

30 °C and 37 °C

Lysis Conditions

Native and Denaturing

Lysis Incubation

Temperature (4 °C to 25 °C) and Time (30 minutes to overnight)

IPTG Concentration

0.25 mM, 0.50 mM, 1.0 mM, 1.5 mM

Induction Time

1-24 hours

Reducing Agents

5% BME, 100 mM DTT, 100 mM DTE, 20 mM TCEP

Proteases

PMSF

3.3 Other Considerations
When efforts to express BAF180 in E. coli failed, several different options were
explored. Often, large proteins are found in inclusion bodies, where they are insoluble
and inactive. The presence of certain protein tags has been found to increase the
solubility, thus preventing a recombinant protein from being included in an inclusion
body. Fusion tags are polypeptide sequences (such as a 6x His-tag) or proteins (such as
GST) which are expressed in-frame with the recombinant protein, thus resulting in a
fusion protein which contains both the recombinant protein of interest and the tag. The
use of fusion tags has long been known to increase the solubility of some recombinant
proteins expressed in E. coli.26,32-33
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Some of the most commonly used tags are 6x His, GST (glutathione Stransferase), and MBP (maltose binding protein).26 Vectors are available which allow for
in-frame expression of one of these tags with the recombinant protein gene. Fusion tags
also have another benefit in that purification of the fusion protein is simplified because
affinity methods can be employed (such as IMAC for a 6x His-tag). However, there are
drawbacks to using tags during recombinant protein expression. The most notable is that
the fusion tag can disrupt the biological functions of the recombinant protein. For
mechanistic studies, enzymatic cleavage of the fusion tag from the recombinant protein is
often needed.26 Additionally, protein solubility is not equivalent with protein quality;
sometimes the soluble proteins are biologically inactive, which essentially negates the use
of a solubility tag.34-35
Possible co-expression of chaperone proteins was also explored. Chaperone
proteins aid in properly folding newly synthesized proteins into their native state.
Overexpression of recombinant proteins in E. coli often leads to the production of
inclusion bodies, where the desired protein is improperly folded and isolated. Coexpression of prokaryotic chaperone proteins, particularly DnaK and GroEL, has been
used to increase the yield of some recombinant proteins.26-27,33-35 DnaK and GroEL are
already present in E. coli cells; however, when a recombinant protein is overexpressed,
there are insufficient quantities of these chaperones and the recombinant protein is
misfolded. The chaperones can be co-expressed in the same cell as the recombinant
protein by placement on a separate vector (such as those available from Takara Bio Inc.)
or by placement on the same vector as the recombinant gene (Duet system by Novagen).
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However, the over-expression of these chaperone proteins can have detrimental effects on
protein production and on the cell overall, such as cell growth inhibition and enhanced
proteolysis of the protein.34-38

3.4 Conclusion
While fusion tags and co-expression of chaperone proteins were considered, these
were not tried for a few reasons. One, there was doubt whether the fusion tag would be
enough to overcome the size of BAF180. They work well with smaller proteins, but the
relatively small size of the fusion tags (28 kDa for GST and 43 kDa for MBT)26 in
relation to BAF180 (190 kDa) made it doubtful that the tag would be enough to
encourage the proper folding of BAF180. Additionally, there was doubt whether the
prokaryotic chaperones would be able to properly fold all of the BAF180 protein; there
was a significant possibility that the chaperones would be insufficient, resulting in partial
folding of BAF180.
There are many possible reasons why BAF180 failed to express in E. coli cells. A
few of the most likely are the protein size (190 kDa), presence of multiple domains (9
domains), and the presence of rare codons. Both size and the presence of several domains
can influence the expression of recombinant proteins.26 Large proteins and multi-domain
proteins often fail to express or are found in inclusion bodies. Additionally, E. coli and
other prokaryotic expression systems are limited in their ability to create posttranslational modifications (PTMs) on recombinant proteins. Though PTMs on BAF180
are relatively unexplored, there are a few known sites of phosphorylation, which may
influence the activity (see Section 1.3.3). Possibly the biggest obstacle to BAF180
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expression in E. coli (and other bacterial systems) is the codon usage. Though
Rosetta(DE3) cells were used for its several rare tRNAs, BAF180 has so many rare
codons that this may not have been sufficient; 19 codons have a usage difference greater
than 10% (Table 3.2). Though other bacterial systems are available, such as B. subtilis
and L. lactis, the same concerns exist, particularly about codon usage and size (Table
3.3).

Table 3.2: Table showing the codons with a high difference in usage between E. coli and BAF180. %
difference refers to how much more often a codon is used in BAF180 versus the host. Number refers to
how many times that codon is used in BAF180.
Amino Acid

Codon

% Difference

Number

Ala

GCA

13.0

31

Ala

GCT

24.2

32

Arg

AGA

25.0

26

Arg

AGG

17.5

19

Arg

CGA

11.8

18

Asn

AAT

23.8

49

Cys

TGT

21.4

14

Glu

GAG

10.3

57

Gly

GGA

15.0

23

Ile

ATA

15.0

17

Leu

CTT

12.9

36

Lys

AAG

13.3

56

Phe

TTT

13.1

37

Pro

CCA

28.3

48

Pro

CCT

15.0

37

Ser

TCT

11.3

27

STOP

TAA

35.7

1

Thr

ACA

32.3

25

Thr

ACT

10.9

15
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Table 3.3: Codon usage comparisons of BAF180 to bacterial expression systems. The number of codons
with a certain percentage difference are noted. % difference refers how much more often a codon is used in
BAF180 versus the host.

% Difference

Codons 10-14.99%:
Codons 15-19.99%:
Codons 20-29.99%:
Codons 30-39.99%:
Codons 40-40.99%:
Codons ≥ 50%
Total codons ≥10%
difference:
STOP codons %
diff:

Codons 10-14.99%:
Codons 15-19.99%:
Codons 20-29.99%:
Codons 30-39.99%:
Codons 40-40.99%:
Codons ≥ 50%
Total codons ≥10%
difference:
STOP codons %
difference:

Bacteria

E. coli B

9
5
3
2
0
0

E. coli K12
10
2
5
2
0
0

C. crescentus
5
6
6
5
3
4

S. lividans
4
6
8
1
4
6

L. lactis
9
4
2
1
1
0

B. subtilis
5
2
1
1
0
0

B. megaterium
9
3
0
2
0
0

19

19

29

29

17

9

14

36.36

35.71

80

90.97

39.99

39.08

32.87

P. fluorescens P. haloplanktis
5
8
4
5
3
0
2
0
0
2
1
0

P. putida
10
2
2
1
3
1

M. smegmatis H. elongata
2
3
5
5
8
10
4
5
6
2
3
2

L. lactis subsp
C. salexigens cremoris MG1363
3
6
6
4
10
4
3
1
3
0
2
1

15

15

19

28

27

27

16

66.46

40

77.87

93.64

65.22

84.05

31
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Chapter 4 : The Use of Pichia pastoris as an Expression
System
The yeast Pichia pastoris (Pichia) has become increasingly popular as a
recombinant host over the last decade. Pichia is a methylotrophic budding yeast that is
often found in its vegetative state (i.e. not mating).39 A methylotrophic yeast is capable of
utilizing methanol as its sole carbon source. Similar to E. coli, Pichia has a fast doubling
time (approximately 90 minutes in rich medium like YPD)40 and is relatively inexpensive
to grow. But unlike E. coli, Pichia is capable of performing post-translational
modifications and it has eukaryotic protein machinery, which makes it more likely that
the recombinant protein will be folded correctly.41 Expression in Pichia has become
preferred over other yeast heterologous systems, such as S. cerevisiae, partly because
Pichia has a strong preference for respiratory growth over fermentative growth. This
allows Pichia cultures to be grown to extremely high cell densities, as toxic ethanol (the
product of fermentation) is not present.40-44
However, for all its advantages, Pichia has one major drawback. The
glycosylation pattern produced in Pichia is different from that produced in human.
Glycosylation of proteins often occurs during secretion. Though proteins produced in
Pichia are often less hyperglycosylated than recombinant proteins produced in S.
cerevisiae,45 Pichia produces glycosylation patterns that are different enough from
human glycosylation patterns that an immune response can be triggered in a patient. This
is especially important in recombinant pharmaceutical production. To overcome this
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problem, new strains have recently been engineered that mimic the human glycosylation
pattern (such as YSH44 and the GlycoSwitch system).42-43,45

4.1 Choosing a Promoter
Several promoters are commercially available for recombinant protein expression
in P. pastoris. The two most common promoters are the GAP promoter (constitutive) and
AOX1 promoters (inducible by methanol). Both of these are strong promoters capable of
similarly high levels of recombinant protein expression.40-48
The AOX1 promoter is inducible by addition of methanol. An inducible promoter
is exactly what it sounds like: it promotes gene expression when induced. This can be an
advantage for the production of some proteins, particularly toxic ones, as the protein is
not expressed during the growth phase. A culture is first grown to a particular density
before the AOX1 promoter is induced by addition of methanol. Using an AOX1 promoter,
the recombinant protein can reach up to 30% of the cell biomass.42 However, there are
disadvantages to using the AOX1 promoter. Because it uses methanol as an inducer, it is
unsuitable for large scale expression, because methanol is highly flammable.40-52
Additionally, the fast production of recombinant protein may result in unfolded or
inactive proteins, as an inducible promoter makes a lot of protein all at once.
On the other hand, the GAP promoter is a constitutive promoter. A constitutive
promoter allows for the constant production of the recombinant protein. This type of
promoter does not require an inducer, as it is always “on”. Some researchers have
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reported higher recombinant protein production with the AOX1 promoter than the GAP
promoter, while others have reported the opposite.42-46,50,52-55
Considering the size of the BAF180 protein (190 kDa), it was hypothesized that
continuous expression of the protein (under control of the GAP promoter) might be more
favorable than inducible expression, in terms of cellular stress and protein folding.44,46,56
Synthesis of a lot of protein all at once might be toxic to the cell or impede growth or
there might not be sufficient levels of chaperone proteins available for folding the
protein.40-48,50,53-55,57 The GAP promoter is found in pGAPZ vectors.

4.2 Choosing an Expression Strain
There are several Pichia strains commercially available. Wild-type (WT) strains
include Y-11430 and X33. Other strains have mutations in a biosynthesis pathway (such
as his4 mutants), AOX1/2 mutants, protease-deficient strains, and glycosylation
mutants.43,45 Strains with a mutation in a biosynthesis pathway, such as his4, are only
able to grow if the vector (containing the replacement HIS4 gene) has been integrated.45
Other strains have mutations in one or both of the AOX genes, because cells with AOX
mutations can sometimes produce larger quantities of recombinant protein.43,45
Most of the protease activity in yeast is contained in the membrane bound
vacuoles.56,58 Upon cell lysis, the organelles release their contents. Cell lysis can happen
during cell growth, as the cell density increases. The proteases are released into the media
wherein secreted proteins are targeted. Therefore, protease-deficient strains have been
developed. Most often, these strains have been engineered to be deficient in PEP4. PEP4
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is a gene that activates carboxypeptidase Y and protease B1 in vacuoles, therefore
mutants without PEP4 do not have either of these proteases.40-41,43-46,48,58 The use of
protease-deficient strains has improved extracellular expression in about 10% of cases,41
but there is no reported success of using a protease-deficient strain to increase yield of an
intracellularly produced protein.40-41 Protease-deficient strains have several problems,
such as much slower growth, faster death on agar plates, lower transformation
efficiencies, lower levels of expression, and difficulty utilizing the methanol-inducible
AOX1 promoter.40-41,43,45 Use of a protease-deficient strain is generally not recommended
unless absolutely necessary.45 The WT strain X33 was chosen for expression because it
was readily available.

4.3 Integration of A Recombinant Gene into the Pichia pastoris
Genome
Expression of a recombinant gene into Pichia involves the integration of the gene
into the Pichia genome through homologous recombination. The plasmid containing the
recombinant gene is linearized in a location which shares homology to a location in the
Pichia genome. Usually this is accomplished by cutting a plasmid within the promoter
and then transforming this linearized construct (“expression cassette”) into Pichia cells.
The free DNA ends then promote recombination of the plasmid into the genome, usually
with a single-crossover event.45-46 Incorporation of the recombinant gene is far more
stable41-44,46 than the E. coli method of simply inserting a plasmid with its own replication
system into the cell. Actually, there are no autonomous plasmids available for Pichia,
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because Pichia seems to spontaneously integrate the plasmid into its genome
anyway.41,44,59
Due to homologous recombination, multiple copies of the expression cassette can
sometimes be integrated into the genome. These “jack-pot” clones are very rare,
occurring spontaneously approximately 1% of the time.60-61 This percentage can be
increased by constructing a vector that has multiple copies of the gene in the vector
itself.45 Identification of high-copy number clones is time-consuming and laborious, as it
usually requires screening of hundreds of clones. One of the commonly used techniques
to isolate multi-copy strains is step-wise increase in antibiotic concentration, where
colonies are plated on subsequently higher and higher concentrations of the antibiotic.4041,45

Interestingly, while logic would dictate that more copies of the gene would equal

more protein, this is not always the case. Sometimes, integration of more than one copy
actually leads to a decrease in the recombinant protein production.43,45,60

4.4 Choosing to Use Pichia as the heterologous system for
BAF180 Production
Pichia was chosen as the expression system for BAF180, because the Pichia
codon usage is similar to the usage for BAF180. BAF180 contains a lot of rare codons,
even when compared to the usage in humans (15 codons have a usage difference greater
than 10%; see Table 4.1). As such, once E. coli failed to express BAF180, other
expression systems were investigated. Complete codon analysis was performed on 12
different systems to identify which system had codon usage closest to BAF180: 4
bacterial, 6 yeast, and 2 insect. The results are shown in Table 4.2.
122

Table 4.1: Codon usage comparisons of BAF180 to humans (native host). The number of codons with a
percentage difference greater than 10 are shown. Note that % difference refers to how much more often a
codon is used in BAF180 versus the host. Number refers to the number of times that codon is used in the
BAF180 gene sequence.

Amino Acid

Codon

% Difference

Number

Ala

GCA

10.88

31

Asn

AAT

23.98

49

Asp

GAT

16.65

65

Cys

TGT

18.02

14

Glu

GAA

17.89

86

His

CAT

18.67

23

Ile

ATT

11.94

37

Leu

CTT

11.49

36

Lys

AAA

16.60

84

Phe

TTT

23.40

37

Pro

CCA

14.45

48

STOP

TAA

70.30

1

Thr

ACA

21.17

25

Tyr

TAT

11.67

42

Val

GTT

14.76

28
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Amino Acid
Ala
Ala
Ala
Ala
Arg
Arg
Arg
Arg
Arg
Arg
Asn
Asn
Asp
Asp
Cys
Cys
Gln
Gln
Glu
Glu
Gly
Gly
Gly
Gly
His
His
Ile
Ile
Ile
Leu
Leu
Leu
Leu
Leu
Leu
Lys
Lys
Met
Phe
Phe

Codon Homo sapiens P. pastoris S. cervisae S. pombe Y. lipolytica K. lactis Z. bailii C. crescentus S. lividans L. lactis P. putida E. coli K12
GCA
10.88
10.27
4.84
8.24
22.21
7.94
16.80
31.37
25.44
-1.49
21.36
13.01
-20.75
GCC
-9.54
4.71
7.99
12.07
-15.09
10.82
-3.35
-27.77
-23.08
14.36
-0.60
GCG
-9.53
-4.90
-9.91
-7.51
-7.11
-7.01
-8.99
-32.40
-31.70
-9.53
-24.48
-36.65
-0.02
-11.75
-4.45
28.81
29.34
-3.35
23.87
24.25
GCT
8.19
-10.08
-2.92
-12.80
26.49
26.37
-1.05
25.89
24.99
AGA
6.19
-20.26
-20.45
4.69
14.27
-30.44 -15.14
AGG
-0.90
4.41
-0.64
9.82
15.43
6.07
1.14
17.23
15.36
14.46
16.67
17.55
-32.79
14.16
14.06
14.06
13.49
1.54
14.02
11.82
CGA
8.27
9.18
12.38
2.79
10.08
3.67
8.79
12.38
7.48
-42.68
-32.16
6.22
-38.70
-28.38
CGC
-2.42
10.83
CGG
-10.58
4.94
5.65
3.46
-2.05
6.06
5.76
-11.48
-22.11
3.02
-6.02
2.57
-9.09
-7.01
-24.45
-3.65
-8.24 -13.32
-3.62
-0.95
-24.19
-11.85
-28.55
CGT
-0.56
AAC
-23.98
-22.56
-12.04
-5.37
-54.04
-15.72 -21.54
-51.36
-63.58
4.08
-48.81
-23.76
48.81
23.76
AAT
23.98
22.56
12.04
5.37
54.04
15.72
21.54
51.36
63.58
-4.08
GAC
-16.65
-5.15
1.93
7.66
-28.39
5.78 -11.41
-40.00
-55.35
11.02
-31.90
1.78
GAT
16.65
5.15
-1.93
-7.66
28.39
-5.78
11.41
40.00
55.35
-11.02
31.90
-1.78
TGC
-18.02
0.11
-0.66
-1.86
-17.98
11.15
-1.99
-49.36
-53.57
14.60
-44.29
-21.38
TGT
18.02
-0.11
0.66
1.86
17.98
-11.15
1.99
49.36
53.57
-14.60
44.29
21.38
CAA
6.29
-28.21
-36.47
-38.84
13.84
-38.59 -14.58
18.77
24.91
-49.38
9.09
2.39
CAG
-6.29
28.21
36.47
38.84
-13.84
38.59
14.58
-18.77
-24.91
49.38
-9.09
-2.39
GAA
17.89
3.82
-10.19
-7.69
35.67
-14.72
9.66
31.47
39.22
-20.65
12.34
-10.30
20.65
-12.34
10.30
GAG
-17.89
-3.82
10.19
7.69
-35.67
14.72
-9.66
-31.47
-39.22
-3.95
-0.65
7.85
13.55
22.86
18.74
-8.87
27.08
15.04
GGA
2.72
-4.93
6.17
26.43
14.18
-36.15
-27.84
23.43
-57.78
-9.95
GGC
2.43
22.35
16.81
19.52
1.83
5.40
5.50
1.81
-2.00
2.82
12.19
2.60
GGG
-10.53
4.60
2.55
5.65
9.08
11.48
11.10
-17.38
18.51
-7.69
5.38
-22.02
-25.54
-21.22
-10.26
-39.67 -33.23
GGT
-49.87
13.42
-26.26
-5.80
-18.67
-3.96
3.14
11.65
-26.66
6.60 -12.91
-31.19
CAC
-6.60
12.91
5.80
CAT
18.67
3.96
-3.14
-11.65
26.66
31.19
49.87
-13.42
26.26
20.62
19.49
2.02
17.51
14.99
ATA
5.17
4.02
-5.26
0.03
19.18
-2.51
5.63
-4.83
9.22
-23.13
-2.72 -13.08
-62.10
-58.93
10.56
-44.52
ATC
-17.12
-1.62
3.50
5.23
7.45
41.49
42.45
-12.58
27.01
-10.16
ATT
11.94
-2.41
1.76
-9.25
3.94
8.87
CTA
3.14
-0.88
-3.85
1.38
5.48
-2.73
-4.04
9.36
-0.03
7.89
5.09
-12.14
4.07
6.76
11.39
9.73
12.34
5.99
0.13
-18.69
9.99
CTC
-2.43
9.20
11.01
CTG
-14.86
16.93
-45.60
-33.55
17.29
-39.92
-23.46
-16.97
7.07
11.56
16.03
21.39
2.40
18.29
12.95
CTT
11.49
8.18
11.75
-1.12
6.83
11.56
4.88
18.45
-7.44
-19.31
5.95
-18.49
-2.69
7.19
7.33
-28.32
6.22
TTA
-0.12
-8.63
-20.02
TTG
8.73
-19.62 -15.15
10.97
14.16
-1.34
3.45
6.10
4.90
-14.94
-10.82
-6.71
52.43
50.35
-19.49
31.17
-13.28
AAA
16.60
13.04
2.39
-1.89
44.34
7.39
15.05
-44.34
-7.39 -15.05
-31.17
13.28
AAG
-16.60
-13.04
-2.39
1.89
-52.43
-50.35
19.49
0.00
0.00
0.00
0.00
0.00
0.00
0.00
ATG
0.00
0.00
0.00
0.00
0.00
-15.85
-57.86
-66.28
5.65
-49.17
-13.07
TTC
-23.40
-57.41
1.59
-32.25
-24.49 -22.62
24.49
49.17
13.07
TTT
23.40
15.85
57.41
-1.59
32.25
22.62
57.86
66.28
-5.65

Codon Difference Comparison of BAF180 to Host Organism
E. coli S. frugiperda
12.25
15.52
0.99
2.61
-34.57
-16.43
19.71
-0.07
22.60
9.00
0.79
15.72
14.09
10.78
-23.93
-8.17
-1.10
3.79
-27.38
-16.20
-13.87
-39.21
13.87
39.21
3.36
-23.51
-3.36
23.51
-21.53
-24.49
21.53
24.49
-2.63
-10.03
2.63
10.03
-1.87
14.70
1.87
-14.70
17.45
-0.30
-5.25
5.25
-3.42
7.19
-8.78
-12.13
-4.07
-24.74
24.74
4.07
14.88
6.10
-14.45
-24.48
18.38
-0.43
1.71
7.43
5.53
-3.83
-22.69
-6.98
14.15
12.83
-6.91
-1.98
2.49
-1.75
-16.92
24.74
16.92
-24.74
0.00
0.00
-9.26
-42.96
9.26
42.96

T. ni
16.95
-3.49
-12.42
-1.04
4.96
0.18
9.09
-2.53
2.87
-14.57
-41.31
41.31
-23.23
23.23
-19.39
19.39
-11.76
11.76
3.40
-3.40
-0.40
6.48
8.06
-14.14
-26.05
26.05
9.17
-24.38
15.21
1.90
-5.53
-2.07
9.70
-2.57
-1.43
23.55
-23.55
0.00
-45.04
45.04

Table 4.2: Codon usage comparisons of BAF180 to 14 different expression systems. A positive percentage
means the codon usage is biased towards BAF180 (i.e. that particular codon is used more often in
BAF180). A negative percentage means the codon usage is biased towards the host organism (i.e. that
particular codon is used more often in the host organism).
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Amino Acid
Pro
Pro
Pro
Pro
Ser
Ser
Ser
Ser
Ser
Ser
STOP
STOP
STOP
Thr
Thr
Thr
Thr
Trp
Tyr
Tyr
Val
Val
Val
Val

Codon Homo sapiens P. pastoris S. cervisae S. pombe Y. lipolytica K. lactis Z. bailii C. crescentus S. lividans L. lactis P. putida E. coli K12
CCA
14.45
0.43
0.39
15.01
31.68
-7.70
2.84
38.02
38.01
-0.40
27.60
28.34
CCC
-13.05
4.33
3.85
2.05
-28.20
10.38
-4.45
-14.99
-21.46
10.41
-4.01
5.94
CCG
-5.18
-2.52
-5.92
-3.57
-3.52
-3.71
1.12
-49.06
-43.37
-3.09
-43.67
-49.33
CCT
3.78
-2.24
1.68
-13.49
0.04
1.03
0.49
26.03
26.82
-6.92
20.08
15.05
AGC
-3.16
11.70
9.86
10.93
9.66
13.13
6.85
-11.38
-6.28
10.51
-19.96
-11.86
AGT
5.87
5.83
4.91
4.78
13.63
5.35
6.85
18.16
16.49
-2.62
11.60
6.60
TCA
7.45
4.35
1.48
2.97
14.64
2.75
9.11
19.13
18.87
-6.48
17.13
7.12
TCC
-9.30
-7.26
-3.50
-0.61
-17.53
-2.86
-4.17
-4.38
-24.00
6.81
-2.87
1.73
TCG
-4.61
-7.96
-8.80
-7.90
-15.11
-8.46
-8.39
-40.65
-24.54
-4.59
-23.73
-14.94
TCT
3.74
-6.66
-3.95
-10.18
-5.29
-9.91 -10.24
19.11
19.46
-3.62
17.83
11.35
TAA
70.30
49.26
52.88
40.93
54.02
45.85 62.50
80.01
90.97
35.99
77.87
35.71
TGA
-46.62
-19.85
-22.57
-20.91
-15.63
-18.27 -37.50
-47.26
-17.42 -22.37
-11.67
-35.71
TAG
-23.67
-29.41
-30.31
-20.03
-38.39
-27.57 -25.00
-32.76
-73.55 -13.62
-66.20
0.00
ACA
21.17
21.17
15.21
19.27
31.70
18.99 20.11
42.72
40.45
6.00
37.94
32.25
ACC
-4.90
-0.07
3.78
5.84
-23.55
3.15
-1.28
-37.27
-34.38
11.26
-38.78
-21.35
ACG
-22.46
-8.85
-11.74
-10.20
-9.27
-9.48 -11.03
-29.99
-29.53 -10.80
-16.66
-21.78
ACT
6.19
-12.26
-7.25
-14.91
1.12
-12.67
-7.80
24.54
23.46
-6.46
17.50
10.87
TGG
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
TAC
-11.67
-9.12
-0.04
9.28
-38.41
-1.74 -18.25
-10.01
-49.97
19.36
-27.74
-2.58
TAT
11.67
9.12
0.04
-9.28
38.41
1.74 18.25
10.01
49.97 -19.36
27.74
2.58
GTA
3.64
-0.17
-5.58
-5.20
9.96
-2.34
-0.21
13.68
10.71
-7.89
4.99
-2.06
GTC
-2.65
-2.09
0.29
3.52
-15.01
-1.79
-3.14
-30.28
-33.69
4.33
-8.32
3.53
GTG
-15.75
11.40
11.50
16.80
-2.31
13.01
0.80
-9.19
-6.35
16.29
-19.32
-9.12
GTT
14.76
-9.14
-6.21
-15.12
7.36
-8.88
2.55
25.79
29.33 -12.72
22.65
7.65

E. coli S. frugiperda
23.80
14.44
13.42
-8.58
-55.30
-9.76
18.08
3.90
-4.17
2.67
5.09
7.15
11.85
5.18
-1.39
-8.20
-19.07
-11.84
7.69
5.05
36.36
36.62
-9.09
-18.31
-27.27
-18.31
34.07
22.23
-21.58
-7.00
-25.41
-15.97
12.92
0.74
0.00
0.00
12.63
-26.84
-12.63
26.84
1.78
-1.80
2.93
-7.36
-12.66
-3.75
7.94
12.91

T. ni
16.35
-9.00
-8.76
1.41
1.56
6.20
5.90
-6.01
-9.34
1.70
33.33
-28.89
-4.44
26.47
-9.75
-11.51
-5.22
0.00
-31.73
31.73
-2.69
-10.18
1.42
11.44

BAF180 codon usage was similar to that of Pichia; only 11 codons had a usage
difference greater than 10%, meaning that only 11 codons were used more than >10%
more frequently in BAF180 than in Pichia (Table 4.3).
Table 4.3: Codon usage comparisons of BAF180 to Pichia pastoris. The number of codons with a
percentage difference greater than 10 are shown. Note that % difference refers to how much more often a
codon is used in BAF180 versus the host. Number refers to how many of that particular codon are found in
the BAF180 gene sequence.
Amino Acid

Codon

% Difference

Number

Ala

GCA

10.3

31

Arg

CGC

10.8

15

Asn

AAT

22.6

49

Gln

CAG

28.2

41

Gly

GGC

22.3

30

Lys

AAA

13.0

84

Phe

TTT

15.9

37

Ser

AGC

11.7

25

STOP

TAA

49.3

1

Thr

ACA

21.2

25

Val

GTG

11.4

26

Pichia pastoris was chosen because it is a eukaryotic expression system, therefore
it is capable of performing post-translational modifications and it has eukaryotic protein
machinery. This makes it more likely that the recombinant protein will be folded
correctly.41 Pichia also has codon usage similar to BAF180, making it more likely that
the protein will be transcribed from the DNA.
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Chapter 5 : Cloning and Expression of BAF180 in Pichia
pastoris
After attempts to express BAF180 in E. coli were unsuccessful (see Chapter 3),
the yeast Pichia pastoris was chosen. There were two primary reasons why P. pastoris
was chosen (more details in Chapter 4):
(1) Eukaryotic system: P. pastoris is a eukaryotic organism, capable of
performing post-translational modifications in a manner similar to humans. It
also possesses eukaryotic transcriptional machinery.
(2) Codon Usage: BAF180 has unusual codon usage. The codon usage of P.
pastoris is similar to BAF180 and has only 11 codons have a usage difference
greater than 10% (as opposed to 19 for E. coli).
The pGAPZA vector was chosen for expression because it contains the constitutive GAP
promoter. A constitutive promoter permits constant low level expression of a
recombinant gene; in other words, the promoter is always “on.” It was hypothesized that
constant low-level production of BAF180 would be more favorable in terms of cellular
stress and protein production. Continuous low level synthesis of BAF180 might be less
toxic to the cell than the synthesis of a large amount of protein at one time (as happens
with inducible promoters). Additionally, continuous low level expression may increase
the probability of BAF180 folding correctly. BAF180 is such a large protein that the
protein folding machinery (such as chaperone proteins) may be more likely to fold
BAF180 correctly if the machinery is doing so constantly and not being bombarded all at
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once as happens with an inducible promoter. In this chapter, several topics are discussed
including the cloning of BAF180 into P. pastoris. Cell growth conditions and lysis
procedures were also investigated to determine which conditions resulted in the highest
expression and recovery levels of BAF180. The expression of BAF180 was confirmed
with western blot.

5.1. Materials
Pichia pastoris wild-type strain X33 and pGAPZA vector were purchased from
Invitrogen (Carslbad, CA). Zeocin (cat. ant-zn-1p) was purchased from Invivogen (San
Diego, CA). The BAF180 gene sequence (pBabepuroBAF180; isoform 2; GenBank:
AF177387.1) was a gift from Ramon Parson’s lab (Addgene #41078).7 Primers were
purchased from Integrated DNA Technologies (IDTDNA: Coralville, IA). Q5
polymerase (M0491), T4 ligase (M0202), all restriction enzymes, TriDye 1 kb ladder
(N3272), and Color Prestained Broad Range Protein Marker (P7712) were purchased
from New England BioLabs (Ipswich, MA). PCR mutagenesis was performed on the GStorm GS482 Thermocycler (Gene Technologies, UK). Tryptone, peptone, yeast extract,
and dextrose were purchased from Amresco (VWR: Radnor, PA). Urea, sodium
phosphate monobasic (NaH2PO4), Lyticase from Arthrobacter luteus,
phenol:chloroform:isoamyl alcohol (25:24:1), chloroform:isoamyl alcohol (24:1), sodium
acetate, and 100% ethanol were purchased from Sigma Aldrich (St. Louis, MO).
Zirconia/silica disruption beads (0.5 mm) were purchased from Research Products
International Corp. (Mt. Prospect, IL). DNA purification kits (Zyppy™ Plasmid Miniprep
Kit, Zymo Gel Extraction Kit, and Zymo DNA Clean & Concentrator™) were purchased
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from Zymo Research Corp. (Irvine, CA). The Wizard® SV Gel and PCR Clean-Up Kit
(cat. A9281) was purchased from Promega Corp. (Madison, WI). Samples were
concentrated with the Savant Refrigerator Condensation Trap and Savant Speed Vacuum
Concentrator (ThermoFisher: Waltham, MA). E. coli subcloning strain DH5α, Ampicillin
(cat. BP1760), 0.45 µm nitrocellulose membrane (cat. 77010), 0.45 µm PVDF membrane
(cat. 88585), blotting paper (cat. 8860), NuPAGE Tris-Acetate gels 3-8% (cat. EA0375),
NuPAGE LDS Sample Buffer 4x (cat. NP0007), NuPAGE Tris-acetate running buffer
(LA0041), NuPAGE transfer buffer (cat. NP0006), NuPAGE antioxidant (cat. NP0005),
NuPAGE reducing agent (cat. NP0004) and Pierce Fast Western Blot Kit, ECL substrate
(cat. 35050) were purchased from ThermoFisher (Waltham, MA). Anti-PBRM1 antibody
(cat. 12563-1-AP, rabbit polyclonal) was purchased from Proteintech (Rosemont, IL).
Western blot transfer was performed using a Hoefer TE22 transfer tank (Holliston, MA).
Ponceau staining solution (cat. AC2125) was purchased from Azure Biosystems (Dublin,
CA). Dialysis membranes were purchased from Spectrum Labs (Rancho Dominguez,
California): Spectra/Por 1 (6-8 kD MWCO membrane; part 132660) and Spectra/Por 6
(50 kD MWCO membrane; part 132544). SDS, glycine, Tris hydrochloride, Tris base,
glycerol, guanidine hydrochloride, and Protease Inhibitor Cocktail (cat. 97063-970) were
purchased from Amresco (VWR: Radnor, PA). EDTA was purchased from Mallinckrodt
Baker Inc. (Phillipsburg, NJ). NaCl was purchased from EMD Millipore (Billerica, MA).
MicroPulser electroporator and 0.2 cm electroporation cuvettes (cat. 1652086) were from
Bio-Rad, Inc. (Hercules, CA). PMSF (phenylmethylsulfonyl fluoride, cat. 215740050)
was purchased from Acros Organics.
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5.2 Construction and Transformation of Expression Plasmid
Before BAF180 could be cloned into Pichia pastoris, a few modifications needed
to be made to the gene sequence. (1) A Kozak consensus sequence was added to facilitate
gene expression; (2) Insertion of a spacer between 5' restriction enzyme site and the
Kozak consensus sequence; (3) The 3' restriction enzyme site was changed to allow for
directional cloning; (4) The endogenous stop codon was deleted; (5) An enterokinase site
was inserted.
A Kozak consensus sequence was added immediately upstream of the start codon,
for use as a transcription initiation start site (Figure 5.1). The BAF180 sequence
contained a start codon, but a yeast-specific Kozak consensus sequence needed to be
added because the chosen vector did not contain one. To make the Kozak sequence, three
adenosine residues were added upstream of the BAF180 start codon (AAAATGG).
Literature indicated that higher initiation rates are observed when adenosine residues are
located at the -3 to -1 positions and when a guanine is located at the +4 position relative
to the start codon (the guanine was already present).61-62 A spacer of 6 base pairs was
added between the 5' restriction enzyme site and the Kozak consensus sequence (Figure
5.1). Ligation efficiency is decreased when a restriction enzyme site and a start codon are
immediately adjacent to each other.
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Original DNA Sequence (from Addgene):
TAGGAATTCATGGGTT
EcoRI Start
codon

DNA Sequence After Mutation:
Kozak Sequence
TAGGAATTCGAACTCAAAATGGGTT
Spacer
EcoRI

Figure 5.1: Insertion of the Kozak consensus sequence and a spacer into the BAF180 sequence, to facilitate
expression in the yeast Pichia pastoris. A spacer was added between the restriction enzyme site (EcoRI)
and the Kozak consensus sequence.

Additionally, the 3' restriction enzyme site was changed to allow for directional
cloning. The group who constructed the parent vector (pBabepuroBAF180) used EcoRI
on the 5' and 3' ends of the gene. When the same restriction enzyme site is used on both
ends of the gene, there is a possibility that the gene will be inserted in the 3' to 5'
direction instead of the correct 5' to 3' direction. To facilitate directional cloning, the 3'
site was changed to KpnI (GGTACC) (Figure 5.2). Analysis of the BAF180 sequence
revealed limited options for the choice of restriction enzyme; of all commercially
available enzymes, only 67 restriction enzymes did not cut within the BAF180 sequence.
When comparing those to the available sites in pGAPZA, only five enzymes remained:
EcoRI, PmlI, KpnI, SacII, and NotI. PmlI was eliminated as it creates blunt ends. EcoRI
was eliminated as it is already being used on the 5' end. KpnI is downstream of EcoRI
and creates hanging ends. KpnI was chosen partially because the Thompson lab has had
success with this enzyme in the past.
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As mentioned, the pGAPZA vector was chosen for expression of BAF180. The
pGAPZA vector has a 6x His-tag downstream of the gene. The stop codon already
present in the BAF180 gene sequence was deleted so that a His-tag could be included on
the recombinant protein, because His-tags can be used for affinity purification of a
recombinant protein. Additionally, an enterokinase site (GAC GAC GAC GAC AAG)
was included to cleave off the His-tag after purification, as tags can sometimes interfere
with mechanistic studies (Figure 5.2).
PBRM1 DNA Sequence:
5’ – GAAAATGTTTAATCACATCATTACGTTTCTTTTATATAGAAGCATAAAGAGTTGTGGATCAGGAATTC – 3’
Stop Codon

EcoRI

DNA Sequence After Mutation:
Enterokinase
5’ – GAAAATGTTGACGACGACGACAAGGGTACCTCACATCATTACGTTTCTTTTATATAGAAGCATAAAGAGTTGTGGATCAGGAATTC – 3’
No Stop Codon

KpnI

Original EcoRI
Site

Figure 5.2: Modifications on the 3' end of the BAF180 DNA sequence. Deletion of stop codon was done to
allow expression of 6x His-tag on the C-terminus of BAF180. The His-tag would be cleaved off after
purification using enterokinase. The 3' restriction enzyme was changed to KpnI to allow for directional
cloning of BAF180 into the pGAPZA vector.

The PCR modifications (insertion of Kozak consensus sequence, insertion of
spacer, alteration of 3' restriction enzyme site, and insertion of an enterokinase site) were
accomplished using the following primers: (Color key: blue – GC clamp; red – EcoRI
site; italics – Kozak sequence; black – spacer; purple – BAF180 gene; green – KpnI site;
pink – enterokinase site; dark orange – pGAPZA vector):
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Forward:
GCGCTGGTACGTAGGAATTCGAACTCAAAATGGGTTCCAAGAGAAGAAG
Reverse:
GCGCTAATGATGTGAGGTACCCTTGTCGTCGTCGTCAACATTTTCTAGGTT
GTA
PCR conditions were as recommended by NEB for the Q5 Polymerase: 98 °C for 30
seconds, 30 cycles of 98 °C for 10 seconds, 76.3 °C for 30 seconds, 72 °C for 2 minutes
followed by a final elongation time of 2 minutes at 72 °C. The PCR product was purified
and concentrated before digesting. The modified BAF180 (i.e. PCR product) and the
pGAPZA vector were digested with EcoRI and KpnI; 2000 ng of modified BAF180 and
2000 ng of pGAPZA vector were digested with 10 units (2 µL) of each enzyme. The
digests were purified and pGAPZA and BAF180 were ligated together in a 5:1 ratio
(insert:vector) using T4 ligase. The pGAPZA-BAF180 construct (Figure 5.3) was
transformed into E. coli DH5α cells (for propagation) via electroporation.
Electrocompetent E. coli DH5α cells were prepared according to the Bio-Rad
MicroPulser manual; the electroporation procedure was from the manual as well.31 It
should be noted that pGAPZA contains the sh ble gene, conferring zeocin resistance.
Therefore, zeocin was used for antibiotic selection. Because of this, low-salt LB at pH 7.5
had to be used for all procedures in E. coli, as zeocin is only active at low-salt
concentrations and at that pH.61 Transformants were grown on low-salt LB plates with 25
µg/mL zeocin overnight at 37 °C. The positive transformants were selected and cultured
in low-salt LB with 25 µg/mL zeocin at 37 °C and 250 rpm. BAF180-pGAPZA plasmid
was isolated from these cells using a miniprep kit.
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Figure 5.3: Plasmid map of the pGAPZA-BAF180 construct. BAF180 is highlighted in teal. The EM7
promoter allows for replication of the plasmid in E. coli. The GAP promoter and AOX1 terminator are for
use in yeast. The restriction enzyme sites EcoRI and KpnI are noted, as is the enterokinase site and 6x Histag. Image created with SnapGene software.
A. pGAPZA-BAF180

Enterokinase
Site
TGA

Kozak Sequence

B. pGAPZA
PGAP

His
Tag

BAF180

PGAP

AOX1
Term

PT

PE

ZeoR

CYC
1TT

TGA
His
MCS Tag

AOX1
Term

PT

PE

ZeoR

CYC
1TT

Figure 5.4: Linearized pGAPZA-BAF180 and control pGAPZA plasmids. (A) The linearized pGAPZABAF180 plasmid. pGAPZA-BAF180 was linearized with AvrII, which cuts within the GAP promoter. This
linearization creates an expression cassette which is incorporated into the P. pastoris genome via
homologous recombination. (B) The linearized pGAPZA vector. pGAPZA was linearized with AvrII and
used as a positive control for transformation. Abbreviations: CYC1 TT: CYC1 transcription terminator
region; GAP: constitutive GAP promoter; ZeoR: Sh ble gene, conferring zeocin resistance; PT: TEF1
promoter, controls expression of the Sh ble gene in P. pastoris; PE: EM7 promoter, controls expression of
the Sh ble gene in E. coli; AOX1 Term: AOX1 transcription terminator region.

Before transformation into P. pastoris X33 cells, 4000 ng of pGAPZA-BAF180
was linearized with 20 units (1 µL = 5 units) of AvrII for 16 hours at 37 °C. AvrII cuts
within the GAP promoter, thereby allowing for homologous recombination at that same
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site in the P. pastoris genome (Figure 5.4A).45,56,61 Homologous recombination results in
incorporation of the linearized plasmid into the P. pastoris genome.45,61 As a positive
control, pGAPZA was linearized using the same restriction enzyme (Figure 5.4B) and
transformed into P. pastoris cells as well. Electrocompetent X33 cells (80 μL) and 10 μg
of linearized pGAPZA-BAF180 (or control pGAPZA) were combined in a
microcentrifuge tube and subsequently transferred to a cold 0.2 cm electroporation
cuvette. The cells were incubated on ice for 5 minutes.61 A Bio-Rad MicroPulser (under
the setting “Pic”) was used to transform the cells.63 Immediately after pulsing the
cell/plasmid mixture, 1 mL of ice-cold 1 M sorbitol was added to the cuvette; sorbitol is
used to stabilize the electroporated cells, because they can be sensitive to osmotic
pressure.61 It was very important that the sorbitol be added immediately, as
transformation efficiency decreases exponentially with time delay.63 The mixture of
cells/plasmid/sorbitol was transferred to a 15 mL tube and incubated at 30 °C for 2 hours
without shaking. Various amounts of the transformation mixture (5 µL, 10 µL, 15 µL, 25
µL, 50 µL, 75 µL, 100 µL, 125 µL, 150 µL, 175 µL and 200 µL) were spread on YPDS
(YPD with sorbitol) plates with 100 µg/mL zeocin and grown for 3 days at 30 °C.61
Colonies possessing the zeocin resistance gene grow better at lower densities, which is
why various amounts of the transformation mixture was used.61 The transformation of
pGAPZA-BAF180 resulted in 6 very small colonies (~1 mm) and the transformation of
pGAPZA resulted in 2 colonies. Consultation with another lab experienced in P. pastoris
expression suggested that the recommended zeocin concentration (100 µg/mL) is too
high and noted that it is not used in that lab. This lab uses 25 µg/mL, 50 µg/mL, and 75
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µg/mL. Therefore, the low transformation efficiency may be a result of the high zeocin
concentration.
The transformation products were purified to ensure that there were no mixed
colony transformants, as mixed colony transformants have a tendency to lose the foreign
DNA.61 The six colonies were streaked on YPD plates with 25 µg/mL zeocin, and grown
for approximately 42 hours. Each of these colonies were removed and re-streaked on
plates with 100 µg/mL zeocin and grown for 3 days at 30 °C. Isolating single colonies
was difficult as the cell density was very high. After consultation with the other lab, a
new method for plating for single colonies was used, wherein a single colony was picked
up and added to 200 µL YPD. A toothpick was dipped in the media and used to streak
new plates (YPD with 100 µg/mL zeocin). These resulting single colonies were used to
create freezer stock.

5.3 Preliminary Test for Protein Expression
An initial test for BAF180 expression was performed using cultures grown at 4
time-points. Zeocin selection was only used for plates; liquid YPD cultures did not have
any zeocin added. A pGAPZA-BAF180 transformant (BAF180 X33) was grown for 3
days at 30 °C on a YPD plate with 100 µg/mL zeocin. A single colony was used to
inoculate 10 mL of YPD and was grown overnight at 30 °C and 225 rpm. Four separate
cultures were created from this initial stock, each culture having 2 mL of overnight
culture added to 50 mL fresh YPD. Consequently, all the cultures stem from the same
colony, thereby eliminating the possibility of expression differences between colonies.
Each of the 4 cultures were grown at 20.5 °C and 225 rpm, and 1 culture was removed
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every 24 hours. The temperature of 20.5 °C was chosen because it was hypothesized that
this lower temperature would increase the probability of BAF180 production. These cells
were harvested by centrifuging at 12,000 g for 15 minutes at 4 °C and lysed using the
method presented by Johnson et al.64 Harvested cells were re-suspended in lysis buffer
(50 mM Tris-Cl, pH 7.4, 1 mM PMSF) at 2 mL/gram cell (PMSF is highly unstable in
aqueous solutions and therefore needed to be added immediately prior to use). The cell
suspension was then added to 1.5 mL microcentrifuge tubes along with 0.5 mm
zirconia/silica disruption beads. The quantities used for each are shown in Table 5.1.
Volumes of zirconia/silica beads were measured by displacement. Each tube was
vortexed on maximum speed for 30 seconds, followed by a 30 second rest on ice; this
cycle was repeated a total of 6 times. The samples were then centrifuged at 12,000 g for
15 minutes at 4 °C and the lysate collected. 8 M urea was added to the cell debris to
recover any insoluble protein.
Table 5.1: Ratios of cell suspension and zirconia/silica disruption beads used in the initial screening for
BAF180 production.
Time Point

Cell Suspension

Zirconia/Silica Beads

0 hour

~500 µL

~250 µL

24 hour

~500 µL

~250 µL

48 hour

~650 µL

~150 µL

72 hour

~680 µL

~320 µL

96 hour

~680 µL

~320 µL
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All samples were visualized on SDS-PAGE to determine if BAF180 production
occurred (Figure 5.5A & B). Additionally, the media was tested to confirm that BAF180
was not being secreted from the cell (Figure 5.5C). Results suggested that there was no
BAF180 present in the soluble fraction (lysate), but a band around 190 kDa (the size of
BAF180) was seen for the 96 hour insoluble fraction. Surprisingly, bands ~190 kDa were
seen in the 72 hour media and 96 hour media samples. P. pastoris secretes very low
levels of native proteins43,45,65-67 and the pGAPZA vector does not have a secretion signal,
therefore no protein should be seen in the media. It was suspected that these bands are
present because some of the cells were being lysed during cell growth.43
A.

O hr,
lysate

24 hr,
lysate

48 hr,
lysate

72 hr,
lysate

B.

96 hr,
lysate

260 kDa

O hr,
Ins

24 hr,
Ins

48 hr,
Ins

72 hr,
Ins

96 hr,
Ins

260 kDa

140

140

100

100

70

70
50

50

40
40
35

35

C.

O hr,
media

24 hr,
media

48 hr,
media

72 hr,
media

96 hr,
media

260 kDa
140
100
70

50
40

Figure 5.5: SDS-PAGE results from the initial screening for BAF180 production in Pichia pastoris X33
cells; BAF180 is approximately 190 kDa. (A) The soluble fraction (i.e. lysate); no band was seen at 190
kDa. (B) The insoluble fraction; a band about 190 kDa was seen for the 96 hour sample. (C) The media
samples; bands at ~190 kDa were seen for the 72 hour and 96 hour media samples. The band for BAF180 is
found in the red box.
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When using yeast as a heterologous host, it is possible for multiple copies of the
recombinant gene (i.e. BAF180) to be integrated into the genome. Though these are rare
occurrences, the presence of multiple copies can increase recombinant protein
yield.45,56,60 Both BAF180 low-producing (likely 1 copy) and high-producing (likely
more than 1 copy) clones were identified via SDS-PAGE of BAF180 X33 lysate (Figure
5.6). On YPD plates, WT X33 cells consistently formed larger colonies than highproducing BAF180 clones (Figure 5.7A) grown under the same conditions (30 °C, 72
hours) and WT X33 cells appeared slightly more white in color than high-producing
BAF180 X33 cells (Figure 5.7B). Colonies of high-producing clones were noticeably
“stickier” on solid media as well. In liquid media, there were no significant changes in
the cellular masses of WT X33 cultures and BAF180 X33 cultures. However, highproducing BAF180 cell cultures were significantly more viscous than cultures of lowproducing BAF180 cells or WT X33 cells. Additionally, low-producing BAF180 cells
and WT X33 both compacted much better during centrifugation than high-producing
cells did, so a higher centrifuge speed was required. High-producing BAF180 cells were
also harder to re-suspend during the lysis procedure, which resulted in increasing the
buffer:cell ratio (3mL/gram from 2 mL/gram).
High-producing cells were only discovered after visualizing the lysate on SDSPAGE. Therefore, the high-producing cells needed to be obtained from the soluble lysate.
200 μL of soluble lysate was added to 3 mL of YPD and grown at 30 °C for 20-24 hours.
Luckily, this culture grew and plates were made. Various volumes of the high-producing
culture were added to YPD plates, as decreasing the cell density on plates can improve
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growth.61 The plates were grown at 30 °C for 3 days and then used to re-streak for single
colonies. A single colony was used to inoculate a 5 mL YPD culture, which was grown
overnight at 30 °C with 225 rpm. Freezer stock was obtained from this culture.
LP

HP
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140
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Figure 5.6: SDS-PAGE comparison of low-producing (LP) and high-producing (HP) clones of BAF180
X33 cells. The high-producing clones were identified by visual comparison between the soluble lysates of
multiple clones. All cells were lysed using the same method. BAF180 (190 kDa) is within the red box.

A.

B.

Figure 5.7: Direct visual comparison of colonies of WT X33 cells (left) and colonies of high-producer
BAF180 X33 cells (right). (A) Differences in colony size between the two cell types. (B) Differences in
color of the colonies.
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5.4 Optimization of Growth Conditions
In order to obtain maximum expression levels of BAF180, growth conditions
were optimized. This involved the manipulation of growing temperature, time, and
growing media.64,68-70

5.4.1 Investigating the Role of Temperature and Time on BAF180
Production
The temperature used during heterologous cell growth has been demonstrated to
change the yield and activity for several proteins.64,68-70 Three temperatures were tested:
30 °C, 25 °C, and 20.5 °C to study the influence of temperature on BAF180 production.
While yeast is normally grown at 30 °C, lowering the temperature can result in a higher
quantity of “active” protein; this is especially important for proteins destined for
mechanistic studies. As mentioned previously, the constitutive GAP promoter was chosen
because it allows for continuous protein production during cell growth. Lowering the
temperature slows cell growth which would subsequently result in a slower rate of
BAF180 production. It was hypothesized that a slower rate of protein production would
give the cell more time to properly fold the recombinant protein, because the quantity of
protein present would be less and the protein would not overwhelm the cell’s protein
folding machinery. Therefore, a lower temperature might result in more functional
BAF180 being produced.
The growing time is related to the cell density as it takes a certain amount of time
for a culture to reach exponential growth, where it is growing the fastest. Because
lowering the temperature slows down cell growth, the time that the cultures require to
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reach exponential growth changes; therefore, temperature and time were tested in
tandem. Since the GAP promoter was chosen (constitutive, not inducible), the exact point
of exponential cell growth was not needed. The time to reach exponential cell growth is
important with inducible promoters (such as T7 and AOX1), as it is best to add the
inducer (IPTG or methanol) at the beginning of this phase. To determine if the stage of
cell growth, and thus cell density, affected the expression of BAF180 different growing
times were tested: 24 hours, 48 hrs, 72 hrs, 96 hrs, and 120 hrs. It was hypothesized that a
higher cell density would result in more BAF180. However, at higher cell densities the
cells can burst and release proteases, which would degrade BAF180.
To test the effects of temperature and time on the production of BAF180,
BAF180-containing X33 cells were streaked on YPD plates containing 100 µg/mL zeocin
and grown at 30 °C for 3 days. A 10 mL YPD culture was inoculated with 1 colony and
grown overnight at 30 °C and 225 rpm. YPD cultures (50 mL each) were inoculated with
2 mL of the overnight culture and grown at 30 °C for 24, 48, 72, 96, or 120 hours. Every
24 hours, a different culture was removed and spun down at 12,000 g for 15 minutes at 4
°C. The cells for each time point were lysed and the lysate visualized on SDS-PAGE
(Figure 5.8). This procedure was repeated for tests at 20.5 °C and 25 °C; the overnight
culture conditions remained the same. At least 6 replicates of each time and temperature
combination were compared to determine changes in protein content. The results shown
in Figure 5.8 are representative of the results obtained. Results repeatedly indicated that
growing the cells at 25 °C was ideal (Figure 5.9); 24 and 48 hour time spans did not
exhibit any significant difference, so 24 hours was chosen for brevity.
145

48 hr

24 hr

A.

sol

sol

ins

ins

72 hr

96 hr

sol

sol

245 kDa
190
135
100
80

58
46
48 hr

24 hr

B.

sol

sol

ins

72 hr
ins

sol

96 hr
sol

245 kDa
190
135
100
80
58
46

24 hr

C.

sol

48 hr
ins

sol

96 hr

72 hr
ins

sol

ins

sol

ins

245 kDa
190
135
100
80
58
46

Figure 5.8: SDS-PAGE gels displaying the soluble (s) and insoluble (i) lysate fractions for BAF180 X33
cells. Cells were grown at different temperatures and times and the BAF180 content was compared. Results
repeatedly demonstrated that 25 °C was optimal. (A) 20.5 °C; (B) 25 °C; (C) 30 °C. The band for BAF180
is found in the red box.
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Figure 5.9: SDS-PAGE of lysates from BAF180 X33 cells grown at 25 °C. All lysates shown are the
soluble fractions. Results repeatedly demonstrated that optimal growing time was 24 or 48 hours. There
was no significant difference in BAF180 content between the 2 time spans; therefore, 24 hours was chosen
for brevity. The band for BAF180 is found in the red box.

5.4.2 Influence of Media Composition
Experiments were also conducted to determine if pH or media composition would
have a significant impact on cellular growth and BAF180 production.64,68-70 Each 50 mL
culture was started from 2 mL of the same 20 mL overnight culture (25 °C, 225 rpm, ~16
hrs). The 50 mL cultures were grown at 25 °C for 24 hours. YPD was used as the base
media for all the tests; pH was varied (4 or 6.7) and various additives (glycerol, sorbitol,
NH4OH, dextrose) were included (Figure 5.10). Interestingly, the pH of the culture had
the most significant impact on cell density; normal YPD had approximately 4x higher
cell growth than YPD at pH 4. However, YPD+G results demonstrated the opposite
effect; pH 4 grew better than pH 6. Results indicate that growing the cells in YPD results
in the highest expression levels of BAF180 (Figure 5.11).
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A. YPD (1% yeast extract, 2% peptone,
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C. YPD, added 5% NH4OH at 5 hrs
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dextrose at 5 hrs
E. YPD+G, pH 4 (YPD + 1% glycerol)
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G. YPDS (YPD + 18.2% sorbitol)
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Figure 5.10: Comparison of growth mediums. All cells were grown at 25 °C for 24 hours and lysed in a 5
mL tube with a 1:1 ratio of lysate:beads. (A) Graphical representation of the cell densities observed for the
different cultures; (B) Visual comparison of cultures. Growth mediums were: A: YPD (normal pH of 6.7);
B: YPD, pH 4; C: YPD, 5% NH4OH at 5 hours; D: YPD, 5 mL 20 % dextrose at 5 hours; E: YPD+G, pH 4
(YPD + 1 % glycerol); F: YPD+G (normal pH); G: YPDS (YPD + 18.2 % sorbitol); H: YPD in baffled
flask; I and J: YPD.
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Figure 5.11: Optimization of media composition and pH. All gels were run using the same ladder as seen
on the far left side. Some media compositions resulted in more or less BAF180 being produced, though the
general protein composition of the cells did not change significantly. All cells were grown at 25 °C for 24
hours and lysed in a 5 mL tube with a 1:1 ratio of lysate:beads. Growth mediums were: A: YPD (normal
pH of 6.7); B: YPD, pH 4; C: YPD, 5% NH4OH at 5 hours; D: YPD, 5 mL 20 % dextrose at 5 hours; E:
YPD+G, pH 4 (YPD + 1 % glycerol); F: YPD+G (normal pH); G: YPDS (YPD + 18.2 % sorbitol); H: YPD
in baffled flask; I and J: YPD. The band for BAF180 is found in the red box.

5.4.3 Influence of Culture Volume on BAF180 Production
After preliminary tests were performed to determine optimal growth conditions,
culture scale-up conditions were tested. Because yeast growth can be highly dependent
on available oxygen,71-77 it was unknown whether the increase in volume would impede
growth and/or BAF180 production. Though the GAP promoter does not rely on oxygen
as much as the AOX1 promoter, tests were still performed. In tandem with culture scaleup experiments, different time spans were tested to determine if the larger culture
volumes required a longer growing period. All initial tests were done with 50 mL cultures
that had been inoculated with 2 mL of overnight culture. For scale-up experiments, the
amount of overnight culture added to a new culture varied depending on the final culture
volume. For culture volumes of 100 mL, 3.5 mL of overnight culture was used. Larger
culture volumes (200 mL and 500 mL) were inoculated by taking aliquots from a 50 mL
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24 hour culture; 5 mL was used to inoculate a 200 mL culture and 10 mL was used for
500 mL. Conditions tested are shown in Table 5.2. Each culture was harvested and lysed
in the same manner and the soluble fractions were visualized on SDS-PAGE. As shown
in Figure 5.12, the amount of BAF180 produced did not vary significantly with culture
volume or time. It appeared that the quantity of oxygen did not affect BAF180
production, as increasing the volume did not significantly affect BAF180 content.
Therefore, all subsequent culture volumes were increased to 500 mL so a larger volume
of lysate could be obtained.
Once high-producing cells were discovered, a brief scale-up test was performed
again. In this case, a 15 mL overnight culture was used. Culture volumes of 50 mL, 100
mL, and 500 mL were investigated; as before, the amount of overnight culture used to
inoculate the fresh cultures varied depending on the volume. 50 mL cultures were
inoculated with 2 mL of overnight, while 3.5 mL was used for the 100 mL culture and 5
mL of overnight was used for 500 mL culture. Again, scale-up did not significantly affect
BAF180 production (Figure 5.13). Results indicate that ideal growing conditions for
BAF180-producing cells are: 25 °C, 225 rpm, 24 hours, 500 mL YPD inoculated with 5
mL of overnight culture.
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Table 5.2: The combinations of culture volume and growth time used during scale-up testing. Also
displayed are the various volumes of overnight culture added to the larger culture.

Culture volume

Volume of overnight
culture added

Growth time
(hours)

50 mL

2 mL

24

100 mL

3.5 mL

24

100 mL

3.5 mL

48

200 mL

5 mL

24

500 mL

10 mL

24

260 kDa

260 kDa

140

140

100
100

70

70
50
50
40
40

Figure 5.12: Culture scale-up testing. To determine how expression of BAF180 changes when the culture
volume changes, multiple experiments were run and the lysates compared. Above are representative
samples of the different combinations; all combinations were grown with low-producing cells at 25 °C and
225 rpm shaking. All fractions shown are the soluble fractions and all cells were lysed in the same manner.
As can be seen, culture volume did not significantly affect BAF180 production, suggesting that scaling-up
the growth of BAF180-producing cells was possible. The band for BAF180 (~190 kDa) is in the red box.
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Figure 5.13: Scale-up testing of high-producer cells. Once the high-producing strains were discovered and
isolated, scale-up conditions were tested again. There was no significant difference in BAF180 content
between the different culture volumes. Cells were grown at 25 °C with 225 rpm shaking. The fractions
shown are the soluble fractions and all cells were lysed in the same manner. As can be seen, culture volume
did not significantly affect BAF180 production, suggesting that scaling-up the growth of BAF180producing cells was possible. The band for BAF180 is found in the red box.

5.5 Optimization of Lysis Conditions
To ensure the highest recovery of BAF180, lysis conditions were manipulated and
optimized. Lysis of P. pastoris cells involves harvesting the cells from the culture and resuspending them in a lysis buffer. The cell suspension is combined with 0.5 mm beads
wherein they are subjected to repeated mechanical agitation. Buffer composition, lysis
mixture volume, agitation time, and the ratio of cell suspension to beads were
investigated in an effort to maximize the recovery of BAF180.
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The initial lysis conditions were based on the procedures outlined in the
Invitrogen manual61 and in publications from Dr. P. Murthy’s lab.64,68 These protocols
involved harvesting the P. pastoris cells via centrifugation (12,000 g for 15 minutes at 4
°C), followed by wash and subsequent re-suspension in a lysis buffer at a ratio of 2 mL
buffer per gram cell. A volume of cell suspension was combined in a tube along with
zirconia/silica beads (0.5 mm) and the mixture of cells and beads were vortexed multiple
times for a duration of 30 seconds, followed by 30 second rest on ice.61,64,68 The lysate
was recovered after further centrifugation (soluble fraction). Insoluble proteins were
extracted by addition of 8 M urea to the cell debris (insoluble fraction).
Three lysis buffers were examined to determine if the buffer composition affected
the lysis efficiency and BAF180 protein stability (Figure 5.14). The buffers were as
follows: Buffer 1 – 50 mM Tris-Cl, pH 7.4 with 1 mM PMSF;64,68 Buffer 2 – 50 mM
NaH2PO4, pH 7.4; 1 mM PMSF; 1 mM EDTA; 5 % glycerol;61 Buffer 3 omitted EDTA
from buffer 2. Since BAF180 is a very large protein (190 kDa), attempting to refold it
into its native state after denaturation during would be very difficult, therefore the goal
was to determine which buffer composition resulted in the largest amount of BAF180 in
the soluble fraction of the lysate. When using buffer 1, BAF180 was primarily found in
the insoluble fraction. For buffer 2, BAF180 repeatedly appeared in the soluble fraction.
Therefore, buffer 2 was chosen for all future experiments. It was hypothesized that the
EDTA and glycerol found in buffer 2 had a stabilizing effect on the protein: glycerol
slows down the kinetic energy of the solution and EDTA inhibits metalloproteases.
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Figure 5.14: Comparison of the soluble (sol) and insoluble (ins) fractions for lysis with buffer 1 and with
buffer 2. Though the bands are faint, the gel shows that most of the BAF180 (190 kDa) protein is found in
the insoluble fraction (8 M urea) when using buffer 1, but found in the soluble fraction when using buffer 2.
Since the BAF180 protein is so large, attempting to refold it into its native state after denaturation during
lysis would be very difficult. Therefore, the buffer that had more BAF180 in the soluble fraction was
chosen for all future work. Each fraction shown was lysed under the same conditions (1.5 mL tube, 1:1
ratio), except for the buffer composition. The lysis fractions shown here were from low-producing cells.
The band for BAF180 is found in the red box.

Various volumes of lysis mixture (total volume of cell suspension and beads)
were tested to determine if the total volume impacted recovery of BAF180. It was
considered that perhaps the amount of dead space in the tube might affect how the cells
and beads interacted (such as number of collisions). In a 1.5 mL tube, total volumes of
0.75 mL, 1 mL, and 1.25 mL were tested. In a 5 mL tube, total volumes of 4 mL and 4.5
mL were tested. There was no significant difference in the amount of BAF180 recovered
when comparing lysis volumes (Figure 5.15). Lysis in 5 mL tubes was most time
efficient, though recovery of the lysate was more difficult than for 1.5 mL tubes;
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however, this trade-off was considered to be worth it because it reduced the overall time
required for cell lysis. A volume of 4 mL lysis mixture in a 5 mL tube was chosen for
future experiments.
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Figure 5.15: Effects of total volume and cell:bead ratio. Three cultures (A, B, C) were grown at 25 °C for
24 hours, all started from the same seed culture. All cultures were lysed in buffer 2 (50 mM NaH2PO4, 1
mM PMSF, 1 mM EDTA, 5 % glycerol, pH 7.4); cells were re-suspended at 2 mL/g cell pellet. Different
volumes and different ratios of lysate:beads were tested. The differences in lysate content indicate that total
volume and ratio of cells:beads did not a have a significant impact. All fractions shown are soluble
fractions. BAF180 (~190 kDa) is the intense band between 260 and 140 kDa marker (in red box).

The ratio of cell suspension:beads was tested to determine if the ratio affected
BAF180 recovery. It was hypothesized that there might be an optimal ratio to ensure the
most favorable interactions between the cells and beads (such as number of collisions).
Ratios of 1:1, 2:1, 3:1, and 4:1 were tested (Table 5.3), but no significant difference in
BAF180 content was observed for each of the ratios used (Figure 5.15 and Figure 5.16).
A ratio of 3:1 was chosen for future work because it was easiest to remove the lysate after
centrifugation, meaning that it was easier to separate the supernatant from the beads at
this ratio.
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Table 5.3: Volumes used when testing different volumes of cells and beads, in both a 1.5 mL tube and a 5
mL tube. All ratios are cells:beads.

Ratio

1.5 mL Tube

5 mL Tube

1:1

500 µL:500 µL

2 mL: 2 mL

2:1

500 µL:250 µL

3 mL:1.5 mL

3:1

3 mL:1 mL

4:1

A

1

2

3

800 µL:200 µL
1 mL:250 µL

B

1

2

3

C

260 kDa

260 kDa

260 kDa

140

140

140

100
70

100
70

100

50

50

40

40

1.
2.
3.

A sol 1.5 mL
B sol 1.5 mL
C sol 1.5 mL

1

2

3

70
50
40

1.
2.
3.

A sol 5 mL 1:1
B sol 5 mL 1:1
C sol 5 mL 1:1

1.
2.
3.

A sol 5 mL 2:1
B sol 5 mL 2:1
C sol 5 mL 2:1

Figure 5.16: Lysis of high-producing cells. Three cultures were grown at 25 °C for 24 hours, all started
from the same seed culture. All cultures were lysed in buffer 2 (50 mM NaH2PO4, 1 mM PMSF, 1 mM
EDTA, 5 % glycerol, pH 7.4); cells were re-suspended at 2 mL/g cell pellet. Different volumes and
different ratios of lysate:beads were tested. The differences in lysate content indicated that volume and ratio
did not a have a significant impact on BAF180 recovery. These gel images also demonstrate the variation
in BAF180 content between cultures, possibly due to inactivation of PMSF over time. The band for
BAF180 is found in the red box.

The established methods for lysing yeast cells are enzymatic treatment and
mechanical agitation. Mechanical agitation was chosen for use because it is more costefficient than enzymatic lysis. Zirconia/silica beads are added to the cell suspension and
the mixture is subjected to vortexing for 30 seconds, followed by a 30 second rest on ice.
The number of cycles was varied to determine how it affected BAF180 recovery. Repeats
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of 6, 8, 10, 12, and 16 were tested (Figure 5.17). It was determined that 12 cycles
consistently yielded the most BAF180 in the soluble fraction.

Buffer 1, 1.5 mL
6x

8x

12x

Buffer 2, 1.5 mL
6x

8x
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Figure 5.17: Experimental results comparing buffers 1 and 2, the total volume, and the number of cycles.
All samples shown are soluble fractions and were lysed using a 1:1 ratio. Note that the total volume did not
make a difference in lysate content. However, buffer type and number of cycles did. It can be seen that
BAF180 (190 kDa) is more prevalent in the buffer 2 soluble lysate samples than in buffer 1. This is likely
due to the presence of glycerol and EDTA in buffer 2. Additionally, the number of cycles did not
significantly affect lysate content, though there was a small, but reproducible increase in BAF180 content
for 12 cycles. The band for BAF180 is found in the red box.

Once the high-producing clones were discovered, volume and ratio experiments
were performed again to verify that the results would not be different (Figure 5.16).
High-producing cells were harvested by centrifuging at 17,000 g for 30 minutes at 4 °C.
Both centrifugation speed and time were increased due to the increased culture viscosity
of high-producing cells. After decanting the media, the cells were re-suspended in
breaking buffer at a ratio of 3 mL/gram cell (this was increased from the previous 2
mL/gram cell because a larger volume was necessary to re-suspend the BAF180 high157

producing cells as intercellular adhesion was high, resulting in cells that were noticeably
“stickier”).
Additionally, the effect of the protease inhibitor composition was examined in
relation to BAF180 recovery. It was thought that perhaps a more stable protease inhibitor
would yield more consistent results. Use of PMSF gave inconsistent results, likely due to
its instability and short half-life in aqueous solutions (30-60 minutes). The amount of
time between starting and finishing lysis did vary and this likely impacted BAF180
recovery. Comparisons were done between PMSF and a protease inhibitor cocktail
purchased from VWR. PMSF inhibits only serine proteases, while the protease inhibitor
cocktail from VWR inhibits serine proteases (AEBSF, Aprotinin, and Leupeptin),
cysteine proteases (E-64, Leupeptin), and aminopeptidases (Bestatin). Also, the lysis
buffer contains EDTA, a metalloprotease inhibitor; EDTA was present for both tests.
Larger yields of BAF180 (i.e. more intense bands on SDS-PAGE) were consistently
observed when using the protease inhibitor cocktail (Figure 5.18). All subsequent cell
lysis was performed using the cocktail from VWR instead of PMSF.
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Figure 5.18: Choice of protease inhibitor type. Both PMSF and a protease inhibitor cocktail were used
during lysis and the results were compared. A slightly more intense BAF180 band was consistently seen
when using the protease inhibitor cocktail (PIC). The band for BAF180 is found in the red box.

After testing numerous combinations of the above variables, the optimal lysis
procedure was established as follows: Cells were harvested by centrifuging at 17,000 g
for 30 minutes at 4 °C. After decanting the media, the cells were washed by resuspending them in 100 mL of buffer 2 containing 1 mM PMSF. The cells were spun
down again, decanted, and re-suspended at a ratio of 3 mL/gram cell in buffer 2 with
protease inhibitor cocktail (at the recommended concentration). The cell suspension was
combined with 0.5 mm silica/zirconia beads at a ratio of 3:1 (3 mL cells/1 mL beads,
total volume 4 mL). The cell/bead mixture was vortexed on maximum speed for 12
cycles (30 seconds on vortex/30 sec on ice). The lysate was centrifuged at 17,000 g for 30
minutes at 4 °C and the supernatant was removed (soluble fraction).
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5.6 Confirmation of BAF180
To determine if the 190 kD band seen was an endogenous protein, wild-type X33
(transformed with pGAPZA for zeocin resistance) soluble and insoluble fractions were
compared to the soluble fraction of BAF180 X33 cells (transformed with pGAPZABAF180) (Figure 5.19). Only the soluble lysate of BAF180 cells is shown, because this
experiment was just to demonstrate that a band at the approximate molecular weight of
BAF180 (~190 kDa) is not normally present in X33 cells. The 2 cultures, WT X33 and
BAF180 X33, were treated in the same manner: growth was conducted for 96 hours at
20.5 °C and lysed using the same method. Comparison of lysates and insoluble fractions
of WT X33 did not show a band around 190 kDa. When compared side by side, a band,
approximately 190 kDa was seen only in BAF180 X33 cells (Figure 5.19). This
experiment was also repeated several times after ideal growth conditions were established
(25 °C for 24 hours).
WT X33
sol

ins

BAF180 X33
sol

260 kDa

140

95
72

Figure 5.19: A comparison of the lysates WT X33 cells to the lysate of BAF180 X33 cells. SDS-PAGE
gels (7.5%) showed a band around 190 kDa (expected molecular weight of BAF180) only in the BAF180
X33 fraction. Neither the soluble (sol) nor insoluble (ins) fractions of WT X33 cells displayed a band of the
correct BAF180 size, so it was concluded that BAF180 is not normally expressed in wild type cells. The
band for BAF180 is found in the red box.
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Confirmation of BAF180 was also done using an anti-PBRM1 antibody via
western and dot blots. A dot blot is the same concept as a western blot, except the protein
sample is spotted directly onto the membrane. For the dot blot, 2 µL of protein sample
was spotted onto a 0.45 µm nitrocellulose membrane and allowed to dry; the membrane
was hydrated in wash buffer for 5 minutes. A Pierce Fast Western ECL kit was used; kit
instructions were followed with one exception: a 5 minute wash step was added between
primary and secondary antibody incubations, to remove azide present in the primary
antibody storage solution. Anti-PBRM1 antibody was used at a ratio of 1:1000 (10 µL of
stock antibody was added to 10 mL of Fast Western Antibody Diluent). After incubation
in ECL (enhanced chemiluminescence) substrate, the membrane was imaged with BioRad XRS+ imager (CDD camera). Crude lysates of BAF180 X33 cells and of WT X33
cells (both soluble and insoluble fractions) were spotted onto the membrane and tested
against the antibody. The results (displayed in Figure 5.20) indicate that BAF180 is not
present in WT X33 cells, as no spot was seen. This test served two purposes: one, to
confirm that the protein being produced was BAF180 and two, that this protein is not
endogenous to WT X33 cells.
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Figure 5.20: Confirmation of BAF180 production via dot blot. Crude lysates of BAF180 X33 and WT X33
cells were spotted onto a nitrocellulose membrane and allowed to dry. The membrane was then exposed to
anti-PBRM1 antibody and imaged using a CDD camera. As can be seen, signals were detected for the crude
lysate of BAF180 X33 cells (boxes 1 and 2), but not for WT X33 cells (boxes 3 and 4). Both soluble and
insoluble lysate fractions of each cell were used. Box 1: insoluble fraction BAF180 X33; box 2: soluble
fraction BAF180 X33; box 3: insoluble fraction WT X33 cells; box 4: soluble fraction WT X33 cells.

Western blot experiments were performed using Tris-glycine and Tris-acetate
SDS-PAGE gels. All attempts with the Tris-glycine system were unsuccessful. However,
western blots were successfully carried out using pre-cast NuPAGE Tris-Acetate gels (38%). Tris-acetate gels were chosen because they are thought to be the best option when
transferring large molecular weight proteins.78 1x NuPAGE Tris-acetate running buffer
was prepared with NuPAGE antioxidant. NuPAGE antioxidant is a proprietary formula
purchased from ThermoFisher which is added to the upper chamber of the gel assembly
to ensure that the samples remain reduced; in the neutral pH of Tris-acetate gels, reducing
agents do not travel with the sample and therefore the samples have the potential to be reoxidized during electrophoresis.79 10 µg of sample (quantified via bicinchoninic acid
assay) was prepared and loaded into each well. The gel was run for 1 hour at 150 V. After
running, the gel was removed and incubated for 10 minutes in 100 mL of 2x NuPAGE
transfer buffer with 0.02% SDS and NuPAGE antioxidant. 1x NuPAGE transfer buffer
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was prepared with 0.01% SDS, 10% methanol, and NuPAGE antioxidant. 0.45 µm PVDF
membrane was activated in 100% methanol for 30 seconds, rinsed with water, and
incubated in 1x transfer buffer. Once the gel and PVDF membrane were prepared, the gel
sandwich was prepared and wet transfer was performed at 70 V for 1 hour.80 The PVDF
membrane was air dried and stored overnight at -20 °C.79 The western blot procedure was
carried out the same as for dot blots. Exposure for 55 seconds with a CCD camera
showed multiple bands being recognized (Figure 5.21). The most intense band appears at
approximately 190 kDa, the expected molecular weight of BAF180. The other bands
were a lower weight than this. There are a few possible reasons why multiple protein
bands were recognized: degradation of the protein by proteases is possible, as is
premature termination during DNA translation. The anti-PBRM1 antibody used
recognizes an epitope on the C-terminus of BAF180. For a band to be recognized by the
antibody, the C-terminus of BAF180 must be present, eliminating premature termination
as an option and suggesting that degradation occurs. Further investigations using other
anti-PBRM1 antibodies that recognize epitopes on the N-terminus and in the middle of
the protein are needed before the hypothesis can be confirmed. Regardless, the
concentration of the protease inhibitor cocktail will be increased for future experiments.
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Figure 5.21: Western blot performed on BAF180 lysate samples. The most intense band (top) is thought to
be full-length BAF180 (190 kDa). The reasons that bands of lower molecular weight are present are
currently unknown. The antibody used recognized an epitope on the C-terminus of BAF180.

The recognition epitope of the antibody used was located at the C-terminus.
Therefore, for a signal to be seen, this epitope must be present. Proteintech (the
manufacturer of the antibody) used an immunogen 306 amino acids in length,
encompassing the HMG box to the end of the protein. After researching the relationship
between immunogens and epitopes, analysis was performed using SVMTriP online
software81 to determine the most probable epitope sequences (Figure 5.22).
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A.

Proteintech Immunogen Sequence:
MGEEDSEVIEPPSLPQLQTPLASELDLMPYTPPQSTPKSAKGSAKKEGSKRKINMSGYILFSSE
MRAVIKAQHPDYSFGELSRLVGTEWRNLETAKKAEYEGMMGGYPPGLPPLQGPVDGLVSMG
SMQPLHPGGPPPHHLPPGVPGLPGIPPPGVMNQGVAPMVGTPAPGGSPYGQQVGVLGPPGQQ
APPPYPGPHPAGPPVIQQPTTPMFVAPPPKTQRLLHSEAYLKYIEGLSAESNSISKWDQTLAAR
RRDVHLSKEQESRLPSHWLKSKGAHTTMADALWRLRDLMLRDTLNIRQAYNLENV
Possible Epitopes: (SVMTriP)

Underlined is HMG box sequence

KYIEGLSAESNSISKWDQTL Score: 1.00 Position: 178-197
FGELSRLVGTEWRNLETAKK Score: 0.709 Position: 27-46
RKINMSGYILFSSEMRAVIK Score: 0.619 Position: -1-19
QPTTPMFVAPPPKTQRLLHS Score: 0.538 Position: 154-173

B.
GAP

Brd1

Brd2

Brd3

Brd4

Brd5

Brd6

BAH1

BAH2

HMG

AOX1

New stop
AA1
BAH2
AA -255

Original stop

AA50

Most likely epitope
His
Tag

HMG
178

AA -51

197

AA255

AOX1

AA288-293

Antibody Immunogen

Figure 5.22: The complete immunogen sequence used by Proteintech to create the anti-PBRM1 antibody.
(A) The most likely antibody recognition epitopes are colored and the HMG box sequence is underlined.
(B) The most probable recognition epitope is located 128 amino acids downstream of the HMG box.
Numbering is relative to the HMG box, where the first amino acid of the HMG box is denoted as 1. There
is no 0 position (-2, -1, 1, 2, etc.).

Additionally, PCR mapping of the domains was done to confirm the integration of
the full PBRM1 gene (i.e. BAF180) into the P. pastoris genome (Figure 5.23). Genomic
DNA (gDNA), isolated from the yeast cells as described in the appendix, was used as a
template. Each fragment was generated individually. The fragments cover most of the
gene sequence. The fragments were staggered so that each fragment overlaps with at least
one other to confirm the gene was integrated in the proper order. All PCR reactions had
500 ng of gDNA.
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A.

B.
Fragment 1

Fragment 2

Fragment 3

Fragment 4

Fragment 5

Fragment 6

3 kb
2
1.5
1
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Figure 5.23: Genomic DNA was isolated from BAF180 X33 cells and domain-specific primers were used
to confirm integration of the PBRM1 sequence in P. pastoris. (A) Map of the PBRM1 gene with fragments
numbered and expected sizes (inclusive of primers). (B) PCR products for domain mapping.

5.7 Conclusion
For the first time, full-length BAF180 was successfully produced in a
heterologous host. BAF180 was an enormously difficult protein to clone, likely owing to
the size, presence of multiple domains, presence of many rare codons, frequent base
tracks in the DNA, and instability. Regardless, after much effort, BAF180 was
successfully produced in the yeast Pichia pastoris. To recover the most BAF180, growth
and lysis conditions were optimized. Ideal growth conditions were determined to be 24
hours at 25 °C in 500 mL YPD. The optimal lysis procedure was established as follows:
the cells were harvested by centrifuging at 17,000 g for 30 minutes at 4 °C. The media
was decanted and the cells were washed by re-suspending them in 100 mL of buffer 2
containing 1 mM PMSF. The cells were spun down again, decanted, and re-suspended at
a ratio of 3 mL/gram cell in lysis buffer 2 with protease inhibitor cocktail. The cell
suspension was combined with 0.5 mm silica/zirconia beads at a ratio of 3:1 (3 mL
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cells/1 mL beads, total volume 4 mL). The cell/bead mixture was vortexed on maximum
speed for 12 cycles (30 seconds on vortex/30 sec on ice). The lysate was centrifuged at
17,000 g for 30 minutes at 4 °C and the supernatant was recovered (soluble fraction).
Following growth and lysis optimization, the presence of BAF180 was confirmed
in multiple ways. Lysates of BAF180 X33 cells and WT X33 cells were compared to
confirm that the 190 kD band seen on SDS-PAGE gels of BAF180 X33 lysate was not
endogenous to X33 cells. The possibility of an endogenous X33 protein not appearing on
the gel was considered and dot blot experiments were performed. After probing with an
anti-PBRM1 antibody, comparison of BAF180 X33 and WT X33 lysates (control) proved
that BAF180 was not present in WT X33 cells. Western blot experiments were
successfully carried using the Tris-acetate gel system. Probing the membrane with the
anti-PBRM1 antibody showed multiple protein bands being recognized. This is likely due
to degradation of the protein; more protease inhibitor cocktail will be added in an attempt
to minimize this. Integration of the PBRM1 gene into the Pichia pastoris genome was
confirmed using PCR with genomic DNA and domain-specific primers. Results
supported the hypothesis that the PBRM1 gene was successfully integrated into the host
genome.

167

5.8 References
1.

Xia, W.; Nagase, S.; Montia, A. G., et al., BAF180 Is a Critical Regulator of p21

Induction and a Tumor Suppressor Mutated in Breast Cancer. Cancer Research 2008, 68
(6), 1667-1674.
2.

Robbins-Pianka, A.; Rice, M. D.; Weir, M. P., The mRNA landscape at yeast

translation initiation sites. Bioinformatics 2010, 26 (21), 2651-2655.
3.

Invitrogen. pGAPZ A, B, and C; pGAPZa A, B, and C. Pichia expression vectors

for constitutive expression and purification of recombinant proteins 2010, p. 44.
4.

Bio-Rad Inc., High Efficiency Electrotransformation of E. coli. In MicroPulser

Electroporation Apparatus Operating Instructions and Applications Guide, Rev B ed.; p
12.
5.

Lin-Cereghino, J.; Lin-Cereghino, G., Vectors and Strains for Expression. In

Pichia Protocols, Cregg, J., Ed. Humana Press: 2007; Vol. 389, pp 11-25.
6.

Puxbaum, V.; Mattanovich, D.; Gasser, B., Quo vadis? The challenges of

recombinant protein folding and secretion in Pichia pastoris. Applied Microbiology and
Biotechnology 2015, 99 (7), 2925-2938.
7.

Bio-Rad Inc., Electroporation of Pichia pastoris. In MicroPulser Electroporation

Apparatus Operating Instructions and Applications Guide, Rev B ed.; pp 19-20.
8.

Johnson, S. C.; Yang, M.; Murthy, P. P. N., Heterologous expression and

functional characterization of a plant alkaline phytase in Pichia pastoris. Protein
expression and purification 2010, 74 (2), 196-203.

168

9.

Fickers, P., Pichia pastoris: a workhorse for recombinant protein production.

Current Research in Microbiology and Biotechnology 2014, 2 (3), 354-363.
10.

Felber, M.; Pichler, H.; Ruth, C., Strains and Molecular Tools for Recombinant

Protein Production in Pichia pastoris. In Yeast Metabolic Engineering: Methods and
Protocols, Mapelli, V., Ed. Springer New York: New York, NY, 2014; pp 87-111.
11.

Macauley-Patrick, S.; Fazenda, M. L.; McNeil, B., et al., Heterologous protein

production using the Pichia pastoris expression system. Yeast (Chichester, England)
2005, 22 (4), 249-70.
12.

Cereghino, J. L.; Cregg, J. M., Heterologous protein expression in the

methylotrophic yeast Pichia pastoris. FEMS Microbiology Reviews 2000, 24 (1), 45-66.
13.

Aw, R.; Polizzi, K. M., Can too many copies spoil the broth? Microbial Cell

Factories 2013, 12 (1), 128.
14.

Yang, M.; Johnson, S. C.; Murthy, P. P. N., Enhancement of alkaline phytase

production in Pichia pastoris: Influence of gene dosage, sequence optimization and
expression temperature. Protein expression and purification 2012, 84 (2), 247-254.
15.

Mao, R.; Teng, D.; Wang, X., et al., Optimization of expression conditions for a

novel NZ2114-derived antimicrobial peptide-MP1102 under the control of the GAP
promoter in Pichia pastoris X-33. BMC Microbiology 2015, 15, 57.
16.

Guan, B.; Chen, F.; Lei, J., et al., Constitutive Expression of a rhIL-2-HSA Fusion

Protein in Pichia pastoris Using Glucose as Carbon Source. Applied Biochemistry and
Biotechnology 2013, 171 (7), 1792-1804.

169

17.

Baumann, K.; Carnicer, M.; Dragosits, M., et al., A multi-level study of

recombinant Pichia pastoris in different oxygen conditions. BMC Systems Biology 2010,
4 (1), 141.
18.

Looser, V.; Bruhlmann, B.; Bumbak, F., et al., Cultivation strategies to enhance

productivity of Pichia pastoris: A review. Biotechnology Advances 2015, 33 (6, Part 2),
1177-1193.
19.

Rebnegger, C.; Vos, T.; Graf, A. B., et al., Pichia pastoris Exhibits High Viability

and a Low Maintenance Energy Requirement at Near-Zero Specific Growth Rates.
Applied and Environmental Microbiology 2016, 82 (15), 4570-4583.
20.

Çalık, P.; İnankur, B.; Soyaslan, E. Ş., et al., Fermentation and oxygen transfer

characteristics in recombinant human growth hormone production by Pichia pastoris in
sorbitol batch and methanol fed-batch operation. Journal of Chemical Technology &
Biotechnology 2010, 85 (2), 226-233.
21.

Cos, O.; Ramón, R.; Montesinos, J. L., et al., Operational strategies, monitoring

and control of heterologous protein production in the methylotrophic yeast Pichia pastoris
under different promoters: A review. Microbial Cell Factories 2006, 5, 17-17.
22.

Vassileva, A.; Chugh, D. A.; Swaminathan, S., et al., Expression of hepatitis B

surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter.
Journal of Biotechnology 2001, 88 (1), 21-35.
23.

Güneş, H.; Çalık, P., Oxygen transfer as a tool for fine-tuning recombinant

protein production by Pichia pastoris under glyceraldehyde-3-phosphate dehydrogenase
promoter. Bioprocess and Biosystems Engineering 2016, 39 (7), 1061-1072.
170

24.

Brown, V. Five Fast Tips for Blotting Large Proteins.

http://bitesizebio.com/24228/five-fast-tips-for-blotting-large-proteins/ (accessed 3 April
2017).
25.

Invitrogen NuPAGE FAQs.

https://www.thermofisher.com/search/results?query=EA0375BOX&persona=DocSuppor
t&type=Product+FAQs (accessed 5 April 2017).
26.

Invitrogen, NuPAGE® Technical Guide. 2010.

27.

Yao, B.; Zhang, L.; Liang, S., et al., SVMTriP: A Method to Predict Antigenic

Epitopes Using Support Vector Machine to Integrate Tri-Peptide Similarity and
Propensity. PLOS ONE 2012, 7 (9), e45152.

171

Chapter 6 : Purification of BAF180 in Pichia pastoris
Purification of recombinant BAF180 was the next step after cloning and
optimization of the expression and lysis conditions. As stated in a previous chapter,
BAF180 has not been produced in a heterologous host and therefore has never been
purified from a heterologous host. Researchers utilizing mammalian cells generally
“purify” BAF180 by pull-down assay; this yields only small amounts of BAF180 and as
such is unsuitable for larger studies. The properties of BAF180 were studied before
attempting purification. Multiple purification methods were tried including IMAC (Histag affinity), strong and weak anion exchange (AEX), CHT hydroxyapatite (multi-mode),
hydrophobic interaction chromatography (HIC), size-exclusion (SEC), ultrafiltration, and
dialysis. Only strong AEX was able to purify BAF180 from the crude lysate.

6.1 Materials
SDS, glycine, Tris hydrochloride, Tris base, and glycerol purchased from
Amresco (VWR: Radnor, PA). NaCl was purchased from EMD Millipore (Billerica,
MA). EDTA was purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ). Dialysis
membranes were purchased from Spectrum Labs (Rancho Dominguez, California):
Spectra/Por® 1 (6-8 kD MWCO membrane; part 132660), and Spectra/Por 6® (50 kD
MWCO membrane; part 132544). Macro-Prep High Q® Support (cat. 1580040), and
Econo® glass columns were purchased from Bio-Rad, Inc. (Hercules, CA). Sodium
phosphate monobasic (NaH2PO4) and Whatman Puradisc 25 syringe filters – 1.0 µm PES
membrane (cat. WHA67812510) were purchased from Sigma Aldrich (St. Louis, MO).
Blotting paper (cat. 8860), 0.45 µm PVDF membrane (cat. 88585), NuPAGE Tris172

Acetate gels 3-8% (cat. EA0375), NuPAGE LDS Sample Buffer 4x (cat. NP0007),
NuPAGE Tris-acetate running buffer (cat. LA0041), NuPAGE transfer buffer (cat.
NP0006), NuPAGE antioxidant (cat. NP0005), NuPAGE reducing agent (cat. NP0004)
and Pierce Fast Western Blot Kit, ECL substrate (cat. 35050) were purchased from
ThermoFisher (Waltham, MA). Anti-PBRM1 antibody (cat. 12563-1-AP, rabbit
polyclonal) was received as part of the antibody exchange program at Proteintech
(Rosemont, IL). Western blot transfer was performed using a Hoefer TE22 transfer tank
(Holliston, MA).

6.2 Purification of BAF180 by Anion Exchange Chromatography
Purification of a recombinant protein by ion exchange chromatography uses the pI
of the protein (i.e. its charge at a certain pH) to separate it from other cellular proteins.
Above the pI, the protein is negatively-charged and can be separated by anion exchange
resins; below the pI, the protein is positively-charged and can be separated by cation
exchange resins.82-83 The pI of recombinant BAF180 is calculated to be 6.29. Anion
exchange chromatography (AEX) was chosen because of the known stability of BAF180
at pH 7.4, in lysis buffer 2 (see Section 5.5); since this is above the pI, BAF180 would
carry a net negative charge. A strong anion exchanger was chosen, because the
effectiveness of the resin is not affected by the pH of the buffer system, as weak anion
exchangers are.82,84-85 MacroPrep® High Q was chosen as the strong AEX resin because
it is noted as being good for separating large biomolecules and acidic and neutral
proteins.82,86-89 MacroPrep® High Q is a methacrylate polymer with a quaternary
ammonium group attached.88,90
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A well designed buffer system is critical for anion exchange to be successful.
When designing a buffer system for AEX, some general rules must be considered:
•

The pH of the buffer system should be 0.5-1.5 pH units above the pI of the
protein.83,85,91 Therefore, the pH of the buffer system needed to be between 6.8
and 7.8.

•

The pKa of the buffer system should be within 0.5 pH units of the buffer’s pH.91

•

The protein should be stable in the buffer system. Several different buffer systems
are possible, depending on the pH needed83,85,87-88,91 but Tris was chosen because
previous experiments demonstrated that BAF180 was stable in it. Tris buffers
have an approximate buffering range pH 7.5-8.83,85,87-88

•

An effective buffer system should be greater than 10 mM concentration.83,91-92

Calculating pKa values of various concentrations of Tris at room temperature led to the
decision to use 17 mM Tris at pH 7.6.92 A pH of 7.6 is 1.3 pH units above the pI of
BAF180 (6.29). Elution off an anion exchange column is accomplished by increasing the
salt (NaCl) concentration. Buffers with 0 M, 0.1 M, 0.5 M, and 1.0 M NaCl were
recommended as starting points to determine the salt concentration at which BAF180
elutes.
Samples were prepared for purification by dialyzing crude lysate overnight in 17
mM Tris, pH 7.6. Samples were collected the next day and stored at -20 °C until needed.
Samples were defrosted at room temperature and centrifuged at 17,000 g for 20 minutes
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at 4 °C to reduce viscosity and remove unwanted particulates. The supernatant was
collected and run through a 1.0 µm PES syringe filter before loading onto a column.
Preliminary results indicated that BAF180 was eluting from the resin at 0.5 M NaCl, with
only a few contaminant proteins (Figure 6.1). More precise buffers (0.1 M, 0.2 M, 0.3 M,
0.4 M, 0.5 M NaCl) were used to narrow down this range. BAF180 co-eluted with two
contaminant proteins (~80 kDa and ~70 kDa) at 0.4 M NaCl (Figure 6.2). A buffer with
0.35 M NaCl was used in an attempt to separate these bands, but this did not show any
significant difference (Figure 6.3). More buffers were made at concentrations between
0.35 M and 0.4 M NaCl (0.36 M, 0.37 M, 0.38 M, 0.39 M). The results indicated that
BAF180 was eluting at 0.36 M, 0.37 M, 0.38 M, 0.39 M, and 0.40 M; the contaminants
remained and did not separate from BAF180 (Figure 6.4). Though BAF180 eluted at 0.36
M NaCl and up, 0.4 M NaCl was chosen as the elution concentration in order to
maximize recovery and reduce the dilution factor.
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Flow-Through (0 M NaCl)

Wash A (0 M NaCl)

Wash B (0.1 M NaCl)

Wash C (0.5 M NaCl) Wash D (1.0 M NaCl)

Wash A (0 M NaCl)

Wash B (0.1 M NaCl)

Wash C (0.5 M NaCl)

Wash D (1.0 M NaCl)

Figure 6.1: First attempt at anion exchange purification. Buffers of 0 M, 0.1 M, 0.5 M, and 1.0 M NaCl
were used to elute BAF180 from MacroPrep® High Q resin. This preliminary test indicated that BAF180
was eluting at 0.5 M NaCl. The band for BAF180 is found in the red box.
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Figure 6.2: Anion exchange purification in 0.1 M NaCl increments. More precise buffers were used to
determine the exact NaCl concentration required to elute BAF180 from the anion exchange resin; elution
occurred at 0.4 M NaCl. The band for BAF180 is found in the red box.
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Figure 6.3: Anion exchange purification with Tris buffers with 0.3 M, 0.35 M, and 0.4 M NaCl. Buffers
with 0.3 M, 0.35 M, and 0.4 M NaCl were used to zone in on the exact NaCl concentration required to elute
BAF180 from the contaminant proteins that remained after washing the column with 0.3 M NaCl. Results
indicated that BAF180 eluted after 0.35 M NaCl along with a few other contaminant proteins. The band for
BAF180 is found in the red box.
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Figure 6.4: Anion exchange elution with 0.01 M increments of NaCl. Though BAF180 co-eluted at 0.36 M
NaCl and up, this also decreased the final concentration. To maximize recovery, elution at 0.4 M NaCl was
chosen. The BAF180 band is found in the red box.

Full-length BAF180 always eluted at 0.4 M NaCl, however the sizes of the
contaminant bands sometimes changed. It was thought that these contaminant bands were
other proteins. However, a recent western blot reveals (see Section 5.6) that full-length
BAF180 is being produced but much of it is degraded (Figure 6.5). The antibody used
recognizes an epitope on the C-terminus (see Section 5.6); therefore this epitope must be
present in all the recognized bands. Premature termination during translation was
eliminated as a cause because this would leave fragments containing the N-terminus but
not the C-terminus, where the epitope is located. The use of different antibodies which
recognize epitopes on the N-terminus or in the middle of the protein could be used to
confirm that BAF180 is being degraded and that the other bands seen are fragments of it
(see Appendix A). Proteolytic degradation could explain why BAF180 content varied
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after lysis and why purification results were sometimes inconsistent. Increasing the
protease inhibitor cocktail concentration above the recommended level might result in
less proteolytic BAF180 degradation.

Figure 6.5: Western blot performed on BAF180 lysate samples. The most intense band is thought to be fulllength BAF180 (190 kDa). The antibody used recognized an epitope on the C-terminus of BAF180. Lanes
1 and 3 were crude samples. Lanes 2 and 4 were purified fractions. It is believed that the lower molecular
weight bands are the result of BAF180 degradation by proteases. Exposure was 55 seconds with a CDD
camera and ECL detection.

It is believed that during lysis the BAF180 protein is being degraded by proteases,
even though protease inhibitors are added to the lysis mixture. Proteolytic degradation in
yeast mostly occurs in vacuoles which are membrane bound,56,58 therefore, the protein is
only exposed to them during lysis. Increasing the protease inhibitor cocktail
concentration or changing cocktail type altogether might reduce proteolytic degradation
and result in a higher BAF180 yield.

6.3 Conclusion
For the first time, BAF180 was successfully purified from a heterologous host
using strong anion exchange chromatography. Recent western blot results revealed that
the bands seen on SDS-PAGE gels that were initially thought to be contaminants are
actually BAF180 fragments (likely a result of degradation). The concentration and/or
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composition of the protease inhibitor cocktail should be manipulated in order to eliminate
as much protease activity as possible and increase the yield of BAF180.

6.4 Supplementary Information
The following experiments were run before it was discovered that the other bands
seen in the AEX purified fraction were actually fragments of BAF180. The
“contaminant” proteins, now known to be fragments of BAF180, eluted with full length
BAF180 every time. It was thought that perhaps a protein complex was forming in the
cell or that the “contaminant” proteins had a pI too close to that of BAF180 to be
separated.

Materials
SDS, glycine, Tris hydrochloride, Tris base, glycerol, guanidine hydrochloride,
and imidazole were purchased from Amresco (VWR: Radnor, PA). NaCl and Amicon®
Ultra-15 100 kDa Centrifugal Filter Units (cat. UFC910024) were purchased from EMD
Millipore (Billerica, MA). EDTA was purchased from Mallinckrodt Baker Inc.
(Phillipsburg, NJ). Dialysis membranes were purchased from Spectrum Labs (Rancho
Dominguez, California): Spectra/Por® 1 (6-8 kD MWCO membrane; part 132660),
Spectra/Por 6® (50 kD MWCO membrane; part 132544) and Float-A-Lyzer G2 Dialysis
Device CE (100 kDa MWCO; part G235035). Bio-Scale™ Mini Macro-Prep High Q®
cartridge (cat. 7324122), Bio-Scale™ Mini CHT™ Type I cartridge (cat. 7324322), BioScale™ Mini Macro-Prep DEAE® Cartridge (cat. 7324142), Macro-Prep® t-Butyl HIC
Support (1580090), Macro-Prep High Q® Support (cat. 1580040), and Econo® glass
180

columns were purchased from Bio-Rad, Inc. (Hercules, CA). HisPur™ Ni-NTA Resin
(cat. 88222), 0.45 µm nitrocellulose membrane (cat. 77010), Western Blotting Filter
Paper (cat. 88600), Pierce Fast Western ECL kit (cat. 35050), Pierce Fast Western Blot
Kit, ECL substrate (cat. 35050) and anti-His-tag antibody (cat. PA1-983B) were
purchased from ThermoFisher (Waltham, MA). Urea, sodium phosphate monobasic
(NaH2PO4), Sephadex G-50 Fine (cat. 65080-106), Sephacryl 400-HR (cat. S400HR),
Whatman Puradisc 25 syringe filters – 1.0 µm PES membrane (cat. WHA67812510), and
Corning Spin-X UF 20 concentrators – 100 kDa MWCO (cat. CLS431491-12EA) were
purchased from Sigma Aldrich (St. Louis, MO).

Ni-NTA Affinity Chromatography
Histidine tags (His-tags) are commonly used to purify recombinant proteins via
IMAC (immobilized metal affinity chromatography). Recombinant BAF180 was cloned
with a 6xHis-tag on the C-terminus (see Section 5.2). Ni-NTA affinity purification was
tried several times, both batch and column under native and denaturing conditions.
Initially, a 50 mM Tris buffer, pH 7.4 was tried; the cells were lysed in 50 mM Tris, so
this removed a dialysis step. Both batch and column modes were tried and an imidazole
gradient was used, from 50-250 mM. For batch mode, 10 mL of HisPur® resin slurry was
added to a 50 mL tube and equilibrated with 50 mM Tris, pH 7.4. 15 mL of crude lysate
(in the same buffer) was added to the tube and the mixture was incubated on an orbital
shaker for 30 minutes. The resin was allowed to settle and the supernatant was collected.
15 mL of wash buffer 1 (50 mM imidazole) and 15 mL wash 2 (100 mM imidazole) were
added and collected using the same procedure. 15 mL of elution buffer (250 mM
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imidazole) was added and incubated for 1.5 hours before being collected. Results
demonstrated that BAF180 was not binding to the column and was leaving with the flowthrough.
The next several attempts used buffers recommended by the manufacturer of the
Ni-NTA resin.93 The samples were denatured to ensure that the conformation of the
protein was not hindering the binding of the His-tag; many experiments have shown that
the addition of denaturation agents does not affect the ability of a His-tag to bind with the
Ni-NTA resin.94 In a column (6 cm bed height, 0.7 cm diameter), approximately 2 mL of
resin was equilibrated with 4 mL equilibration buffer (PBS, 6 M GuHCl, 10 mM
imidazole, pH 7.4). Imidazole was included in the equilibration buffer to reduce nonspecific binding.94-99 Approximately 2 mL of crude lysate was mixed with 2 mL of
equilibration buffer. The column was washed with 4 mL of wash buffer (PBS, 6 M
GuHCl, 25 mM imidazole, pH 7.4) and eluted with 4 mL of elution buffer 1 (PBS, 6 M
GuHCl, 250 mM imidazole, pH 7.4). No BAF180 band was observed in any fraction, so a
second elution buffer with a higher imidazole concentration was used in the next trial
(elution buffer 2: PBS, 6 M GuHCl, 500 mM imidazole, pH 7.4). Again, no BAF180
band was observed in any fraction. It was concluded that perhaps BAF180 was degrading
prior to purification, during purification, or that the BAF180 band was too faint to
observe.
After high-producing cells were discovered, Ni-NTA purification was tried again.
New columns were prepared with 3 mL resin slurry (~1.5 mL resin) and equilibrated with
6 mL equilibration buffer (PBS, 6 M GuHCl, 10 mM imidazole, pH 7.4). For this
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attempt, five different columns were prepared, each loaded with a different crude sample.
For each, 500 µL sample was mixed with 1 mL equilibration buffer and loaded onto the
column. Bound proteins were eluted in 3 mL of elution buffer 1 (PBS, 6 M GuHCl, 250
mM imidazole, pH 7.4). BAF180 was found in the flow-through fraction (Figure 6.6). No
wash step was performed; this was a simple test to determine if BAF180 was binding to
the Ni-NTA column at all.
A.

Col. A,
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260 kDa

Col. B,
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Col. A,
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Figure 6.6: Denaturing Ni-NTA purification. BAF180 was found in the flow-through fraction (A),
indicating that it did not bind to the column. No proteins were seen in the elution fractions (B). Both
soluble and insoluble lysate fractions were used. FT stands for flow-through. The BAF180 band is denoted
by the red stars.

Final attempts used a third and fourth buffer system. The third buffer system was
20 mM NaH2PO4, 300 mM NaCl, 6 M GuHCl, pH 7.4. 2 mL of resin slurry was added to
a large column (2 x 23 cm) and equilibrated with equilibration buffer (20 mM NaH2PO4,
300 mM NaCl, 6 M GuHCl, pH 7.4). Imidazole was excluded from this wash buffer to be
sure that the low 10 mM imidazole concentration used in previous equilibration buffers
was not preventing BAF180 from binding. Multiple soluble lysate fractions (of highproducing cells) were combined (~32.5 mL) and mixed with 20 mL equilibration buffer
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before being loaded onto the column. The flow-through was collected and a 5 mL aliquot
was saved; the rest of the flow-through was added back into the column, so the sample
would pass over the Ni-NTA resin bed twice. The column was washed twice with
equilibration buffer. Samples were eluted with ~38 mL elution buffer (20 mM NaH2PO4,
300 mM NaCl, 6 M GuHCl, 300 mM imidazole, pH 7.4) and 2 mL of 1 M imidazole. 1
M imidazole was added to the column in an effort to elute anything that might be bound.
All the samples were concentrated before being run on an SDS-PAGE gel. After
concentration, samples were re-suspended and dialyzed in 50 mM Tris, pH 7.4 and run
on an SDS-PAGE gel (Figure 6.7).
1M
FT 1 FT 2 Wash 1 Wash 2 Elution Imidazole
260 kDa
140
100
70
50
40

Figure 6.7: Denaturing Ni-NTA purification. Soluble fractions were combined and added to a Ni-NTA
column. The flow-through was collected and re-run over the resin bed, so that the sample would pass over
the Ni-NTA resin twice. The column was washed twice with equilibration buffer and elution buffer was
added (300 mM imidazole). A final elution with 2 mL of 1 M imidazole was loaded onto the column to
elute everything that might be bound.

The fourth buffer system was the same as the third buffer system, except the 6 M
GuHCl was replaced with 8 M urea. A 1 mL Ni-NTA resin bed was equilibrated with
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equilibration buffer (20 mM NaH2PO4, 300 mM NaCl, 8 M urea, pH 7.4). Insoluble
lysate fractions (in 8 M urea) were pooled and combined with equilibration buffer and
loaded onto the prepared column. The column was washed with 40 mL of equilibration
buffer before 4 – 1 mL portions of 1 M imidazole was used to elute any bound proteins.
BAF180 was found in all fractions (flow-through, wash, and 1 M imidazole elutions),
which seemed to indicate that some of the His-tagged BAF180 was binding to the NiNTA resin (Figure 6.8). Additional experiments were conducted, adding in a wash step
with 30 mM imidazole and another elution series with 3 M imidazole. The results were
unable to be replicated (Figure 6.9).
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Wash
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100
80
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Figure 6.8: Denaturing Ni-NTA purification with 8 M urea. Insoluble lysate fractions were pooled and
equilibrated with equilibration buffer. The column was washed with equilibration buffer before being
treated to 1 M imidazole. BAF180 was found in most fractions, suggesting that some BAF180 was binding
to the Ni-NTA resin.
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Figure 6.9: Further Ni-NTA attempts with 8 M urea. For this particular experiment and a few others,
aggregates formed during purification. Nevertheless, BAF180 appears to be in the flow-through fraction.
As can be seen, very few proteins are found in the wash or elution steps. The experiment indicated that
BAF180 was not binding to the Ni-NTA resin.

Determination of the Presence of a His-tag
After native and denatured protocols for Ni-NTA purification indicated that
BAF180 was not binding to the Ni-NTA resin, it was thought that this might be because
the protein is so big (190 kDa) and the His-tag is so small (1 kDa), that the protein might
have trouble staying attached to the resin. Later, it was considered that perhaps the Histag was not actually present on the recombinant BAF180 protein. A dot blot was done to
determine if the recombinant BAF180 protein was expressed with a His-tag. The negative
control was WT X33 crude lysate (for which it had already been demonstrated that
BAF180 was not present). The positive control was hPB1-1 (BAF180 protein,
bromodomain 1 only) constructed by previous members of the Thompson lab and
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successfully used in Ni-NTA affinity purification.20 The protein was expressed in E. coli
Rosetta(DE3) cells in the pET30b construct.20 After growth and expression of the protein,
the cells were lysed using a denaturing protocol, as only the His-tag was needed and this
would ensure that the His-tag was exposed. The denaturing protocol was as follows:
Harvested cells were re-suspended in E. coli denaturing lysis buffer (100 mM NaH2PO4,
10 mM Tris-Cl, 300 mM NaCl, 8 M urea, pH 8.0) at 5 mL buffer per gram cell. The cell
suspension was incubated on ice for 1 hour on an orbital shaker. Lysate was collected by
centrifuging the cell suspension at 10,000 g for 25 minutes at 4 °C.20 The sample was
dialyzed overnight in E. coli lysate dialysis buffer (50 mM Tris-Cl, 100 mM NaCl, pH
7.6). This was done primarily to remove urea; urea removal was deemed necessary in
order to run the crude lysate sample on an SDS-PAGE gel and also to ensure that the urea
could not cause any problems during the blot protocol.
In addition, to ensure that the His-tag was not buried within the protein structure,
both samples of BAF180 (crude and anion exchange fraction, see Section 6.2) were
denatured under harsh conditions. Approximately 100 µL of crude BAF180 was added to
500 µL of E. coli denaturing lysis buffer and incubated for 30 minutes at room
temperature. The sample was then incubated for 10 minutes at 95 °C (chosen because this
temperature is used for SDS-PAGE sample preparation) and dialyzed overnight in anion
exchange dialysis buffer (17 mM Tri, pH 7.6). This protocol was repeated for 100 µL of
purified BAF180 sample from anion exchange.
A dot blot was performed using an anti-His-tag antibody. Pierce Fast Western
Blot Kit, ECL substrate was used. A grid was drawn in pencil and 2 µL of each sample
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was spotted onto a nitrocellulose membrane (0.45 µm) and allowed to dry. The
nitrocellulose membrane was then hydrated in 1x Fast Western Wash Buffer for 5
minutes with gentle shaking. The primary antibody solution (10 mL Fast Western
Antibody Diluent, 2 µL anti-His-tag antibody) was incubated with the membrane for 1
hour. The membrane was washed for 5 minutes in wash buffer. The secondary antibody
solution (10 mL Fast Western Antibody Diluent, 1 mL Fast Western Optimized HRP
reagent) was added and incubated with the membrane for 10 minutes. The membrane was
washed 4 times in wash buffer for 5 minutes each, followed by brief incubation in
detection solution (5 mL Pierce ECL Detection Reagent 1, 5 mL Pierce ECL Detection
Reagent 2). The membrane was visualized using a CDD camera. The results (shown in
Figure 6.10) confirm that the positive control (hPB1-1) contains a His-tag and that the
negative control (X33 WT crude) did not contain a His-tag. Most interestingly, none of
the BAF180 samples showed a positive result, indicating, that in both native and
denatured states, the recombinately expressed BAF180 did not contain a His-tag.
During the original construction of the expression plasmid, the purchased
BAF180 DNA was modified using PCR mutagenesis to remove the stop codon present in
the original sequence. The reverse PCR primer was designed to remove the stop codon,
add an enterokinase site, and add a KpnI site. It is most likely that the stop codon was not
removed during PCR modification, therefore causing termination of protein translation
before the His-tag sequence (Figure 6.11). However, the KpnI site was definitely added,
because this restriction enzyme was successfully used to ligate BAF180 into pGAPZA.
The difference in base pair length between deleting the stop codon and inserting the
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enterokinase is very small from that with just the stop codon. This slight difference would
not have been observed on a gel.

1

4

3

2

6

5

Figure 6.10: The results of the His-tag detection dot blot. A grid was drawn on nitrocellulose membrane
and the samples were spotted in different boxes. The box assignments are as follows: (1) hPB1-1, positive
control; (2) X33 WT, negative control; (3) BAF180 crude (native); (4) Anion exchange purified BAF180
(native); (5) Denatured BAF180 crude; (6) Denatured anion exchange purified BAF180. Only box 1 shows
a positive result, indicating that hPB1-1 is the only sample that contained a His-tag.
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Figure 6.11: Possible explanation for why there was no His-tag detected with an anti-His-tag antibody. All
numbering is relative to the HMG box, with the first amino acid or base pair of the HMG box numbered as
1. There is no 0 position (-2, -1, 1, 2, etc). The positions of the antibody immunogen and the most likely
epitope are noted. It was thought that the original stop codon was not eliminated and therefore protein
translation was terminated at this point, preventing a His-tag from being included on the expressed protein.
(A) Amino acid positioning; (B) Base pair positioning.
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Strong Anion Exchange Resin: Bis-Tris and Bis-Tris Propane
Buffers
Other buffers were tried during AEX when it was still believed that the co-eluting
proteins in the purified fraction were contaminants. Decreasing the difference between
BAF180’s pI and the buffer’s pH would result in a smaller negative charge on the
protein, therefore it might elute at a lower NaCl concentration, possibly separate from all
other cellular proteins. The buffer pH was still kept relatively close to pH 7.4, because
BAF180 was shown to be stable at this pH; it was reasoned that a buffer pH further away
from 7.4 would result in decreasing stability of BAF180.
Decreasing the difference between BAF180’s pI and the buffer’s pH required the
use of different buffer systems with lower pKa values. The pKa values of Tris buffers
limited the pH values that could be used; 10 mM Tris has a pKa of 8.10 at 25 °C, and the
pKa increases as the concentration increases. Therefore, the lower limit for the pH of a
Tris buffer was 7.6, which was used. The structures of the different buffer salts was also
considered; it was reasoned that molecules with a structure closer to that of Tris would be
better, since it was already known that the recombinant BAF180 was stable in Tris.
Organic molecules were avoided because of the unknown effect on protein stability and
the likelihood of denaturation.
After analysis of different buffer systems at different concentrations and
temperatures, it was decided to use Bis-Tris next. Bis-Tris has an effective buffering
range of 5.8-7.2.85 A buffer system of 50 mM Bis-Tris, pH 7.3 was tried first; this buffer
needed to be used at 4 °C in order for the pH and pKa values to be in agreement (i.e. keep
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the pKa within 0.5 pH units of buffer pH). A step-wise elution from 0 – 1.0 M NaCl was
used. Results show that most of the cellular proteins and BAF180 were eluting at 0.5 M
NaCl (Figure 6.12). Therefore, this buffer system is essentially useless, because it did not
separate BAF180 from any other proteins.
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Figure 6.12: Anion exchange with 50 mM Bis-Tris, pH 7.3. As can be seen in the gel, most of the cellular
proteins and BAF180 eluted at 0.5 M NaCl. This buffer system did not separate BAF180 from the other
proteins. The purification experiment was conducted at 4 °C.

When the SDS-PAGE results showed that pH 7.3 did not separate BAF180 from
other cellular proteins, the pH was changed to 7.0. With a 50 mM Bis-Tris buffer at pH
7.0, anion exchange was conducted again at room temperature (~20 °C). BAF180 did
elute in a different fraction than many other cellular proteins, though quite a few cellular
proteins eluted in the same fraction as BAF180 (Figure 6.13). BAF180 eluted primarily at
0.4 M and 1.0 M NaCl, though a small amount was seen in 0.3 M NaCl and the flowthrough. The BAF180 elution fraction was not as pure as that achieved with 17 mM Tris
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buffer, pH 7.6. Additionally, BAF180 appears to be eluting at a higher concentration of
NaCl. Increasing the NaCl concentration increases the risk of protein denaturation.
pH values below 7.0 were not attempted, for concern that the pH would start to
denature the BAF180 protein. pH 7.0 is 0.4 pH units away from known stability at pH 7.4
(lysis buffer 2). In fact, proteins can be seen aggregating in the wells at pH 7.0 (Figure
6.13).
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Figure 6.13: Anion exchange with 50 mM Bis-Tris, pH 7.0. BAF180 did separate from many of the cellular
proteins, though quite a few eluted with BAF180. BAF180 eluted at 0.4 M NaCl and 1.0 M NaCl, with a
small amount in the 0.3 M NaCl fraction. The BAF180 elution is not as clean as the elution achieved with
17 mM Tris buffer, pH 7.6 and requires a higher concentration of NaCl to elute. BAF180 is denoted by the
red star.

A Bis-Tris propane (BTP) buffer system was tried next. The pKa of 50 mM BTP
is 7.12 at 20 °C. The effective buffering range for BTP is 6.4-7.3;100 pH 7.4 was chosen.
BAF180 eluted at 0.3 M NaCl, along with several other cellular proteins. Comparing
these results (Figure 6.14) to those from AEX with 17 mM Tris, pH 7.6 (Figure 6.3),
BAF180 eluted at a lower NaCl concentration (0.3 M vs. 0.4 M, respectively). However,
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it eluted with many more contaminant proteins in BTP buffer than in Tris buffer. Since
BAF180 appears to be stable at pH 7.6 (Tris buffer) and elutes with fewer contaminants,
anion exchange was conducted with Tris buffer for all future experiments. The tradeoff
(eluting at a lower NaCl concentration but with more contaminants) was not considered
to be advantageous. It was interesting that the two proteins that co-eluted with BAF180
using the Tris buffer also co-eluted here. It was puzzling at the time why those proteins
always eluted together. It is now understood, however, that the other bands are fragments
of BAF180.
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Figure 6.14: Anion exchange with 50 mM Bis-Tris propane buffer, pH 7.4. Though faint, BAF180 can be
seen eluting at 0.3 M NaCl, along with several other cellular proteins. Even though BAF180 eluted at a
lower concentration of NaCl (0.3 M vs. 0.4 M in 17 mM Tris, pH 7.6), so did other cellular proteins.
BAF180 is denoted by the red star.
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Weak Anion Exchange: DEAE Resin and Tris Buffer
In addition to strong anion exchange media, the weak anion exchanger DEAE was
tried. Bio-Rad’s MacroPrep® DEAE is a weak anion exchanger that is a methacrylate
polymer with a DEAE (diethylaminoethyl) cellulose group attached.82,101 Weak and
strong ion exchangers have different selectivities,84-85 so it seemed worthwhile to try a
weak anion exchanger as well.
The same buffer as for strong AEX was used (17 mM Tris, pH 7.6). Crude lysate
was run through the DEAE cartridge and eluted using various concentrations of NaCl
(Figure 6.15). BAF180 eluted at 0.5 M NaCl, along with many contaminants, though a
faint amount can be seen in the 0.3 M fraction.
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Figure 6.15: DEAE anion exchange. Using 17 mM Tris buffers at pH 7.6, crude lysate was run through the
media and eluted at varying concentrations of NaCl. The BAF180 band (denoted by the red star) was seen
in the 0.5 M NaCl fraction, along with several contaminant proteins.
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Anion Exchange: Prepacked Cartridges vs. Self-Packed Columns
Initially, prepacked cartridges were used. Manipulation of NaCl concentrations
were unable to separate the “contaminant proteins” from BAF180. After possible
variations in buffers were explored, a longer column was tried. In chromatography,
resolution often increases with column length, so there was a possibility that increasing
the column length of Bio-Rad High Q® resin would separate out the two contaminant
proteins (approximately 70 and 80 kDa, see Figure 6.3). Approximately 10 mL resin
slurry was packed into a 0.7 x 20 cm Econo® glass column. Unfortunately, elongating
the column did not separate the three bands (results not shown). The new finding that the
“contaminants” are fragments of BAF180 explain these results.

Hydroxyapatite (Mixed-Mode) Chromatography
Hydroxyapatite chromatography is not often utilized for protein purification, even
though it was first published in the 1950s.84,102 Hydroxyapatite (Ca10(PO4)6(OH)2) is a
mixed-mode (also called multimodal) media (or resin), meaning that its interactions with
the proteins appear to be a combination of electrostatic and metal affinity
interactions.84,102-109
Bio-Rad’s Bio-Scale™ Mini CHT™ ceramic hydroxyapatite type I pre-packed
cartridges were chosen for analysis. CHT is a ceramic hydroxyapatite that is much more
stable than the traditional forms102-109 and CHT can reportedly separate mixtures that
other methods cannot.103-107 Type I is recommended for acidic proteins (the pI of BAF180
is 6.29).103-107
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CHT™ Type I Bio-Scale™ mini cartridge was prepared as directed in manual.110
NaH2PO4 buffers at pH 7.2 were used with increasing concentration to elute the proteins.
The loading buffer had 10 mM NaH2PO4, which was increased step-wise to 400 mM (10
mM, 50 mM, 100 mM, 200 mM, 300 mM, 400 mM). Acceptable purity results were not
obtained with this method. Results demonstrate that BAF180 is eluting in 200 mM
NaH2PO4 along with many other cellular proteins (Figure 6.16).
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Figure 6.16: CHT Type I chromatography. BAF180 elutes at 200 mM NaH2PO4 along with many other
cellular proteins. All concentrations are referring to NaH2PO4 concentration.

Hydrophobic Interaction Chromatography
Hydrophobic interaction chromatography (HIC) takes advantage of the structure
of a protein molecule and its interactions with water. Decreasing salt gradients are used to
elute a bound protein off a column.111-115
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Bio-Rad’s Macro-Prep® t-butyl resin was chosen because it has strong
interactions with proteins that are weakly hydrophobic.116-118 Because BAF180 is soluble
in aqueous solutions, it was reasoned that the degree of hydrophobicity of the protein
cannot be too high, otherwise it would not be soluble in water. Macro-Prep® t-butyl resin
consists of a methacrylate bead with t-butyl and carboxyl groups attached.116-118
Following manufacturer’s instructions, the t-butyl resin was packed into a 1.5 mm x 10
cm Econo® glass column, with the bed height approximately three quarters of the
column height. The elution fraction from anion exchange chromatography (17 mm Tris,
0.4 M NaCl, pH 7.6) was equilibrated to 1 M NaCl by addition of a 2 M buffer (17 mM
Tris, 2 M NaCl, pH 7.6) and loaded onto the prepared HIC column. Flow-through was
collected and subsequent washes were carried out with a decreasing salt gradient (1 M to
0 M NaCl). The samples were then concentrated and run on an SDS-PAGE gel. Results
were inconclusive (not shown).

Size Exclusion Chromatography
Size exclusion chromatography (SEC), also called gel filtration chromatography,
is a fairly simple method. Using porous resin, proteins are separated by molecular weight.
Large proteins cannot enter the pores and are thus eluted first. Smaller proteins are able to
travel through the pores (the degree to which they can enter the pores depends on their
size), and are thus slower to elute.119-123
Sephadex G-50
Sephadex G-50 has an approximate fractionation range of 1-30 kDa, meaning it
can separate proteins with molecular weights of 1-30 kDa;120-122 it was chosen because it
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was readily available. The Sephadex G-50 column was prepared by swelling the resin
particles in 50 mM Tris-Cl, pH 7.4 on a hotplate for approximately 1 hour. The slurry
was then poured into a 2 x 23 cm glass column; the resultant bed height was
approximately 10 cm. Crude lysate was added and 8 – 2 mL fractions were collected
(Figure 6.17). Separation did not occur.
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Figure 6.17: Size-exclusion chromatography of crude BAF180 lysate. 8 – 2 mL fractions were collected
and concentrated. No separation was seen, though dilution was occurring. Note that the lysate used was
from low-producing cells and so the BAF180 band (~190 kDa) was very faint. BAF180 eluted in fractions
5-8. The band for BAF180 is found in the red box.

SEC was also tried with partially purified samples. Anion exchange (AEX) was
able to remove all but 2 contaminant proteins (now known to be degradation products)
from BAF180. This eluent fraction (0.4 M NaCl) was concentrated and run through the
column. 11 – 2 mL fractions were collected and concentrated. Though the bands are faint,
BAF180 still eluted with contaminant proteins (Figure 6.18).
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Figure 6.18: Size-exclusion chromatography of partially purified BAF180. AEX fraction B4 (0.4 M NaCl)
was concentrated and then run through a Sephadex G-50 column. BAF180 still eluted with the other
contaminants (fraction 4), though partial separation did occur. BAF180 is denoted by the red star.

Longer SEC Column Packed with Sephadex G-50
A longer SEC column (0.7 cm x 20 cm) was packed to a bed height
approximately 17 cm (Sephadex G-50) and the 0.4 M AEX fraction was run through. In
chromatography, resolution is dependent on column length.121 30 – 2 mL fractions were
collected. Though the gels were not great, faint bands at ~70 and ~80 kDa (the size of the
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contaminants) can be seen eluting in the same fractions (Figure 6.19). This led to the
supposition that this longer column would not be able to separate BAF180 either.
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Figure 6.19: Size-exclusion chromatography of partially purified BAF180 on a longer column. Though the
bands are very faint, the two contaminant proteins can be seen eluting together in fractions 2-4.

SEC with Sephacryl 400-HR
Another SEC media was tried. Sephacryl 400-HR has a fractionation range of 208,000 kDa. Pre-swelled resin was packed into a 15 x 750 mm column, with a bed height
approximately 500 mm. Concentrated AEX 0.4 M NaCl fraction was loaded onto the
column. The first 23 mL were collected, followed by 34 fractions of 1 mL each. The
results were inconclusive, as no bands were seen (results not shown).
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Ultrafiltration and Dialysis
Attempts were also made to purify by size directly from a crude sample. Both
ultrafiltration and dialysis utilize membranes with distinct molecular weight cut offs
(MWCO), allowing proteins of smaller molecular weight to flow out of the membrane,
while proteins of higher molecular weight are retained.
Ultrafiltration devices are able to dialyze and concentrate samples during
centrifugation. Proteins smaller than the MWCO are able to flow-through the membrane,
as does buffer. For subsequent spins (centrifugation), additional buffer is added. Two
types of ultrafiltration devices were tried, both with a 100 kDa MWCO, but with a
different membrane composition. Merck Millipore’s Amicon® Ultra used a regenerated
cellulose membrane124 and Corning’s® Spin-X® used a PES (polyethylsulfone)
membrane.125
The Amicon® Ultra ultrafiltration devices were tried on early samples; this was
during growth and lysis optimization, so the protein content is not the same as after
optimization. However, after four centrifugation cycles, the sample appears to be
concentrating and the purity is slightly improved (Figure 6.20). Unfortunately, these
results could not be replicated.
A PES membrane has lower protein binding than other membranes.126-127 The
Corning® Spin-X® ultrafiltration devices have a PES membrane. Unfortunately, they did
not serve as an efficient means of purifying BAF180 from endogenous cellular proteins
(Figure 6.21). No significant difference in protein content was observed. MWCO can be
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relative, so the retention of proteins around 100 kDa is not unexpected; however, proteins
50 kDa and below should have been removed. The reason that proteins below 50 kDa
were not removed is not understood.
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Figure 6.20: Ultrafiltration with Amicon® Ultra device. These early samples had not yet been optimized, so
the protein content is different than it is currently. However, after four centrifugation cycles, the sample is
slightly more concentrated and slightly purer.
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Figure 6.21: Ultrafiltration with Corning Spin-X device. The difference in the crude and Spin-X samples is
negligible.
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Additionally, dialysis membranes with 100 kDa (Figure 6.22A) and 50 kDa
(Figure 6.22B) MWCO were tried. Oddly, the protein composition of the BAF180
sample prior to dialysis was nearly the same as after dialysis; it just appeared slightly less
concentrated, though this could have been due to variations in SDS-PAGE loading. It is
unclear why larger pore dialysis membranes were unable to remove the smaller proteins.

A.

Crude

100 kDa
MWCO

B.

50 kDa
MWCO

245 kDa
190
135
100
80
58
46

32

25

Figure 6.22: Dialysis with high MWCO membranes. (A) Overnight dialysis with 100 kDa MWCO
membrane did not appear to improve the purity of crude BAF180 sample. It appears that the dialyzed
sample is slightly less concentrated. (B) Sample purity was not improved with use of a 50 kDa membrane.
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Chapter 7 : Conclusion and Future Work
For the first time, BAF180 has been successfully expressed in a heterologous
host. Though attempts to express BAF180 in E. coli were unsuccessful, expression in the
yeast Pichia pastoris was successful. Using the GAP promoter, BAF180 was cloned and
expressed in wild-type X33 cells. Growth and lysis conditions were optimized and highproducing strains were discovered. BAF180 was successfully purified from crude lysate
using anion exchange chromatography. It was initially believed that, during anion
exchange chromatography, two contaminant proteins were eluting with BAF180 (as seen
in SDS-PAGE gel), so more purification methods were tried. However, western blot
results indicate that the other bands are actually fragments of BAF180. Using an antibody
that recognized an epitope on the C-terminus, multiple protein bands were recognized,
indicating that the so-called “contaminant” proteins are actually fragments of BAF180.
These results suggest that significant amounts of BAF180 are being degraded by
proteases during cell lysis. A higher concentration of protease inhibitor cocktail will be
tried in an effort to increase the yield of full-length BAF180.
In the future, the recombinant BAF180 should be studied using thermodynamic
and kinetic methods such as isothermal titration calorimetry and fluorescence anisotropy.
All possible binding partners should be explored via use of a peptide array featuring posttranslationally modified histone peptides. The results will indicate whether neighboring
PTMs impact the binding of BAF180 to acetylation sites. Neighboring PTMs have been
known to impact the binding of many proteins, sometimes increasing the affinity and
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sometimes decreasing. Kinetic studies (such as ITC) could be performed using the
peptides that had the strongest interactions.
It would also be interesting to determine the structural content of full-length
BAF180 by circular dichroism (% α-helices, % β-sheet, and % random coil); 8 of the
individual domains (not HMG-box) have been cloned and crystallized, but it would be
interesting to see if any of the structural characteristics change due to neighboring amino
acids. Other proposed experiments include determining the role of the HMG-box in
BAF180, confirming proteolytic degradation, determination of gene copy number, and
increasing the yield of full-length BAF180 by using a protease-deficient strain, testing
other promoters, or extracellular expression. These experiments are briefly discussed in
appendix A.
Expression of the individual domains of BAF180 and in vivo experiments have
provided some insight into the roles of BAF180. However, a significant gap in our
knowledge remains between singular domain interactions and cellular impacts of
BAF180: the molecular-level interactions of the complete BAF180 protein are unknown.
The success of finally expressing and purifying full-length BAF180 in a heterologous
host will provide us with the opportunity to study the fine nuances of the protein in vitro.
The intricate interactions with individual cellular components can now be quantified and
fully explored. With this information, small-molecule drugs that target the BAF180
protein can be developed.
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Appendix A: Other Proposed Experiments
Exploring the Role of the HMG-box Domain
Referring back to the introductory chapter, the role of BAF180 in heart
development was mentioned. While phenomenological consequences of BAF180 knockout are known, the exact interactions that cause these events are unknown. The HMG-box
domain of BAF180 may be involved in proper embryonic development. BAF180 is
known to be critical for proper heart development in embryos (see Section 1.4.2.2) and
proper expression of various other HMG-box-containing proteins have been
demonstrated to be required for normal embryonic development.1 It would be interesting
to determine if the role of BAF180 in heart development is reliant on its HMG-box.
BAF180 knockout mice, generated as per Wang et al., could be used to create mice with
different constructs (instead of wild-type BAF180) in the embryo and wild-type BAF180
in the placenta.2 The different constructs would contain different types of domains3 (i.e.
bromodomains, BAH domains, HMG-box domain) and a partial-sequence of BAF180
(all bromodomains, both BAH domains, but no HMG-box). Each embryo would be
studied to determine if each of them are able to survive past embryonic day E12.5-E15.5,
when BAF180 KO mice died.2 Gene expression of each of the embryos could also be
analyzed to see if the same genes that were up-regulated upon BAF180 KO are also upregulated in the mutants.2 The role of BAF180 in maintaining genomic stability and
proper DNA damage repair may also stem from its HMG-box. This theory could be
tested by generating constructs, like those described above, and transfecting them into
BAF180 KO cancer cells. The results of the construct containing just the bromodomains
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and the BAH domains (i.e. lacking the HMG-box) could be used to infer if cancerassociated mutations of BAF180, which often lack the HMG-box, result in genomic
instability and aneuploidy.
Proteolytic Degradation
Western blot experiments were successfully carried out using the Tris-acetate gel
system. When probed with an anti-PBRM1 antibody that recognized an epitope on the Cterminus of BAF180, multiple bands were seen. The most intense band appears at
approximately 190 kDa, the expected molecular weight of BAF180. The other bands
were a lower molecular weight than this. It is believed that degradation of the protein is
causing these small bands. Further western blot experiments should be performed with an
antibody recognizing an epitope on the N-terminus and an antibody recognizing an
epitope near the middle of BAF180 to confirm this hypothesis. Four antibodies are
available from ThermoFisher which recognize epitopes in these regions (Table A.1). The
antibody currently used recognizes an epitope somewhere between amino acids 13291689 (full-length BAF180 is 1689 amino acids long). Experiments using these other
antibodies will provide additional evidence that BAF180 is being degraded.
Table A.1: PBRM1 antibodies available from ThermoFisher.

Antibody Catalog Number
PA5-41591
PA5-27268
730027
730076
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Epitope Region
AA31-80
AA105-374
AA501-637
AA773-917

Determination of Copy Number via qPCR
As mentioned in chapter 4, a recombinant gene is integrated into the Pichia
genome via homologous recombination. Because of this, multiple copies of the gene can
sometimes be inserted (~1% chance). qPCR should be performed to determine the exact
copy number of BAF180 in the high-producing cells. It would also be interesting to test
the low-producing cells as well, since multiple gene copies can sometimes result in
decreased expression levels.4-6
Increasing Yield by Expression in Protease-Deficient Strains
The possible expression of BAF180 in a protease-deficient Pichia pastoris strain
could also be explored. The protease-deficient strains are not recommended for initial
expression attempts as they have some potentially serious problems, such as poor growth
and low transformation efficiency.5-8 However, because so much of the recombinant
BAF180 is being degraded, these strains might be worth a try. It should be noted that
these strains improve the yield only 10% of the time for secreted proteins. No reports
using these to increase intracellular expression levels are available (see Section 4.2).
Increasing Yield by Extracellular Expression
A secretion signal could be added to the N-terminus of BAF180 which would
allow for the secretion of the protein into the growth media. Generally it is recommended
that expression of a protein in a heterologous host be done in the same manner as in its
native host (i.e. if a protein is produced intracellularly in its native host, it should be
intracellularly expressed in the heterologous host.

216

Increasing Yield with the AOX1 Promoter
Expression of BAF180 with the inducible AOX1 promoter could also be tried. The
GAP (used here) and AOX1 promoters are generally thought of as most efficient. Some
proteins are expressed at higher quantities when using the GAP promoter than with the
AOX1 promoter, and visa-versa.5-6,9-16
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Appendix B: Protocols
Preparation of samples for SDS-PAGE on Tris-glycine gels
Protein samples were separated via SDS-PAGE and samples were prepared as follows:
1. Combine in a tube:

20 μL protein sample
5.4 μL 4x SDS-PAGE Loading Buffer
1.4 μL betamercaptoethanol

2. Incubate at 95 °C for 10 minutes
3. Centrifuge 13k g for 1 minute
4. Incubate on ice for 5 minutes

Preparation of Samples for SDS-PAGE on Tris-acetate gels
Protein samples for SDS-PAGE with Tris-acetate gels were prepared differently than for
Tris-glycine gels. The sample preparation was based on guidelines in the NuPAGE
manual.1
1. Combine in a tube:

10 µg protein sample
6.25 μL NuPAGE LDS Sample Buffer
2.5 μL NuPAGE Reducing Agent
H2O to 25 μL

2. Incubate samples for 10 minutes at 70 °C
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Creation of E. coli Freezer Stock
1. Plate cells on LB with the correct antibiotic and grow overnight at 37 °C.
2. Inoculate a 15 mL LB culture (with correct antibiotic) with one colony. Grow
overnight at 37 °C and 250 rpm.
3. Transfer the cultures to 30 mL oakridge tubes and centrifuge at 3000 rpm for 10
minutes at 4 °C.
4. Decant out most of the media, leaving only a little left in the tube (~1-2 mL). Resuspend cells gently.
5. Add 1 mL of re-suspended cells to cryogenic freezer tubes. Add 1 mL cold 50%
glycerol in water. Invert 2-3 times to mix. Store at -80 °C.

Preparation of CaCl2 Chemically Competent DH5α E. coli Cells
This procedure is not original but the origin is unknown.
1. Streak LB plates with DH5α cells. Don’t use an antibiotic as DH5α does not have any
resistance. Grow overnight at 37 °C.
2.

Inoculate 5 mL of LB with 1 DH5α colony. Grow overnight at 37 °C and 250 rpm.

3. Transfer 5 mL culture to a fresh 100 mL culture. Incubate ~2 hours.
4. Remove cells from incubator and place on ice for 10 minutes. Keep the cells cold
during the rest of the procedure.
5. Centrifuge for 3 minutes at 6000 rpm and 4 °C. Decant media.
6. Gently re-suspend cells in 10 mL cold 0.1 M CaCl2. Incubate on ice for 20 minutes.
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7. Centrifuge cells again. Decant supernatant and gently re-suspend cells in 5 mL cold
0.1 M CalCl2/15% glycerol. Aliquot 100 µL into microcentrifuge tubes and store at 80 °C.

Transformation with Chemically Competent E. coli cells
The procedure outlined in the pET30 manual was modified slightly for transformation
of chemical competent E. coli cells.2
1. Remove prepared chemical competent cells (aliquots of 20 µL) from the -80 °C
freezer. Thaw tubes on ice 2-5 minutes.
2. Add 2 µL ligation reaction directly to cells. Pipet to mix. Incubate the tubes
(cells/DNA) on ice for 5 minutes.
3. Heat the tubes at 42 °C for 30 seconds. Remove immediately and place on ice for 2
minutes.
4. Add 80 µL of LB and plate on LB plates with correct antibiotic

Preparation of Electrocompetent E. coli Cells
Electrocompetent E. coli cells were prepared following the protocol outlined in the
“Micropulser Electroporation manual” from Bio-Rad, Inc.3
1. Begin a DH5α/Rosetta(DE3) culture in 5 mL LB. Incubate overnight at 37 °C and
250 rpm.
2. Transfer all 5 mL of the DH5α culture into 500 mL fresh LB. Incubate at 37 °C and
250 rpm until cells reach an OD600 = 0.5-0.7.
3. Chill cells on ice for approximately 20 minutes.
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4. Transfer cells to a cold 500 mL centrifuge bottle and centrifuge at 4000 g for 15
minutes at 4 °C.
5. Decant the media. Resuspend the cell pellet in 500 mL ice-cold 10 % glycerol.
Centrifuge at 4000 g for 15 minutes at 4 °C.
6. Decant the media. Resuspend the cell pellet in 250 mL ice-cold 10 % glycerol.
Centrifuge at 4000 g for 15 minutes at 4 °C.
7. Decant the media. Resuspend the cell pellet in 20 mL ice-cold 10 % glycerol.
Centrifuge at 4000 g for 15 minutes at 4 °C.
8. Decant the media. Resuspend the cell pellet in 500 mL ice-cold 10 % glycerol.
Centrifuge at 4000 g for 15 minutes at 4 °C.
9. Resuspend cell pellet with 10 % glycerol to a final volume of approximately 2 mL.
The cell density should be 1-3 x 1010 cells/mL.
10. Prepare 40 µL aliquots and store at -80 °C.

Native Lysis of E. coli Cells
The native lysis procedure was as follows: cells were re-suspended in native lysis
buffer (100 mM NaH2PO4, 10 mM Tris, 300 mM NaCl, pH 8.0) at 5mL/gram cell and
100 mg/mL lysozyme was added (final concentration: 3 mg/mL). The cell suspension
was incubated on ice for 30-45 minutes before being sonicated at 25% amplitude for 80
seconds (10 sec on/10 sec off). The lysed cells were centrifuged for 10 minutes at 10,000
g and the supernatant recovered. The cell pellet/debris was re-suspended in 5 mL native
lysis buffer.
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Denaturing Lysis of E. coli Cells
For the denaturing lysis protocol, the cells were re-suspended in denaturing lysis
buffer (100 mM NaH2PO4, 10 mM Tris, 300 mM NaCl, 8 M urea, pH 8.0) at 5 mL/gram
cell and incubated on ice for ~1 hour. The suspension was centrifuged at 10,000 g for 10
minutes and the supernatant recovered. To the cell pellet/debris, 5 mL of denaturing lysis
buffer was added and the cells re-suspended.

Electroporation/Transformation of pGAPZA into E. coli DH5α
Cells
The parent vector pGAPZA and the plasmid construct pGAPZA-BAF180 were
transformed into E. coli DH5α cells for propagation. The procedure was slightly modified
from the protocol outlined in the “MicroPulser Electroporation manual” from Bio-Rad,
Inc.3 Note that low-salt LB is used instead of regular LB.
1. Thaw electrocompetent E. coli cells on ice. Wrap an electroporation cuvette in
aluminum foil and place on ice. Place a microcentrifuge tube on ice as well.
2. Add DNA to 40 µL of electrocompetent cells. Mix and incubate on ice for 1 minute.
•

Note: For transformation of pGAPZA, 1 µL of 10 ng/µL was used

•

Note: For transformation of pGAPZA-BAF180, all 20 µL of the ligation
reaction was used

3. Transfer DNA-cell mixture to 0.2 µm electroporation cuvette. Place cuvette in
micropulser slide.
4. With micropulser set to “Ec2’, pulse the electroporation cuvette.
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5. Immediately add 1 mL of low-salt LB to the cuvette. Pipet up and down with a PAGE
gel loading tip.
6. Transfer the cell suspension to a 15 mL tube and incubate for 1 hour at 37 °C and 225
rpm.
7. Pour the cell suspension onto pre-warmed low-salt LB plates with 25 µg/mL zeocin
and incubate overnight at 37 °C. (Note: Zeocin is inactive at high salt concentrations,
hence the use of low-salt LB).

Linearization of pGAPZA-Pb1 Construct Using AvrII
1. Combine 1 µL of AvrII (5 units) per 1 µg DNA (WHICH?). In total, digested 12 µg
of pGAPZA-Pb1 construct. Performed 3 – 4 µg digested because the DNA recovery
limit with the Zymo kit in 5 µg.
DNA
CutSmart
AvrII
H2O

X µL (4000ng)
5 µL
4 µL
to 50 µL

2. Incubated at 37 °C for 16 hours, then purified the DNA digest using the Zymo DNA
Clean and Concentrator kit. Recovered 7380 ng DNA.
3. Used the vacuum centrifuge (Savant Refrigerator Condensation Trap and Savant
Speed Vac Concentrator) to concentrate the recovered DNA.
4. Decided to do another AvrII digest, this time incubated at 37 °C for 2 hours. The
mixture was the same as for the 16 hour digest.
5. Combined both purified digests to final volume of ~8 µL.
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Preparation of Electrocompetent Pichia pastoris X33 Cells
Electrocompetent X33 cells (Pichia pastoris) were prepared as per protocol found in
the pGAPZA manual from Invitrogen.4
1. Begin 5 mL culture of X33 in YPD; incubate at 30 °C and 225 rpm overnight
2. Prepare 500 mL of fresh YPD in a 2 L flask. Inoculate this culture with 200 µL
Alternatively:
1. Begin 5 mL culture of X33 in YPD; incubate 8 hours and 30 °C and 225 rpm
2. Prepare 500 mL of fresh YPD in a 2 L flask. Inoculate this culture with all 5 mL.
Both methods:
3. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend
cells in 500 mL ice-cold sterile distilled deionized water.
4. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend
cells in 250 mL ice-cold sterile distilled deionized water.
5. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend
cells in 20 mL ice-cold sterile 1 M sorbitol.
6. Centrifuge the cells for 5 minutes at 1500 g and 4 °C. Decant media and re-suspend
cells in 1 mL ice-cold sterile 1 M sorbitol. Approximate volume of sorbitol cell
suspension should be 1.5 mL.
7. Keep the cells on ice and use that day. Do not freeze (transformation efficiency
greatly decreases with frozen prepped cells).
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Electroporation/Transformation of Pichia pastoris Cells
A micropulser apparatus from Bio-Rad, Inc. was for the transformation of pGAPZA
and pGAPZA-BAF180 into Pichia pastoris cells. The following procedure, adapted from
the “MicroPulser Electroporation manual” was used.5
1. Combine 80 µL of electrocompetent X33 cells and 10 µg of linearized pGAPZA-Pb1
construct in a 1.5 mL microfuge tube. Transfer the mixture to an ice-cold 0.2 cm
electroporation cuvette using a gel loading tip.
2. Incubate the cuvette on ice for 5 minutes
3. Pulse the cells with the Bio-Rad Micropulser under “Pic” setting. The pulse for this
transformation was 2.00 kV and 5.00 ms.
4. Immediately add 1 mL ice-cold 1 M sorbitol to the cuvette. Pipet gently with a gel
loading tip to mix. Transfer the mixture to a cold, sterile 15 mL tube.
5. Incubate the tube at 30 °C without shaking for 2 hours.
6. Spread 5 µL, 10 µL, 15 µL, 25 µL, 50 µL, 75 µL, 100 µL, 125 µL, 150 µL, 175 µL
and 200 µL onto YPDS (__% yeast extract, __% peptone, __% dextrose, __%
sorbitol) plates with 100 µg/mL zeocin. Grow at 30 °C for 3 days. (Note: Sorbitol was
added to stabilize the transformants).

Purification of Zeocin Resistant Transformants and Selection of
Multicopy Integrants
Transformants resulting from the successful transformation of pGAPZA-Pb1 into
X33 cells needed to be purified to ensure that there were no mixed colony transformants.
The mixed colony transformants have a tendency to lose the foreign DNA.
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1. After successful transformation, streaked the 6 colonies onto 25 µg/mL zeocin plates.
Grew ~42 hours.
2. Remove colonies from 25 µg/mL plates and streak on 100 µg/mL plates. Grow for 3
days.
3. Create freezer stocks of the clones that grew on 100 µg/mL. Start 5 mL YPD
overnight cultures and prep for storage at -80 °C.

Isolation of High-Producer Strains
The high-producer strains were only identified after lysis using SDS-PAGE
visualization. Since the colonies had already been lysed, creation of new colonies was
necessary to form a stock of high-producer cells.
1. Take 200 µL of the soluble lysate and add to 3 mL YPD. Grow at 30 °C for 20-24
hours.
2. Pour culture onto YPD + zeocin plates. 4 plates were made, each with a different
amount of starter culture added: 150 µL, 200 µL, 250 µL, and 500 µL. Cells grow
better on zeocin plates agar when there is lower cell density.4
3. Grow for 3 days at 30 °C.
4. Make freezer stock using the protocol described in this chapter

Plating for Single Colonies
1. Streak Pichia pastoris clone on YPD agar + 100 µg/mL zeocin. Grow 3 days at 30
°C.
2. Pick up one colony from this plate using a toothpick.
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3. In a 1.5 mL epi tube, add 200 µL YPD. Gently swirl the toothpick in the media to
dislodge the colony. The purpose of this step is to dilute the number of cells that get
plated in the next step.
4. Using a new toothpick, streak on YPD agar + 100 µg/mL zeocin. Grow 3 days at 30
°C.

Creation of Freezer Stock from Pichia pastoris Cells
After successfully plating for single colonies (see notes), freezer stocks needed to
be made. Single colonies from the same plate were grow up in a series of 5, 7, and 10 mL
cultures. They were grown overnight at 30 °C and 225 rpm. The three different volumes
were grown to ensure that at least one of the cultures would be in exponential mode.
Colonies from 5 separate plates (therefore 5 separate parent strains) were grown in this
manner. The following day, 800 µL of culture (do not spin down) and 200 µL of 100 %
glycerol, sterilized were combined in a 2 mL cryogenic vial and flash frozen in liquid
nitrogen and immediately transferred to storage at -80 °C.

Isolation of genomic DNA from Pichia pastoris
Lysis of Yeast Cells
Reagent needed: Lyticase
1. The desired P. pastoris strain was streaked onto YPD plates and grown for 2-3 days at
30 °C.
2. 25 U of lyticase solution was added to a PCR tube and one colony, approximately 2
mm, was suspended in the solution.
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3. The samples were incubated in the PCR machine for 30 minutes at 30 °C.
4. The sample was frozen at -80 °C for 15 minutes, then thawed at room temperature,
and vortexed on medium speed to release the intracellular contents.
5. This freeze, thaw, and vortex step was repeated a second time.
Phenol-Chloroform Extraction
Reagents needed:

Phenol:Chloroform:Isoamyl alcohol (P:C:I, 25:24:1)
Chloroform:Isoamyl alcohol (C:I, 24:1)
TE Buffer: 50 mM Tris-HCl, 0.5 mM EDTA, pH 7.5

1. The lysed cell suspension was diluted in 250 µL TE buffer and 250 µL P:C:I was
added.
2. The solution was vortexed gently then centrifuged at 17,000 g for 2 minutes at 4 °C.
3. The top layer (aqueous phase, DNA containing) was carefully transferred to a clean
tube without disturbing the interface. The volume was approximately 250 µL.
4. To the original tube, 250 µL TE buffer was added.
5. Steps 2 and 3 were repeated and the water phases were combined.
6. To the tube with the aqueous phases, 250 µL C:I was added. This removed the phenol
layer from the remaining aqueous solution.
7. The solution was vortexed gently and centrifuged at 17,000 g for 2 minutes at 4 °C.
8. Any remaining aqueous solution was removed.
Ethanol Precipitation
Reagents needed:

3 M sodium acetate, pH 5.2
100 % Ethanol, ice cold
230

70 % Ethanol
Sterile ddiH2O
1. In a 1.5 mL microcentrifuge tube, 400 µL of the aqueous solution from above (DNAcontaining solution) was combined with 40 µL 3M sodium acetate, pH 5.2 (final
concentration: 0.3 M) and 880 µL 100% ice-cold ethanol. This solution was vortexed.
2. The solution from step 1 above was incubated at -80 °C for 45 minutes and then
centrifuged at 40,000 g for 15 minutes at 4 °C.
3. The DNA pellet was very small, indistinguishable to the naked eye. The supernatant
that contained salts and organic contaminants was removed, leaving a little (~10-30
µL) remaining.
4. The DNA pellet was resuspended in 1 mL 70 % ethanol and then centrifuged at
40,000 g for 15 minutes at 4 °C.
5. The supernatant was carefully removed, again leaving a small amount in the tube. In
this step, a faint opaqueness was noticed on the bottom of the tube.
6. The DNA pellet was dried at 40 °C for approximately 30 minutes. There was still
some supernatant left.
7. Sterile ddiH2O, enough to bring the volume to approximately 50 µL, was added and
the DNA pellet was resuspended.
8. The DNA concentration and purity was determined using the Nanodrop 1000
spectrophotometer (ThermoFisher).
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Optimization of Growth Time
1. Grow up 4 separate 5 (or 7, or 10) mL YPD cultures at 30 °C and 225 rpm overnight.
The 4 cultures were all started from the same parent strain (i.e. single colony on same
plate).
2. Transfer a 2 mL aliquot of the 5 (or 7, or 10) mL culture to fresh 50 mL YPD (in 125
mL flask). Grow at 20.5 °C and 225 rpm over four days. There will be a total of 4
cultures.
3. Combine the remaining culture (from each of the 4 separate) into one tube and spin
down at 12,000 g for 15 min at 4 °C.
4. Every 24 hours, remove one of the cultures and spin it down. Decant the supernatant
into a separate tube and freeze both at -20 °C. There will be a time point sample for 0
hours, 24, 48, 72 and 96 hours.
5. Once all the sample are acquired, lyse the yeast cells with the following procedure:
Lysis buffer:
•

Tris-HCl 50 mM, pH 7.4

•

PMSF 10 mM

Add 2 mL lysis buffer/gram cell pellet.
Aliquots of 1 mL of re-suspended cell pellet were added to 0.5 mm zirconia/silica
disruption beads (0.5 mL) and lysed with vortex for 30 sec by vigorous mixing followed
by 30 sec incubation on ice. This mix/freeze cycle was repeated a total of 6 times.
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Samples were collected by centrifugation at 12,000 g for 15 min at 4 °C and the
supernatant was removed for further analysis on an SDS-PAGE gel.

Lysis of Pichia pastoris Cells – Procedure
Breaking (Lysis) buffer:

50 mM NaH2PO4, pH 7.4
1 mM EDTA
5% glycerol
1 mM PMSF (add immediately prior to use)

Cells were re-suspended in breaking buffer at 2 mL breaking buffer/gram cell.
This suspension (wash to remove any residual media) was then centrifuged 3,000 g for 5
minutes at 4 °C. The supernatant was decanted and breaking buffer was added to resuspend cells (2 mL breaking buffer/gram cell). In a 1.5 mL tube, 1 mL cell suspension
was combined with 250 µL (measured by displacement) zirconia/silica disruption beads
(0.5 mm). The samples were vortexed on maximum speed for 30 seconds and then rested
on ice for 30 sec. This vortex/rest cycle was repeated a total of 12 times. The lysis
mixture was centrifuged at 12,000 g for 15 minutes at 4 °C. The lysate (soluble fraction)
was transferred to a new 1.5 mL tube. To the tube with cells/beads, 1 mL 6 M urea was
added to extract any insoluble proteins. A 200 µL pipet tip was used to loosen the cell
debris from the wall of the tube and then the tube was vortexed to re-suspend completely.
Both the lysate and the urea/cells/beads tubes were centrifuged at 12,000 g for 15 minutes
at 4 °C. The lysate was transferred to a third tube and the urea extraction was transferred
to a different tube. Both tubes were centrifuged at 20,000 g for 15 minutes at 4 °C to
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clear them. The cleared lysate and urea extraction were transferred to different tubes for
storage.
Aliquots of 1 mL of re-suspended cell pellet were added to 0.5 mm zirconia/silica
disruption beads (0.5 mL) and lysed with vortex at max speed for 30 sec followed by 30
sec incubation on ice. This mix/freeze cycle was repeated a total of 6 times. Samples
were collected by centrifugation at 12,000 g for 15 min at 4 °C.

Dot Blot
These experiments were performed with 0.45 µm nitrocellulose membrane and Pierce
Fast Western Kit, ECL substrate.
1. Spot 2 µL of protein sample onto 0.45 µm nitrocellulose membrane. Allow to dry
completely. Hydrate the membrane in 1x wash buffer for 5 minutes.
2. Prepare primary antibody solution by combining 10 mL of antibody diluent with 10
µL of anti-BAF180. Incubate membrane in solution for 1 hour at room temperature
with gentle shaking.
3. Remove membrane from antibody solution and wash for 5 minutes with 1x wash
buffer.
4. Prepare secondary antibody solution by combining 10 mL of antibody diluent with 1
mL Optimized HRP Reagent. Incubate membrane in solution for 10 minutes.
5. Remove membrane from antibody solution and perform 3 consecutive washes, 5
minutes each, with 1x wash buffer
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6. Prepare ECL detection reagent by combining 5 mL ECL detection reagent 1 and 5
mL ECL detection reagent 2. Incubate membrane briefly (5 minutes max).
7. Take images using a CDD camera

Western Blot Transfer
1. Transfer SDS gel from gel box to 2x NuPAGE transfer buffer with 0.2% SDS.
Equilibrate for 10 minutes
2. Cut a notch on corner of membrane to indicate direction
3. Active the PVDF membrane by submerging it in 100% methanol for 30 seconds.
Briefly wash the membrane in water to decrease the alcohol concentration, then place
in 1x NuPAGE transfer buffer with 0.1% SDS
4. Place blotting paper and sponges in 1x NuPAGE transfer buffer with 0.1% SDS
5. Assemble the cassette (see ) 6-7
Black Side of Cassette
Sponge

Blotting paper (3 pieces)

Gel
Membrane
Blotting paper (3 pieces)

Sponge

Grey Side of Cassette
Figure B.1: Assembly of a western blotting “sandwich”.

6. Place cassette in tank with the grey side facing the anode (black).7-8
7. Run at 70 V for 1 hour
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Appendix C: PCR Programs and Primers
Testing for Presence of Individual Domains
Table C.1: PCR conditions for BAF180 KpnI domain test. Testing Bromodomain 1 (D1) → D3; D3 → D5,
D3 → D6.

Program
Name

BAF180 KpnI
domain test

Domains
D1 -> D3
D3 -> D5
D3 -> D6

For Use with
Primers
92, 97
96, 101
96, 103

Product
Temp
Time
Size
(°C)
Initial Denaturation:
95
30 sec
1323
# Cycles: 30
1138
Denat:
95
30 sec
Anneal:
59
30 sec
Elong:
1 min 20 sec
68
Final Elongation
5 min
68
Hold
4

Table C.2: PCR conditions for BAF180 domain test 1. Testing start codon to end of bromodomain domain
3 (D3), D1 → D3, D3 → D6, and D6 → stop codon.

Program
Name

BAF180
Domain Test 1

Domains
Start -> D3
D1 -> D3
D3 -> D6
D6 -> Stop

For Use with
Primers
322, 97
92, 97
251, 103
102, 47

Product
Size
1452
1323
1500
2583

Temp
Time
(°C)
Initial Denaturation:
95
30 sec
# Cycles: 30
Denat:
30 sec
95
Anneal:
48
20 sec
Elong:
68
90 sec
Final Elongation
5 min
68
Hold
4

Table C.3: PCR conditions for BAF180 domain test 2. Testing from start codon to end of D2, D1 → D2,
D2 → D3, D3 → D4, D4 → D5, D5 → D6.

Program
Name

BAF180
Domain Test 2

Domains
Start -> D2
D1 -> D2
D2 -> D3
D3 -> D4
D4 -> D5
D5 -> D6

For Use with
Primers
322, 295
92, 95
94, 97
138, 99
98, 101
253, 254

Product
Size
852
723
909
693
732
747
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Temp
(°C)
Initial Denaturation:
95
# Cycles: 30
Denat:
95
Anneal:
49
Elong:
68
Final Elongation
68
Hold
4

Time
30 sec
20 sec
15 sec
45 sec
5 min

Table C.4: PCR conditions for BAF180 domain test 3. Testing for presence of D1 → D3 and D3 → D6.

Program
Name

Domains
D1->D3
D3->D6

BAF180
Domain Test 3

For Use with
Primers
92, 97
96, 103

Product
Temp
Time
Size
(°C)
1323
Initial Denaturation:
95
30 sec
# Cycles: 30
1500
Denat:
20 sec
95
Anneal:
50-60 15 sec
Elong:
1 min 40 sec
68
Final Elongation
5 min
68
Hold
4

PCR Program for Modification of BAF180 Gene Sequence
(insertion of Kozak consensus sequence, deletion of stop codon,
insertion of enterokinase site, 3' KpnI site)
Table C.5: PCR conditions for modification of BAF180 gene sequence: insertion of Kozak consensus
sequence, deletion of stop codon, insertion of enterokinase site, and modification of 3' restriction enzyme
site to KpnI.

Program
Name

For Use with
Primers
328/329

SH 328/329

Temp
Product Size
(°C)
Initial
4985 Denaturation:
98
# Cycles: 30
Denat:
98
Anneal:
76.3
Elong:
72
Final Elongation
72
Hold
4
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Time
30 sec
10 sec
30 sec
2 min
2 min

Table C.6: BAF180 primer sequences.

Archive
Number

092
093
094
095
096
097
098
099
100
101
102
103
136
137
138
139
140
141
142
143
146
147

Sequence

Name

GGTGGTCATATGCCAAGCAGGAAAAGGAGG
A
GCTGCTGGTACCATTGTCTTGCCCATCTTC

BAF180 Bromo1 forward
BAF180 Bromo1 reverse
BAF180 Bromo2 forward
BAF180 Bromo2 reverse
BAF180 Bromo3 forward
BAF180 Bromo3 reverse
BAF180 Bromo4 forward
BAF180 Bromo4 reverse
BAF180 Bromo5 forward
BAF180 Bromo5 reverse
BAF180 Bromo6 forward
BAF180 Bromo6 reverse
BAF180-bd1 fwd (Ase 1)

GGTGGTCATATGGATGGGCAAGACAATCAG
G
GCTGCCGGTACCTGAGCCATATTGAAGTGC
CAT
GGTGGTCATATGGCACTTCAATATGGCTCA
GCTGCTGGTACCGGTGGCTGAAGAGATCAT
GC
GGTGGTCATATGAGCATGATCTCTTCAGCCA
C
TCCTCCGGTACCGAGTTTGGGAGAAGCCAT
GTC
GGTGGTCATATGGCTTCTCCCAAACTCAA
GCTGCTGGTACCCTCTTGAATCAGCAAAGTC
ACATT
GGTGGTTCTAGAATGCCAAATGTGACTTTGC
TGATTC
GCTGCTGGTACCTGTGGTATAGCTGAGTGCC
G
GGTGGTATTAATATGCCAAGCAGGAAAAGG
AGGA
GGTGGTATTAATATGGATGGGCAAGACAAT
CAGG
GGTGGTATTAATATGGCACTTCAATATGGCT
CA
GGTGGTATTAATATGAGCATGATCTCTTCAG
CCAC
GGTGGTATTAATATGGCTTCTCCCAAACTCA
A
GGTGGTATTAATATGCCAAATGTGACTTTGC
TGATTC
GGTGGTAAGCTTCCAAATGTGACTTTGCTGA
TTC
CGTGCTGCGGCCGCAGTTGTGGTATAGCTG
AGTGCCG
GGTGGTATTAAT ATGTCCATGGGTTCCA
GCTGCTGGTACCAACATTTTCTAGGTTGTAT
GC
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BAF180-bd2 fwd (Ase 1)
BAF180-bd3 fwd (Ase 1)
BAF180-bd4 fwd (Ase 1)
BAF180-bd5 fwd (Ase 1)
BAF180-bd6 fwd (Ase 1)
BAF180-bd6 fwd (hind3)
BAF180-bd6 rev (Not1)
BAF180 fwd (Ase1)
BAF180 rev (Kpn1)

249
250
251
252
253
254
255
256
257
258
259
308
309
322
323
324
328

GGTGGTGCTCTTCCAACCCAAGCAGGAAAA
GGAGGA
GGTGGTGCTCTTCCAACGATGGGCAAGACA
ATCAGG
GGTGGTGCTCTTCCAACGCACTTCAATATGG
CTCA
GGTGGTGCTCTTCCAACAGCATGATCTCTTC
AGCCAC
GGTGGTGCTCTTCCAACGCTTCTCCCAAACT
CAA
GGTGGTCTGCAGTTATGTGGTATAGCTGAGT
GCCG
GGTGGTGGTCATATGCCCAAGCAGGAAAAG
GAGGA
GGTGGTGGTCATATGCGATGGGCAAGACAA
TCAGG
GGTGGTGGTCATATGCGCACTTCAATATGGC
TCA
GGTGGTGGTCATATGCAGCATGATCTCTTCA
GCCAC
GGTGGTGGTCATATGCGCTTCTCCCAAACTC
AA
GGCGAAGCTT TTCCATGGGTTCC

BAF180 Bromo1 forward
BAF180 Bromo2 forward
BAF180 Bromo3 forward
BAF180 Bromo4 forward
BAF180 Bromo5 forward
BAF180 Bromo6 reverse
BAF180 Bromo1 forward
BAF180 Bromo2 forward
BAF180 Bromo3 forward
BAF180 Bromo4 forward
BAF180 Bromo5 forward
BAF180 fwd_outer
(whole protein)
CGCGCCGGATCC GTGATTAAAC
BAF180 rev_outer
(whole protein)
CGGGTACC ATGGGTTCCAAGAGAAGA
BAF180, full length,
forward
CCGGCGAATTC CTGATCCACAACTCTTTATG BAF180, full length,
reverse
GGCGCC GTCCCTATTTCAATCAATTGAA
5' GAP
gcgctggtacgtagGAATTCGAACTCAAAatgggttccaa Modifications of BAF180
gagaagaag
gene sequence, fwd

329

GCGCTAATGATGTGAGGTACCCTTGTCGTCG
TCGTCAACATTTTCTAGGTTGTA

Modifications of BAF180
gene sequence, rev

336
337

GCG CGT TGC ATA ATG ATG TGG AGA AAG
GCG CCT GGG CAT AAC TTA AAG TAT TCC
TT
GCG CGA GCA GCT CCA TTA CAA T
GGC CCT CCT TCT GAG GAA CAA TTG
GCG CAG TGC AAA GAA GGA AGG
GCG CCC TTG GTT CAT CAC ACC

BAH1 forward
BAH1 reverse

338
339
340
341
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BAH2 forward
BAH2 reverse
HMG forward
HMG reverse

Copyright Permissions

Regarding Figure 1.5:

Creative Commons Attribution License (CC BY)

This article is available under the terms of the Creative Commons Attribution License (CC
BY).
You may distribute and copy the article, create extracts, abstracts, and other revised
versions, adaptations or derivative works of or from an article (such as a translation), to
include in a collective work (such as an anthology), to text or data mine the article,
including for commercial purposes without permission from Elsevier. The original work
must always be appropriately credited.
Permission is not required for this type of reuse.

Copyright © 2017 Copyright Clearance Center, Inc. All Rights Reserved.
Comments? We would like to hear from you. E-mail us at customercare@copyright.com

Regarding Figure 1.13:
The sketch of the outline of the human body is in the public domain. All notations are
original. [http://diagrampic.com/printable-human-body-outline/]
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Regarding Crystal Structures:
All crystal structures were found on Protein Data Bank (PDB).1-2 As such, they are in the
public domain. Images were manipulated using Protein Workshop.3
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